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TARGET VALIDATION AND PHARMACOLOGICAL CHARACTERIZATION OF NOVEL
NMDAR MODULATORS
Kiran Sapkota, Ph.D.
University of Nebraska, 2016
Supervisor: Daniel T. Monaghan, Ph.D.
Abstract
The N-methyl-D aspartate receptors (NMDARs) are ligand-gated ion channels, which play important
roles in learning and memory. Excessive activity of NMDARs is implicated in damage due to stroke and
neurodegenerative diseases, whereas hypoactivity of NMDARs contributes to schizophrenia. The initial
goal of my dissertation is to evaluate the potential role of the GluN2D-containing NMDARs in
neuropathological, behavioral and cognitive alterations associated with schizophrenia and characterize the
pharmacology and mechanisms of action of NMDAR modulators which could potentially be used to
modulate these receptors in schizophrenia.
A subanesthetic dose of the NMDAR antagonist ketamine elicits symptoms of schizophrenia.
This property led to the well-supported theory of NMDARs-hypofunction in schizophrenia. We found
that ketamine increases [14C]-2-deoxy-glucose uptake in the medial prefrontal cortex and entorhinal
cortex in wild type (WT) but not in GluN2D-knock out (KO) mice. Ketamine also increases locomotor
activity and gamma-band oscillatory power in WT but not in GluN2D-KO mice. These results suggest a
critical role of GluN2D-containing NMDARs in ketamine-induced schizophrenia-like symptoms in mice.
Also, consistent with a role for GluN2D in schizophrenia is that the GluN2D-KO mice displayed impaired
spatial memory acquisition and reduced parvalbumin (PV)-immunopositive staining compared to control
mice.
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To develop NMDAR modulator for treating schizophrenia and other neurological diseases, we
characterized several different naphthalene and phenanthrene based compounds for their positive
allosteric modulator (PAM), negative allosteric modulator (NAM) and competitive antagonistic activity at
NMDARs. We discovered that UBP684 and UBP753 are general NMDAR PAMs, UBP792 is a
GluN2C/GluN2D-preferring NAM and UBP791 is a GluN2C/GluN2D-preferring competitive antagonist.
Subsequent studies identified the mechanisms of action of the new compounds. The general
PAMs UBP684/UBP753 increase agonist efficacy. They increase the channel open probability (Popen), and
prolong the deactivation time upon glutamate removal. They bind to both the inactive and active states of
the receptor and stabilize the glutamate-bound state of the GluN2 ligand-binding domain (LBD). The
GluN2C/GluN2D-selective NAM UBP792 is a non-competitive antagonist and acts in a voltageindependent manner. Like the PAMs UBP684 and UBP753, UBP792 also acts by stabilizing the GluN2
LBD.
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Chapter 1 Introduction
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1

NMDARs, schizophrenia, and NMDAR modulators

1.1

N-methyl-D-aspartate receptors (NMDARs)

L-Glutamate is the primary excitatory neurotransmitter in the vertebrate central nervous system
(Watkins, Evans 1981) and glutamatergic neurotransmission is mediated by two subtypes of
receptors (i) ionotropic glutamate receptors (iGluRs; ligand-gated ion channels) that mediate the
fast synaptic responses and (ii) metabotropic glutamate receptors (mGluRs; G-protein coupled
receptors, GPCRs) that cause slow synaptic effect (Traynelis, Wollmuth et al. 2010, Conn, Pin
1997). The ligand-gated ionotropic glutamate receptors are further divided into 3 subtypes. They
are named for agonists which selectively activate them (NMDA, AMPA and kainate)
(Krogsgaard-Larsen, Honore et al. 1980, Watkins 1962, Curtis, Watkins 1963, Johnston, Kennedy
et al. 1979, Traynelis, Wollmuth et al. 2010, Monaghan, Bridges et al. 1989, Watkins, Evans
1981, Dingledine, Borges et al. 1999). Pharmacological studies with antagonists confirmed the
classification based on agonists (Biscoe, Evans et al. 1977, Davies, Watkins 1979, McLennan,
Lodge 1979, Evans, Francis et al. 1978, Evans, Francis et al. 1979). The ionotropic glutamate
receptors are also classified as NMDA and non-NMDA receptors (Monaghan, Bridges et al.
1989, Seeburg 1993, Young, Fagg 1990). Autoradiographic studies also show the anatomical
distribution of different types of glutamate receptors (Monaghan, Holets et al. 1983, Monaghan,
Cotman 1985, Monaghan, Cotman 1982).

1.1.1

Structure and pharmacology of NMDARs

When rat GluN1 receptors were first cloned and expressed in Xenopus oocytes, they exhibited
pharmacological properties similar to neuronal NMDARs. Hence, these NMDARs were
considered to be homomeric receptors similar to AMPA and kainate receptors (Moriyoshi, Masu
et al. 1991). However, the current which was believed to be from homomeric GluN1 receptors is
actually from heteromeric NMDARs formed by GluN1 and endogenously expressed GluN2
subunits in Xenopous laevis oocytes (Schmidt, Hollmann 2008, Schmidt, Hollmann 2009). Four
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other subunits of NMDAR were later cloned and they formed functional NMDARs when coexpressed with GluN1 subunit in Xenopus laevis oocytes (Monyer, Sprengel 1992, Monyer,
Burnashev et al. 1994, Meguro, Mori et al. 1992, Ikeda, Nagasawa et al. 1992, Ishii, Moriyoshi et
al. 1993). For rat proteins, these subunits were originally named as NR2A-D and for mouse
proteins, they were named as ε1-4. Now, these subunits are referred to as GluN2A-D
(Collingridge, Olsen et al. 2009).
Most of the N-methyl-D-aspartate receptors (NMDARs) expressed in brain are heterotetrameric complexes (Karakas, Furukawa 2014, Laube, Kuhse et al. 1998, Ulbrich, Isacoff 2008,
Schorge, Colquhoun 2003, Sobolevsky, Rosconi et al. 2009, Lee, Lü et al. 2014) composed of
two glycine-binding obligatory GluN1 subunits (Johnson, Ascher 1987) and either two similar or
different glutamate-binding GluN2 subunits or a combination of GluN2 and GluN3 subunits or
two GluN3 subunits (Figure 1.1) (Hollmann 1999, Brothwell, Barber et al. 2008, Jones, Gibb
2005, Brickley, Misra et al. 2003, Perez-Otano, Schulteis et al. 2001, Ciabarra, Sullivan et al.
1995, Sucher, Akbarian et al. 1995, Cavara, Orth et al. 2009, Chatterton, Awobuluyi et al. 2002,
Smothers, Woodward 2007, Smothers, Woodward 2009, Awobuluyi, Yang et al. 2007, Madry,
Mesic et al. 2007). Upon activation, these receptors allow Ca2+, Na+ and K+ through the receptor
ion channel and show voltage-dependent block by magnesium (Mayer, Westbrook et al. 1984,
Ascher, Nowak 1988). The GluN1 subunit is encoded by a single gene which has 22 exons. Exon
5, 21 and 22 can be alternatively spliced to yield 8 GluN1 splice variants (Sugihara, Moriyoshi et
al. 1992, Hollmann, Boulter et al. 1993) whereas GluN2 subunits (GluN2A-D) are encoded by
four separate genes (Monyer, Burnashev et al. 1994, Monyer, Sprengel 1992, Ishii, Moriyoshi et
al. 1993, Ikeda, Nagasawa et al. 1992, Kutsuwada, Kashiwabuchi et al. 1992). The subtype of the
GluN2 subunits (GluN2A-D) in the receptor complex determines the electrophysiological,
biochemical and pharmacological properties of NMDARs (Monyer, Burnashev et al. 1994,
Vicini, Wang et al. 1998, Ishii, Moriyoshi et al. 1993, Buller, Larson et al. 1994). NMDARs are
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often thought of as being diheteromeric where two GluN1 receptors co-assemble with two same
GluN2 subunits (e.g. GluN1-1a/GluN2B) (Dingledine, Borges et al. 1999). However, studies
have shown that triheteromeric NMDARs (e.g. GluN1/GluN2A/GluN2B) also exist in the brain
regions and that these receptors have different pharmacological properties compared to diheteromeric NMDARs (Hansen, Ogden et al. 2014, Cheriyan, Balsara et al. 2016, Rauner, Kohr
2011, Tovar, McGinley et al. 2013, Hatton, Paoletti 2005, Brickley, Misra et al. 2003, Jones,
Gibb 2005, Brothwell, Barber et al. 2008, Chazot, Stephenson 1997). The relative contribution of
diheteromeric and triheteromeric NMDARs during synaptic transmission is still not clear.
NMDARs are distinct from AMPA and kainate receptors in that (i) require simultaneous binding
of two distinct agonists, glycine (or D-serine) and L-glutamate for channel activation, (ii) also
require several simultaneous excitatory inputs to sufficiently depolarize and relieve Mg2+
blockade (Mayer, Westbrook et al. 1984, Nowak, Bregestovski et al. 1984) and hence NMDAR
functions as a molecular coincidence detector (Bliss, Collingridge 1993, Paoletti, Bellone et al.
2013) (iii) they also have high Ca2+ permeability. Ca2+ acts as a NMDAR second messenger and
activates a variety of Ca2+ -dependent signaling pathways that underlie synaptic plasticity under
normal physiologic conditions (Lisman, Yasuda et al. 2012) and neuronal death under
pathological conditions. NMDARs display remarkably slow activation and deactivation kinetics,
which enable them to have distinct roles in coincidence detection in associative learning and to
participate in oscillatory pattern generation. NMDAR activation is also voltage dependent, which
provides an essential property for associative learning and oscillatory pattern generation.

5

A.

B.

Figure 1.1 Schematic diagram of NMDAR structure
(A) Schematic representation of 4 modular domains: amino-terminal domain (ATD); ligand-binding domain (LBD),
transmembrane domain (TMD) and C-terminal domain (CTD) of GluN1 and GluN2 subunits of NMDARs. (B)
Schematic diagram of NMDARs subunit composition showing assembly of two glycine-binding GluN1 and two
glutamate-binding GluN2 subunits forming a ‘dimer of dimers’ structure which is permeable to cations such as Ca2+, Na+
and K+. Numbers 1-4 in each subunit represent the transmembrane domains (1, 3, and 4) and the re-entrant loop (2) lines
the pore of the channel.
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Each subunit of the NMDAR (or any ionotropic glutamate receptor) consists of four
modular domains: (i) an extracellular amino-terminal domain (ATD), (ii) an extracellular ligandbinding domain (LBD), (iii) a pore-forming transmembrane domain (TMD) and (iv) a
cytoplasmic C-terminal domain (CTD) as shown in the Figure 1.1. A crystal structure of
GluN1/GluN2B with intact ATD, LBD and TMD shows that NMDARs are formed by dimers of
heterodimers and that the ATD and LTD in NMDARs are more tightly packed than those of nonNMDARs (Karakas, Furukawa 2014). Previously reported high-resolution crystal structures of
NMDARs with isolated ATDs and ABDs also have provided the information about the
quaternary arrangements of subunits (Furukawa, Gouaux 2003, Furukawa, Singh et al. 2005,
Karakas, Simorowski et al. 2009, Karakas, Simorowski et al. 2011, Farina, Blain et al. 2011).
Although previous studies had suggested a possible arrangements of GluN1 and GluN2 subunits
in 1-1-2-2- fashion (Schorge, Colquhoun 2003, Qiu, Hua et al. 2005, Papadakis, Hawkins et al.
2004), recent studies with cross-linked cysteine residues in NMDARs (Salussolia, Prodromou et
al. 2011, Riou, Stroebel et al. 2012) as well as crystal structures, suggest that the GluN1 and
GluN2 subunits in NMDARs are arranged in a 1-2-1-2 manner (Karakas, Furukawa 2014, Lee,
Lü et al. 2014).
Both the ATD and LBD form bi-lobed clamshell structures and have sequence homology
to bacterial periplasmic amino acid binding proteins. The extracellular ATD is the most diverse
region with 20 - 35 % identical residues between functional classes of glutamate receptors
(Hansen, Furukawa et al. 2010) and there is no sequence identity between NMDA and nonNMDARs. There is 35 - 55 % sequence identity among GluN2A-D NMDAR subunits and 15 %
sequence identity between GluN1 and GluN2A-D subunits (Furukawa 2012). ATD in iGluRs
harbors many putative sites for allosteric modulators (Hansen, Furukawa et al. 2010, Paoletti
2011, Gielen, Retchless et al. 2009).
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The LBD is highly conserved among different subunits within different glutamate
classes. Clampshell structure of the LBD is formed by S1 domain and S2 domain which form
glycine binding site in GluN1 and glutamate binding site in GluN2 subunits. S1 segment is
located on N-terminal side of M1 helix and forms the one half of the clamshell. The S2 segment
is located between M3 and M4 helices and contributes to other half of the clamshell (Stern-Bach,
Bettler et al. 1994). Each of the LBDs in iGluRs are connected to transmembrane helices by three
short linkers (Sobolevsky, Rosconi et al. 2009) through which they control the gating of NMDAR
channel pore (Kazi, Gan et al. 2013, Dai, Zhou 2013, Talukder, Wollmuth 2011). Glycine
(Johnson, Ascher 1987, Kleckner, Dingledine 1988, Forsythe, Westbrook et al. 1988), and Dserine (Mothet, Parent et al. 2000, Martineau, Baux et al. 2006, Schell, Molliver et al. 1995,
Yang, Ge et al. 2003) act as co-agonists of NMDARs. It is reported that glycine acts as a coagonist at extra-synaptic NMDARs and D-serine at synaptic NMDARs (Papouin, Ladépêche et
al. 2012). Other studies also provided evidence for glycine binding at GluN1 LBD (Hirai, Kirsch
et al. 1996, Furukawa, Gouaux 2003, Kuryatov, Laube et al. 1994) and glutamate binding at
GluN2 LBD of NMDARs (Furukawa, Singh et al. 2005, Laube, Hirai et al. 1997).
The TMD of NMDARs has 3 membrane passing segments (M1, M3 and M4) and one reentrant pore loop (M2). The M2 loop of NMDARs has sequence and structural homolgy to the Ploop of potassium channels (Kuner, Seeburg et al. 2003, Wood, VanDongen et al. 1995).
Variations in amino acid residues in the TMD are attributed to distinctive pore properties of
NMDAR, AMPA receptors and KA receptors (Traynelis, Wollmuth et al. 2010). QRN site near
the apex of the pore loop is important in controlling the permeability of cations through the
channel. High Ca2+ permeability of NMDARs is attributed to DRPEER motif in GluN1 subunit,
which serves as a binding site for Ca2+ and is located in the extracellular vestibule near Cterminal to the M3 helix (Watanabe, Beck et al. 2002). The M4 helix controls the assembly and
trafficking of the receptors (Schorge, Colquhoun 2003, Kaniakova, Lichnerova et al. 2012).
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Single amino acid residue (Ser632 in GluN2A and Leu657 in GluN2D) in the M3 region of
GluN2 subunits controls the NMDAR subtype-specificity of Ca2+ permeability, single-channel
conductance and Mg2+ block (Retchless, Gao et al. 2012). Also, the aspargine reside at the tip of
M2-loop, which lines the pore of the channel, is important for Ca2+ permeabilty and Mg2+ block
of NMDARs (Kuner, Wollmuth et al. 1996, Wollmuth, Kuner et al. 1998). TMD contains binding
sites for NMDAR channel blockers such as PCP, ketamine and MK-801. Amino acids residues at
or near Q/R/N site or along the permeation pathway are critical for block by these channel
blockers (Kashiwagi, Masuko et al. 2002, Mori, Masaki et al. 1992, Chen, Lipton 2005,
Limapichat, Yu et al. 2012, Chang, Kuo 2008, Sakurada, Masu et al. 1993).
The intracellular CTD is the most diverse region between different subunits of NMDARs
not only in the amino acid sequence but also in length. This region contains binding sites for
intracellular proteins involved in receptor trafficking, localization and signaling (Lau, Zukin
2007, Collingridge, Isaac et al. 2004). A motif (HLFY) in the CTD of GluN2 subunit
immediately after the M4 helix is important for the release of NMDARs from endoplasmic
reticulum (Hawkins, Prybylowski et al. 2004). The CTD also has multiple phosphorylation sites.
The CTD of GluN2A and GluN2B are targets for CaM Kinase II, tyrosine kinase, protein kinase
C and protein kinase A (Omkumar, Kiely et al. 1996, Wang, Salter 1994, Moon, Apperson et al.
1994, Tingley, Ehlers et al. 1997, Leonard, Hell 1997). In the GluN1 CTD, PKC phosphorylates
S890 and S896 residues and PKA phosphorylates S897 residues (Tingley, Ehlers et al. 1997,
Sánchez-Pérez, Felipo 2005). Similarly, in GluN2A CTD, PKC phosphorylates at S1291, S1312
and S1416 (Gardoni, Bellone et al. 2001, Jones, Leonard 2005) and PKA phosphorylates at S900
and S929 (Krupp, Vissel et al. 2002). In GluN2B CTD, PKC phosphorylates at S1303 and S1323
(Omkumar, Kiely et al. 1996, Liao, Wagner et al. 2001) and CaM kinase II at S1303 residue
(Omkumar, Kiely et al. 1996). Other novel phosphorylation sites on GluN2A- and GluN2Bcontaining hippocampal NMDARs have also been identified using mass spectrometry (Ghafari,
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Höger et al. 2012). The CTD of GluN1has has also been shown to reduce mean open time and
channel open probability (Popen) through Ca2+ dependent calmodulin binding (Ehlers, Zhang et al.
1996) . It is believed that the NTD modulates agonist potency, deactivation time, Popen and mean
open/shut time (Yuan, Hansen et al. 2009, Gielen, Retchless et al. 2009). However, the CTD can
also regulate the gating properties of NMDARs. GluN2 CTD deletion increases the glutamate
deactivation time and reduces the peak Popen of synaptic NMDARs and NMDARs expressed in
HEK cells (Mohrmann, Köhr et al. 2002, Rossi, Sola et al. 2002, Punnakkal, Jendritza et al.
2012).

1.1.2

Developmental expression of NMDARs in brain

The developmental expression pattern of different NMDAR subunits changes during postnatal
life altering the properties of NMDARs. In general, in rodents there is greater expression of
GluN2B, 2D and 3A in early life compared to the expression of GluN2A, 2C and 3B, which peak
later in life (Laurie, Bartke et al. 1997, Wenzel, Fritschy et al. 1997). There is a regional variation
in gene expression of these subunits as well (Goebel, Poosch 1999, Monyer, Burnashev et al.
1994). The GluN2D protein expression is high in embryonic days, reaches its peak level at P7 and
reduces in adulthood. In contrast, GluN2C is absent in embryonic brain, starts increasing after P6,
peaks at P20 and remains at steady levels afterwards (Laurie, Bartke et al. 1997). GluN2A
receptors are predominantly expressed in cortex, hippocampus and cerebellum and GluN2B are
highly distributed in forebrain areas. GluN2C-containing receptors are mainly expressed in
cerebellum and GluN2D subunits are expressed in midbrain and thalamus (Monyer, Sprengel
1992).
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1.2

Schizophrenia

NMDARs are involved in a variety of neurological and neuropsychiatric disorders. In particular,
NMDAR involvement in schizophrenia suggests that it may be possible to treat schizophrenia
with NMDAR modulating agents. The goal of Chapter 2, is to determine if GluN2D subunits
contribute to schizophrenia related neuronal activation and behaviors induced by NMDAR
antagonists. Thus, a brief overview of the relevant pathophysiology of schizophrenia is presented
here. Such findings would suggest that GluN2D potentiators may be useful for treating
schizophrenia.
Schizophrenia is a chronic psychiatric disorder, which affects nearly 1 % of the
population worldwide. It is a complex trait that results from both genetic and environmental
etiological factors (Sullivan, Kendler et al. 2003). People with schizophrenia show three
categories of symptoms: 1) positive- hallucinations, delusions and thought disorder 2) negativeanhedonia, deficit in social interaction, depression and 3) profound cognitive deficits in attention,
learning and memory (Robert Freedman 2003). For decades, schizophrenia research was mainly
focused on the dopamine hypothesis, which postulates that schizophrenia symptoms arise from
excessive dopaminergic neurotransmission mainly in the striatum and a deficit in dopaminergic
transmission in frontal brain areas such as prefrontal cortex (PFC) (Davis, Kahn et al. 1991).
However, studies have shown that blocking of dopamine receptors has been able to improve only
the positive symptoms of schizophrenia and not improve the negative and cognitive symptoms.
Thus, current therapies are usually sufficient to allow schizophrenia patients to leave the hospital,
but not sufficient for them to maintain jobs and social relationships. Amphetamine induces only
positive symptoms of schizophrenia and (Davis, Chen et al. 2003) clozapine does enhance PFC
activity by an unknown mechanism and this agent has some beneficial effects on negative and
cognitive schizophrenia symptoms. Since antipsychotics typically are effective in treating
positive symptoms only, dopamine alone cannot account for all of the neuropathological
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symptoms of schizophrenia. Hence, involvement of another neurotransmitter in schizophrenia has
been sought and growing body of evidence implicates NMDAR hypofunction in the
pathophysiology of this disease.

1.2.1

NMDAR hypofunction in schizophrenia

The NMDAR hypofunction hypothesis of schizophrenia is mainly derived from the evidence of
psycho-behavioral effects of NMDAR antagonists phencyclidine (PCP) and ketamine (Javitt,
Zukin 1991, Tamminga 1999, Anis, Berry et al. 1983). These compounds were able to cause
schizophrenia-like symptoms in healthy individuals and exacerbated the symptoms in people with
schizophrenia (Krystal, Karper et al. 1994). A sub-anesthetic dose of ketamine in healthy subjects
produces a broad range of symptoms, behaviors and cognitive deficits similar to that seen in
schizophrenics (Krystal, Karper et al. 1994, Lahti, Koffel et al. 1995, Malhotra, Pinals et al.
1997). NMDAR channel blockers like ketamine- and PCP-induced psychotic disorders that more
broadly mimic the diverse symptoms of schizophrenia-thought disorder, cognitive disorder and
negative symptoms than that seen with amphetamine induced psychosis (Abel, Allin et al. 2003,
Lahti, Weiler et al. 2001, Morgan, Mofeez et al. 2004). Antipsychotics like clozapine and
haloperidol were effective in reducing the symptoms induced by ketamine (Malhotra, Pinals et al.
1997, Lahti, Weiler et al. 2001, Oranje, Gispen-de Wied et al. 2002). Schizophrenia-like
behavioral symptoms are displayed by the NMDAR hypofunction mouse model of reduced
GluN1 expression (Mohn, Gainetdinov et al. 1999) and haloperidol and clozapine were able to
rescue the associated deficits in prepulse inhibition (Duncan, Moy et al. 2006). Human studies
also support the theory of reduced NMDAR function in schizophrenia. The activity of D-amino
acid oxidase (DAAO) is increased and the level of the endogenous ligand for NMDARs, Dserine, is decreased in the brain and blood of schizophrenics (Madeira, Freitas et al. 2008,
Hashimoto, Fukushima et al. 2003). This finding is supported by the finding that increasing the
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level of the co-agonist D-serine has shown beneficial, but limited, effects in several clinical trials
(Tsai, Lin 2010).
NMDAR hypofunction in schizophrenia might be due to reduced expression and/or
activity of NMDARs particularly in GABAergic inhibitory interneurons (Snyder, Gao 2013).
Since, single interneurons form connections with several pyramidal neurons, NMDAR
hypofunction of a single interneuron may disinhibit the firing of several cortical pyramidal
neurons (Homayoun, Moghaddam 2007). This response accounts for the ability of NMDAR
antagonists to increase the general excitatory levels within the PFC as seen in fMRI studies in
humans or [14C]-2-deoxyglucose in rodent studies.
While aberrations in dopamine activity cannot explain all of the symptoms of
schizophrenia, hypoactivation of NMDAR can explain all of the symptoms as well as explain the
role of dopamine as it is regulated by NMDAR activity (in particular by GluN2D). Hence, the
NMDAR hypofunction hypothesis (Figure 1.2), which relies primarily on reduced NMDARmediated neurotransmission particularly due to reduced NMDAR activity in PV-positive
GABAergic interneuron and its possible role on etiology and pathology of the disease, has drawn
much interest in this field.
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Figure 1.2 NMDAR hypofunction hypothesis of schizophrenia
During normal physiological condition, there is a balance between excitatory function of pyramidal cells and inhibitory
function of GABAergic interneurons. However, during some pathological conditions such as schizophrenia, there is a
reduction in inhibitory function by GABAergic interneurons which causes disinhibition of pyramidal cell’s firing. Animal
models of schizophrenia could be mimicked by blocking NMDARs in the GABAergic interneurons by open channel
blockers like ketamine and MK-801, which also leads to a reduction in GABA release in the synapses thereby causing
disinhibition of pyramidal cells.

1.2.2

Genes associated with schizophrenia

Gene association studies have identified several NMDAR-related risk genes that either directly or
indirectly alter NMDAR function (e.g., DAAO - the D-serine metabolizing enzyme and ErbB4 - a
protein that associates with PSD-95 and hence with NMDARs). Other schizophrenia-linked risk
genes are GRIN2B; G72 (a gene encoding a protein that binds to DAAO), neuregulin-1
(modulates NMDAR activity), and dysbindin (which is concentrated in glutamatergic terminals)
(Harrison, Weinberger 2004, Greenwood, Light et al. 2012, Harrison, Owen 2003, Allen, Bagade
et al. 2008). In addition, GluN3A gene is increased in DLPFC in schizophrenia (Mueller,
Meador-Woodruff 2004).
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1.2.3

NMDARs in parvalbumin cells and schizophrenia

NMDARs in parvalbumin (PV)-containing GABAergic interneurons, are thought to be important
in schizophrenia. PV-cells are fast spiking interneurons which express the calcium binding
protein called PV and receive NMDAR-dependent excitatory input from pyramidal cells (Jones,
Bühl 1993). Impairment in normal functioning of these fast spiking PV-cells is considered to
underlie cognitive disturbance in psychiatric disorders (Uhlhaas, Haenschel et al. 2008, Roopun,
Cunningham et al. 2008, Gonzalez-Burgos, Lewis 2008). PV-cells have neuronal network
functions such as feedback and feed-forward inhibition, generation of gamma oscillations and
transmission of information between cortical areas (Bartos, Vida et al. 2007). Synchronous
neuronal activity of these cells produces gamma oscillations (30-80 Hz) (Sohal, Zhang et al.
2009, Cardin, Carlén et al. 2009), which are correlated with cognitive tasks like planning,
learning, attention and memory (Uhlhaas, Singer 2010, Sohal, Zhang et al. 2009). Gamma
oscillations are critical for the normal flow of neuronal activity within and between cortical
regions, which is essential for cognitive processes (Fries 2009). NMDARs in PV-containing cells
have been shown to be involved in potentiation or disruption of gamma rhythms. Selective
deletion of NMDARs from PV-cells leads to deficit in gamma oscillation induction, and the
development of schizophrenia-like phenotype (Carlen, Meletis et al. 2011, Korotkova, Fuchs et
al. 2010, Belforte, Zsiros et al. 2009). Several possible mechanisms might be involved in the
disruption of inhibitory function in schizophrenia, many of may converge to the PV-cells as a
central player.
Various studies support the association between NMDAR function and PV-containing
interneurons. Blocking of NMDAR activity reduces either the expression of PV or the number of
PV-positive interneurons. Selective deletion of NMDARs from PV-containing cells leads to a
deficit in gamma oscillation induction (Carlen, Meletis et al. 2011). A chronic administration of
ketamine to rats reduces the number of PV-immunoreactive interneurons in the hippocampus of
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rats, which is correlated with the strengthening of oscillations resulting from an acute
administration of ketamine (Kittelberger, Hur et al. 2012). Reduced expression of PV and
GAD67, an enzyme responsible for GABA synthesis in the brain, has been found in multiple
studies involving postmortem brain from schizophrenics (Benes, Berretta 2001, Reynolds, Zhang
et al. 2001, Lewis, Hashimoto et al. 2005, Hashimoto, Volk et al. 2003). Reduction of GAD67
occurs mainly in PV-positive interneurons (Beasley, Reynolds 1997, Hashimoto, Volk et al.
2003) and PV- positive interneuron loss occurs in mammillary bodies (Bernstein, Krause et al.
2007) and cortical layers III and IV (Beasley, Reynolds 1997). Similar changes occur with
pharmacologically-induced NMDAR hypofunction. Ketamine also reduces the expression of PV
and GAD67 in cultured neurons (Kinney, Davis et al. 2006). Likewise, a sub-chronic dose of PCP
administration causes a deficit in the reversal of learning and a reduction in PV-positive
interneurons in rat hippocampus (Abdul-Monim, Neill et al. 2007). Repeated administration of a
sub-anesthetic dose of ketamine induces neuronal nitric oxide synthase and c-FOS gene
expression in the hippocampus of rats (Keilhoff, Becker et al. 2004).
Treatment with NMDAR antagonists during early development or rearing in stressed
environment also has an impact on PV-expression. Postnatal exposure to MK 801 reduces PV
levels in the cingulate cortex (Turner, DeBenedetto et al. 2010). Rats treated with PCP in
postnatal life (P7, 9 and 11) have reduced PV-positive cells in the mPFC as adults (Kaalund,
Riise et al. 2013). Rearing rats in isolation also reduces the PV-expression in the adult
hippocampus (Harte, Powell et al. 2007, Schiavone, Sorce et al. 2009) and rearing in an enriched
environment increases the number of PV-positive cells in the basolateral amygdala and a
reduction in anxiety-like behavior (Urakawa, Takamoto et al. 2013).
NMDAR activity is critical for maturation of PV cells during development. In mice,
maturation of PV-interneurons begins at the end of 1st week of postnatal life (Lecea 1995,
Doischer, Hosp et al. 2008). At P5, they start responding to glutamate and GABA transmission
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and express PV by P7 (Lecea 1995, Sauer, Bartos 2010) and they mature into fast spiking
inhibitory neurons in another three weeks (Okaty, Miller et al. 2009, Doischer, Hosp et al. 2008).
Inhibitory networks play an important role in experience-dependent refinement of neuronal
circuits, which starts at the end of 1st week and lasts through 4th week of postnatal life of rodents
(Lema Tomé, Miller et al. 2008, Huang 2009). Hippocampal PV-interneurons, among all other
interneuronal subtypes, receive the highest number of glutamatergic synapses from the thalamus
(Gulyas, Megias et al. 1999). Expression of NMDARs in PV-cells is high in early postnatal life
and undergoes profound functional changes during adolescence (Wang, Gao 2009). Studies also
have shown that there is a switch in the subtype of GluN2 subunit expressed in PV-cells during
development. This switch is also affected by treatment with NMDAR antagonists (Kinney, Davis
et al. 2006, Zhang, Sun 2011). Taken together, the activity of NMDARs appears to be critical for
the maturation process of PV-cells. Although there is no definite answer to why the level of PV in
these cells goes down in schizophrenia, one possible explanation might be that PV expression is
decreasing in response to a reduced excitatory drive from pyramidal cells after having a decreased
calcium influx due to reduced NMDAR activity (Zhang, Behrens et al. 2008).

1.2.4

Role of specific NMDAR subtypes in schizophrenia

Different NMDAR subtypes have distinct anatomical and developmental patterns of expression
and different physiological properties. Studies have measured the expression level of different
subtypes of NMDARs in postmortem brain from schizophrenics. In thalamus from younger
schizophrenics, there was an increase in GluN2B and a decrease in transcripts for the NMDARs
associated proteins NF-L, PSD 95 and SAP 102 (Clinton, Meador-Woodruff 2004). The same
researchers also reported that the thalamus from older schizophrenics have a reduced level of
GluN1 and GluN2C and increased level of NF-L and SAP-102 transcripts (Clinton, Haroutunian
et al. 2003). Although there was no difference in ligand binding to NMDA, AMPA and kainate
receptors between post mortem hippocampal tissue of healthy people and schizophrenics, there
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was lower GluN1 and higher GluN2B expression in schizophrenics (Gao, Sakai et al. 2000).
GluN1 and GluN2A, but not GluN2B, expression was increased in the dorsolateral prefrontal
cortex (DLPFC) and the occipital cortex of patients with schizophrenia (Dracheva, Marras et al.
2001). Reduced GluN1 mRNA in DLPFC and reduced GluN2C mRNA in frontal cortex
schizophrenics was also reported (Weickert, Fung et al. 2013). Since GluN1 is critical for
NMDAR activity, reduction in GluN1 subunits in the hippocampus of schizophrenia may suggest
reduced NMDAR-mediated neurotransmission in the hippocampus and other brain regions,
supporting the NMDAR hypofunction hypothesis of schizophrenia.
Various studies show how altering the levels of different NMDAR subunits can affect
behavior and cognition in mice. GluN1 hypomorphic mice show social withdrawal, working
memory and attention deficits, and basal metabolic reduction in the brain (Bickel, Lipp et al.
2007, Duncan, Miyamoto et al. 2002, Duncan, Moy et al. 2004, Halene, Ehrlichman et al. 2009).
Transgenic mice with overexpressed GluN2B receptors in forebrain show enhanced performance
in different learning and memory tests (Cao, Cui et al. 2007). In contrast, mice lacking GluN2C
receptor subunits show deficits in associative and working memory suggesting its functional role
in cognition, which is impaired in schizophrenia (Hillman, Gupta et al. 2011). It has been
reported that postnatal ablation of GluN1 subunit selectively from cortical and hippocampal PV
interneurons, results in schizophrenia-like symptoms after adolescence (Belforte, Zsiros et al.
2009). These mice show novelty-induced hyperlocomotion, a reduced preference for sweets (a
model of anhedonia), a deficit in spatial working memory and impaired prepulse inhibition (PPI),
reduced expression of PV and GAD67 in cortical neurons. However, they do not have such
deficits if GluN1 is ablated at a post-adolescent age. Also, removing the GluN1 subunit from PVcells impairs spatial working and spatial recognition memory (Korotkova, Fuchs et al. 2010). A
targeted disruption of the GluN2A subunit in mice reduces NMDAR-mediated currents, reduces
long-term potentiation (LTP) at the hippocampal CA1 synapses and moderately impairs spatial
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learning (Sakimura, Kutsuwada et al. 1995). Mice lacking GluN2B in the forebrain have impaired
spatial and non-spatial memory (von Engelhardt, Doganci et al. 2008). NMDAR knockout (KO)
in the hippocampal CA1 region impairs reference memory (McHugh, Blum et al. 1996) whereas
deleting NMDAR in the hippocampal CA3 or DG region impairs working memory (McHugh,
Jones et al. 2007, Niewoehner, Single et al. 2007). PCP increases striatal dopamine release and
motor impairment in WT and GluN2A KO mice but not in GluN2D KO (Hagino, Kasai et al.
2010, Yamamoto, Kamegaya et al. 2013). Together, these studies provide genetic evidence of
NMDARs in behaviors that are impaired in schizophrenia. We can also observe in these studies
that different subunits of NMDAR are responsible for different aspects of behavioral and
cognitive impairments relevant to schizophrenia. This is the rationale for my Chapter 2 in which
we have tried to explore the role of GluN2D subunits in schizophrenia related behavioral,
neurological and cognitive impairments.

1.2.5

Glutamatergic agents for schizophrenia treatment in future

As discussed in previous sections, reduced NMDAR function is involved in pathophysiology of
schizophrenia. Other studies have implicated the reduced function of metabotropic glutamate
receptor in schizophrenia. Hence, drugs that enhance overall glutamatergic function could be
alternative or supplementary therapeutic agents for current antipsychotic treatments (Duncan,
Zorn et al. 1999, Goff, Coyle 2001). Use of allosteric modulators is a better option than the use of
agonists as therapeutics. Glutamate agonists would induce excitation of all glutamatergic
synapses, which would cause neuronal cell death by excitotoxicity and seizures. Studies have
shown beneficial effects after the treatment with agents that enhance NMDAR function. When
glycine, D-serine or D-cycloserine, which are NMDAR co-agonists, were administered as a
supplement to antipsychotic treatments in patients with schizophrenia, they were able to improve
negative and cognitive symptoms (Goff, Henderson et al. 1999, Goff, Tsai et al. 1999, Javitt,
Zylberman et al. 1994, Heresco-Levy, Javitt et al. 1999). As an alternative approach to increase
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brain D-serine levels, it is possible to reduce the catabolism of D-serine by administration of the
D-amino acid oxidase (DAAO) inhibitor AS057278. Interestingly, this agent normalizes PCPinduced behavioral deficits in mice. Combining a DAAO inhibitor with a low dose of D-serine
shows superior activity than either agent alone in reducing NMDA antagonist MK-801
(dizocilpine)-induced deficit in prepulse inhibition (Hashimoto, Fujita et al. 2009, Adage, Trillat
et al. 2008). Increasing the synaptic glycine level by use of a glycine reuptake inhibitor
glycyldodecylamide inhibits PCP-induced hyper-locomotion more effectively than the direct use
of glycine itself (Javitt, Sershen et al. 1997). Another approach to enhance glutamate receptor
response would be to increase synaptic L-glutamate levels by using glutamate reuptake inhibitors,
like EAAT3 antagonists. However, high levels of glutamate could be detrimental to normal
functioning cells. NMDAR antagonist-induced behavioral effects such as hyper-locomotion and
stereotypy (repetitive behavior) could also be due to the action of increased glutamate release,
which may enhance the function of non-NMDARs like AMPA and kainate receptors. However, it
has been found that blocking the activity of AMPA/kainate receptors by the antagonist LY293558 can partially reverse ketamine-induced deficit in working memory (Moghaddam, Adams
et al. 1997). Synaptic levels of L-glutamate can also be reduced by activation of presynaptic
group II metabotropic glutamate autoreceptors (mGluR2/3). Activation of those receptors by LY354740 reduces glutamate release and the behavioral activation induced by PCP in the rat
(Moghaddam, Adams 1998).
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1.3

Allosteric modulators of NMDARs

Under normal physiological conditions, NMDARs activate cellular signaling cascades important
for growth, development, learning and memory. Under pathological conditions, it NMDARs can
activate cellular signaling pathways that lead to excitotoxic neuronal cell death. Ca2+ entering
through NMDARs activates Ca2+/calmodulin-dependent protein kinase II (Giese, Fedorov et al.
1998, Lisman, Yasuda et al. 2012, Pettit, Perlman et al. 1994, Miller, Kennedy 1986), protein
kinase A (Roberson, Sweatt 1996), protein kinase C (Malinow, Schulman et al. 1989, Malinow,
Madison et al. 1988, Lovinger, Wong et al. 1987) and phosphoinositide-3-kinase (PI3K) (Kim,
Lee et al. 2011, Man, Wang et al. 2003) which are important in causing long-term changes in
synaptic strength during development as well as during the process of learning and memory.
However, in pathological conditions such as in ischemia, there is increased release of glutamate
(Benveniste, Drejer et al. 1984, Nilsson, Hillered et al. 1990, Qureshi, Ali et al. 2003, Kanthan,
Shuaib et al. 1995) that causes hyperactivation of NMDARs leading to excitotoxicity and cell
death (Choi 1988, Choi, Maulucci-Gedde et al. 1987, Choi 1992, Olney 1969, Rothman, Olney
1987). Early studies, showing that the blockade of NMDAR activity can protect against
neurological damages in ischemia and brain injury, were (Faden, Demediuk et al. 1989, Ozyurt,
Graham et al. 1988, Simon, Swan et al. 1984, Swan, Meldrum 1990, McIntosh, Vink et al. 1989).
However, no related therapeutic agents have made to the clinic for these indications.
Until today, very little progress has been made in the development of NMDAR
modulators. Still, most of the compounds, which had been shown to be effective in preclinical
studies, are unable to translate into therapeutic benefit in humans. One of the reasons for this
might be that the blockade of all NMDARs may cause undesired side effects such as
psychotomimetic effects. Also, these antagonists non-selectively block all NMDARs throughout
the brain both hyper-activated and normal functioning receptors in healthy brain areas. If we
could block only the over-activated NMDARs that are responsible for pathology, without having
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any effect at inactive receptors, or normal-functioning receptors, it should be possible to improve
the therapeutic benefit to side effect ratio. Also, as discussed before, there is hypoactivation of
NMDAR function in schizophrenia. Thus, selectively enhancing the activity of those NMDARs
responsible should be beneficial. Hence, a drug that acts at allosteric sites and targets a specific
NMDAR subunit should be beneficial for both of these scenarios and they should display fewer
side effects compared to the side effects from the use of channel blockers or competitive
antagonists. This type of drug would not only be an important agent in treating pathological
conditions, but also would serve as a valuable tool for experimental purposes. Recent progress in
NMDAR modulators has been reviewed (Monaghan, Irvine et al. 2012).

1.3.1

Positive allosteric modulators (PAMs) of NMDARs

Compounds that bind to an allosteric site and enhance NMDAR activity are called positive
allosteric modulators (PAMs) of NMDARs. Since these types of modulators often have an
increased therapeutic/toxicity ratio, interest in finding allosteric modulators is growing. Such
NMDAR PAMs may be helpful in treating schizophrenia where there is evidence of hypofunction
of these type of receptors (Olney, Newcomer et al. 1999).
Various NMDAR PAMs have been identified in the last few years. Different studies have
been conducted to identify the structural features required for potentiating activity and to identify
their binding sites. The pyrrolidone derivative PYD-106 is a GluN2C selective PAM, which binds
at the ATD/LBD interface of GluN2C-containing NMDARs (Khatri, Burger et al. 2014). PYD106 binds to the ATD and S1 domains of GluN2C receptors (Khatri, Burger et al. 2014). CIQ is
another PAM that acts at GluN2C/GluN2D-containing NMDARs (EC50 of 2.7 µM at GluN2C and
2.8 µM at GluN2D) (Mullasseril, Hansen et al. 2010) and Thr592 in the M1 region of GluN2D
and the linker region between LBD and NTD is critical for CIQ activity (Mullasseril, Hansen et
al. 2010). The helical segment before M1 in GluN2D subtypes of NMDAR is also critical for the
activity of CIQ (Ogden, Traynelis 2013). One structural modification of CIQ by replacing
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chlorine with the bromine, makes it more GluN2C- (EC50 = 90 nM) than GluN2D- preferring
(EC50 = 220 nM) (Santangelo Freel, Ogden et al. 2013). Similarly, GNE-6901 is a GluN2Aselective PAM which has an EC50 value of 330 nM (Hackos, Lupardus et al. 2016). However, it
also displays significant potentiating activity at GluN2D receptors as well. X-ray crystallography
shows that this compound binds at the GluN1/GluN2A dimer interface of the ligand binding
domains (LBDs) (Hackos, Lupardus et al. 2016). Other GluN2A-selective PAMs, such as GNE0723, with higher potency have also been identified (EC50 = 210 nM at GluN2A) (Volgraf, Sellers
et al. 2016).
Polyamines such as spermine and neurosteroids such as pregnenolone sulfate (PS) are
endogenous modulators of NMDAR. Spermine selectively potentiates GluN1/GluN2B receptors
with an EC50 of more than 100 µM (Benveniste, Mayer 1993, Traynelis, Hartley et al. 1995).
These compounds are thought to bind at the heterodimer interface of GluN1/GluN2B NTD and
by binding to the negatively charged amino acid residues in lower lobe. By binding at this
location, they appear to block the NTD clamshell closure thereby causing NMDAR current
potentiation (Mony, Zhu et al. 2011). Mutation of aspartate residue 669 in the extracellular loop
of heteromeric GluN1a reduces the potentiation by spermine and inhibition by protons and
ifenprodil (Kashiwagi, Fukuchi et al. 1996).
Recently, our group has identified a diverse series of NMDAR PAMs with a unique
pattern of subunit selectivity. Phenanthrene derivatives with a carboxylic acid group at the 3position have NMDAR current-enhancing activity. The UBP512 selectively potentiates the
GluN2A subtype of NMDARs but inhibits GluN2C and GluN2D-containing NMDARs.
Similarly, UBP710 potentiates GluN2A and GluN2B subtypes of NMDARs whereas it inhibits
GluN2C and GluN2D subtypes at higher doses. Naphthalene derivatives with a 2-position
carboxyl group also display NMDAR PAM activity. UBP551 selectively potentiates GluN2D
while inhibiting the other three subtypes of NMDARs (Costa, Irvine et al. 2010). This is the only
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known compound so far with selective GluN2D PAM activity. The mechanisms of action and
possible binding site for these compounds is a focus of our current studies. These compounds act
in a non-competitive and voltage-independent manner. We also observed that the S2 and S1
segments of ligand binding domain were important for subunit-specific potentiating and
inhibitory activity, respectively, and that the N-terminal domain is not required for either types of
NMDAR activity (Costa, Irvine et al. 2010). These compounds also do not bind to the channel
pore. Hence, a possible binding site for these compounds was predicted to be in LBD dimer
interface.
In this current project, we have characterized another series of 2-naphthoic acid
analogues as NMDAR PAMs and have identified compounds such as UBP684 and UBP753 with
greater PAM activity (greater % of maximal efficacy; EMax) at each of the four NMDAR
subtypes. The mechanisms of allosteric modulation and enhancement of NMDAR function by
these compounds are discussed in Chapter 4. Possible binding sites of NMDAR allosteric
modulators with both PAM and NAM activity, as well as of competitive antagonists and channel
blockers, are shown in Figure 1.3.
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Figure 1.3 Potential binding sites of NMDAR allosteric modulators, competitive antagonists
and channel blockers
Schematic diagram of GluN1/GluN2 dimer structure of NMDARs displaying known and predicted binding sites for
different NMDAR PAMs, NAMs, competitive antagonists and channel pore blockers.

1.3.2

Negative allosteric modulators (NAMs) of NMDARs

Although optimal activity of NMDAR is crucial for maintaining normal brain function,
hyperactivity of NMDAR function will lead to excitotoxicity. In such cases, drugs that inhibit
activated NMDARs would be therapeutically beneficial. Inhibitory modulators that bind to sites
other than orthosteric sites are called NMDAR negative allosteric modulators (NAMs). Since
NAMs do not bind to agonist binding site, which is highly conserved among NMDAR subunits, it
provides a high opportunity for getting subtype selectivity.
Compounds such as ifenprodil and ions such as protons and Zn2+ have long been known
for their allosteric inhibitory activity at NMDARs (Williams 1993, Traynelis, Cull-Candy 1990,
Traynelis, Hartley et al. 1995, Peters, Koh et al. 1987, Chen, Moshaver et al. 1997). Zn2+ inhibits
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only GluN2A-containing receptors in nano-molar concentration and inhibits both GluN2A- and
GluN2B-containing receptors in micromolar concentration (Paoletti, Perin-Dureau et al. 2000,
Low, Zheng et al. 2000, Rachline, Perin-Dureau et al. 2005). Ifenprodil selectively inhibits the
GluN2B-containing receptors.
Progress has been made in the last few years in the development of subunit selective and
more potent NMDAR NAMs. A quinazolin derivative QNZ46 allosterically inhibits GluN2C/2Dcontaining NMDARs (Mosley, Acker et al. 2010) and is believed to bind to the amino acid
residues located in ligand binding domain near the interface with TMD (Hansen, Traynelis 2011).
TCN201 and TCN213 are GluN2A specific NAMs which are believed to bind at the heterodimer
interface of both ligand binding domains (LBDs) of GluN1/GluN2A receptors (Bettini, Sava et al.
2010). TCN201 requires glycine for its activity but is a non-competitive NMDAR antagonist
(Edman, McKay et al. 2012). Similarly, DQP-1105 is a GluN2C/2D selective non-competitive
NAM (Acker, Yuan et al. 2011). The anti-inflammatory drug sulfasalazine (Noh, Gwag et al.
2006) and hydrophobic anion dipicrylamine (DPA) (Linsenbardt, Chisari et al. 2013) also have
non-competitive antagonistic action at NMDARs.
Our group has recently identified other NAMs with unique subunit selectivity. We
synthesized and characterized different coumarin and 2-naphthoic acid derivatives for their NAM
activity. A coumarin carboxylic acid derivative UBP608 inhibits GluN2A-containing receptors
with 23-times more selectivity compared with GluN2D-containing receptors (Costa, Irvine et al.
2010) and when substituted with methyl group at 4-position of naphthalene ring, it yielded a
allosteric potentiator (UBP 714) (Irvine, Costa et al. 2012). We also have identified naphthalene
derivatives such as UBP618 and UBP552 as general NMDAR NAMs with high potency (Costa,
Irvine et al. 2012).

26

New novel NAMs with higher GluN2C- and GluN2D- selectivity over GluN2A- and
GluN2B-containing NMDARs have been characterized which are described in the following
chapters. We selected one prototype compound, UBP792, from the series and studied the
mechanisms of its allosteric inhibition at recombinant NMDARs expressed in Xenopus laevis
oocytes as discussed in Chapter 5.

1.3.3

Allosteric modulation of NMDARs by neurosteroids

Neuroactive steroids have long been recognized as allosteric modulators of ionotropic glutamate
and GABA receptors. They can be synthesized endogenously in neural tissues and have sites of
action within the nervous system as well (Gibbs, Russek et al. 2006, Korinek, Kapras et al. 2011).
Endogenous neurosteroids such as pregnenolone sulfate (PS, 3β-hydroxypregn-5-en-20-onesulfate) and pregnanolone sulfate (PAS, 3α-hydroxy-5β-pregnan 20-one sulfate;3α5βS) are
important for maintaining the excitatory and inhibitory balance in central nervous system since
they exhibit both PAM and NAM activity at different receptors inside CNS.
Considerable interest has been shown on neurosteroids research (mainly PS and PAS)
focusing on their mechanisms of action and their in vivo effect after the discovery that PS
potentiated the NMDAR current in spinal cord neuron from chick embryos (Wu, Gibbs et al.
1991). PS inhibits non-NMDA glutamate receptors (AMPA, kainate), GABA-A, glycine and
nicotinic receptors. However, it was found to potentiate agonist-induced responses at neuronal
NMDARs (Wu, Gibbs et al. 1991) as well as GluN2A- and GluN2B-containing recombinant
NMDARs (Malayev, Gibbs et al. 2002, Horak, Vlcek et al. 2006). PS potentiates the glutamate
response at GluN2A- and GluN2B-containing receptors by five to eight fold compared to
GluN2C and 2D-containing receptors (Horak, Vlcek et al. 2006). The neurosteroid chemistry
determines the type of their activity (Kostakis, Smith et al. 2013). The inhibitory neuro-steroid
PAS, which inhibits all NMDAR subtypes, is 4-fold more potent at GluN2C- and GluN2D- than
at GluN2A- and GluN2B-containing NMDARs (Malayev, Gibbs et al. 2002).
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Potentiating activity of PS is dis-use dependent (Horak, Vlcek et al. 2004) (affinity is
higher in absence of agonist) while the inhibitory activity of PAS is use dependent (preapplication does not increase subsequent agonist response) (Petrovic, Sedlacek et al. 2005). PS
dissociates faster from its inhibitory binding site (Horak, Vlcek et al. 2004) than its potentiating
site (Horak, Vlcek et al. 2006). The mechanism of potentiation by PS is by increasing the peak
channel open probability (Popen) (Horak, Vlcek et al. 2004) and the activity is PKA dependent
(Petrovic, Sedlacek et al. 2009). The mechanism of NMDARs inhibition by PAS is by increasing
the mean time in closed state and promoting the desensitized conformations of active receptors
(Kussius, Kaur et al. 2009).
Different studies have tried to identify the possible binding site of PS and PAS at
NMDARs although the precise binding site location is unknown. The M3-M4 loop is important
for both potentiating and inhibitory action of PS (Horak, Vlcek et al. 2006). Another group
reported that the SMD1 region (J/K helices in S2 domain and the M4 domain) is critical for PS
potentiating activity (Jang, Mierke et al. 2004). Replacing this region in GluN2B with the
corresponding region from GluN2D changes the potentiating activity of PS to inhibitory. Since,
PS actions are voltage-independent and thus do not appear to bind within the receptor’s channel
pore (Malayev, Gibbs et al. 2002, Park-Chung, Wu et al. 1997). Also, PS does not compete with
spermine or arachidonic acid for potentiating activity (Park-Chung, Wu et al. 1997). The sites for
NAM and PAM activity of neurosteroids are also different. Point mutation (D813A/D815A) of
residues preceding M4 prevents PS potentiation but not PAS inhibition. A GluN2A-A651T point
mutation in SYTANLAAF at M3/S2 linker region reduces PAS inhibition but not PS potentiation
(Kostakis, Jang et al. 2011). These findings are consistent with previous findings from our
laboratory that replacing S2 domain in GluN2A with the S2 domain from GluN2C eliminated
UBP512 and UBP710 potentiation on GluN2A but did not change the UBP608 inhibition (Costa,
Irvine et al. 2010). The site of action of inhibitory neurosteroid PAS is located at extracellular
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vestibule of the receptor’s channel pore which is accessible only when the receptor is activated
(Vyklicky, Krausova et al. 2015).
Attempts have been made at synthesizing steroid analogues with greater potency than that
of PS. Kudova et al. synthesized a steroidal analogues that was more potent (IC50 = 90 nM) than
PS at NMDARs (Kudova, Chodounska et al. 2015). This compound crosses the blood brain
barrier (Rambousek, Bubenikova-Valesova et al. 2011) and reverses the excitotoxicity-induced
damage and cognitive deficits in an animal model of schizophrenia (Vales, Rambousek et al.
2012).

1.3.4

Allosteric modulation of NMDARs by protons
The pH in the brain is altered during pathological conditions such as ischemia or

schizophrenia. Acidification occurs in ischemia (Nemoto, Frinak 1981, Matsumoto, Obrenovitch
et al. 1990) and schizophrenia (Torrey, Barci et al. 2005, Prabakaran, Swatton et al. 2004, Lipska,
Deep-Soboslay et al. 2006, Halim, Lipska et al. 2008). Since the change in pH affects the activity
of NMDARs as well as the activity of drugs at those receptors, we sought to find out the effect of
different extracellular pH on the activity of UBP PAMs and NAMs, which are described in
Chapters 4 and 5 respectively.
Extracellular, but not the intracellular, protons inhibit NMDARs in a voltage-independent
and non-competitive manner (Traynelis, Cull-Candy 1990, Tang, Dichter et al. 1990) and this
might be an endogenous mechanism of protection from excitotoxic neuronal death during
ischemia as well as in other pathological conditions such as seizures which are characterized by
acidosis in extracellular environment. Proton inhibition depends upon the types of GluN1variants
as well as GluN2 subtypes. The GluN1-1b subunit (presence of exon-5) which has 21 extra amino
acid residues in N-terminal domain (Durand, Gregor et al. 1992) is less sensitive to the tonic
proton inhibition because those extra residues shield or cover the proton sensor site thereby
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decreasing the proton sensitivity and increasing the current follow through the receptor
(Traynelis, Hartley et al. 1995). Proton sensitivity is subunit dependent. The GluN2C subunit is
the least sensitive (IC50 = pH 6.2) while GluN2B and GluN2D subunits are the most sensitive to
protons inhibition (IC50 = pH 7.3) (Traynelis, Hartley et al. 1995). The linker region between M3
and S2 segment of glycine binding site on GluN1 and the linker region between M4 and S2
portion of glutamate binding site on GluN2 controls the pH sensitivity. A mutagenesis study
showed that a mutant mGluN1 (A649C)/GluN2A (A651C) receptor has 145-fold reduction in the
IC50 for protons compared to wild type receptors (Low, Lyuboslavsky et al. 2003).
Protons not only affect the NMDAR function but also affect the activity of NMDAR
modulators such as PS and spermine. Protons affect the PS activity in a subunit dependent
manner. The potentiating activity of PS at GluN2B-containing receptors is independent of pH and
independent of exon-5 (Jang, Mierke et al. 2004, Kostakis, Jang et al. 2011) while at GluN2A
receptors, it is pH dependent (Kostakis, Jang et al. 2011) and the PS potentiation is higher at
lower pH like that of spermine. The inhibitory effect of PS at GluN2D is pH dependent and
enhanced by exon-5 while at GluN2C, PS inhibition is pH independent (Kostakis, Jang et al.
2011). Similarly, the inhibitory activity of PAS is independent of both pH and exon-5. Besides
pH, Ca2+ also affects the potentiation by the PS at GluN2A receptors (Chopra, Monaghan et al.
2015).
There are multiple drug targets for both types of the NMDAR allosteric modulators.
There are very few available drugs like memantine which are effective in neurological disorders.
Hence, there is a need of NMDAR subunit specific modulators for different neurological
diseases. We are potentially interested in developing GluN2D-specific NMDAR potentiators for
treating schizophrenia or autism spectrum disorder. So, an initial goal of my dissertation research
is to evaluate the role of GluN2D-containing NMDARs in schizophrenia related neuronal
functions and to characterize a potent, subunit selective NMDAR PAM.
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1.4

Competitive antagonists of NMDARs

Competitive antagonists are the compounds that compete with endogenous ligands for binding at
orthosteric site. As discussed before, GluN1 has a binding site for glycine and GluN2 has a
binding site for L-glutamate. Since, four different genes encode for the GluN2 family, and GluN2
subunits confer different pharmacological and physiological properties to NMDARs, there is
great potential for pharmacological modulation and distinction among four different NMDAR
subunits (Monyer, Burnashev et al. 1994, Monyer, Sprengel 1992, Ishii, Moriyoshi et al. 1993,
Buller, Larson et al. 1994). Development of antagonists for blocking glutamate-induced
neurotransmission started after the discovery that compounds like α,ε-diaminopimelic acid, D-αaminodipate and HA-966 inhibit glutamate-induced responses in isolated spinal cord from frogs
and rat and mammalian spinal neurons (Evans, Francis et al. 1978, Biscoe, Evans et al. 1977).
Many NMDAR antagonists competing at the glutamate binding site have been developed
(Figure 1.4A). NMDAR antagonist activity was observed for compound (RS)-α-AA, which was
obtained by adding one extra carbon in the glutamate structure (Hall, McLennan et al. 1977).
Replacement of ω carboxy group of (R)-α-AA with a phosphonate group gave compound D-AP5
(Evans, Francis et al. 1982) (Figure 1.4A). More potent antagonists such as CGS19755 and CPP
were derived by incorporating the piperidine and piperazine rings to D-AP5 and D-AP7
respectively (Harris, Ganong et al. 1986, Davies, Evans et al. 1986). However, these glutamate
site antagonists show weak subunit selectivity and the pattern of antagonism by such antagonists
as CPP, D-AP5 and CGS-19755 was in the following order: GluN2A ˃ GluN2B ˃ GluN2C ˃
GluN2D (Feng, Morley et al. 2005, Feng, Tse et al. 2004). However, NVP-AAM077,
quinoxaline-2,3-dione derivative, displayed unusual selectivity for antagonism at GluN2Acontaining receptors (Auberson, Allgeier et al. 2002). It was 100-fold more selective for human
GluN2A- than GluN2B-containing NMDARs. However, in rodents, it is only 7-10 fold selective
for GluN2A over GluN2B-containing receptors (Feng, Morley et al. 2005). Another compound,
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PBPD, displayed higher affinity for GluN2B- and GluN2D-containing NMDARs (Buller,
Monaghan 1997) and the antagonist PPDA, a derivative of PBPD, showed higher affinities for
GluN2C and GluN2D and lowest affinity for GluN2A subunit-containing NMDARs (Feng, Tse et
al. 2004, Morley, Tse et al. 2005). UBP141 and UBP145, derived from the structural modification
of PPDA, although less potent than PPDA, displayed higher selectivity for GluN2D- and
GluN2C- than for GluN2B- and GluN2A-containing NMDARs (Morley, Tse et al. 2005, Costa,
Feng et al. 2009). There affinities were in the following order: GluN2D˃ GluN2C ˃GluN2B˃
GluN2A. Currently UBP141 and UBP145 are the most selective GluN2C/2D antagonists and
they are widely used in research. However, they display only weak selectivity. In an attempt to
develop even more potent and selective competitive antagonists, we have developed another
series of PPDA derivatives, which interact at the glutamate binding site; these results are
presented in Chapter 3.
Other competitive antagonists of NMDAR interact at the glycine binding site of the
GluN1 subunit (Figure 1.4B). The first identified glycine site competitive antagonist was
kynurenic acid (Watson, Hood et al. 1988). Modification of the kynurenic acid structure led to
other potent competitive antagonists such as 5,7-DCKA (Leeson, Baker et al. 1991). The subunit
selective photoaffinity label glycine site antagonist [3H]CGP 61594 was also developed. This
antagonist (CGP 61594) shows higher affinity for inhibition at GluN2B than at GluN2Acontaining NMDARs (Benke, Honer et al. 1999, Honer, Benke et al. 1998). TK-40 is another
glycine site antagonist with Kb values of 21- 63 nM at GluN1 glycine binding site of the four
subtypes (GluN2A-D) of NMDARs (Kvist, Steffensen et al. 2013). It is >100 fold selective for
GluN1/GluN2 receptors compared to GluN3A and GluN3B receptors.
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A.

B.

Figure 1.4 Chemical structures of known NMDAR competitive antagonists
(A) NMDAR antagonists interacting with the L-glutamate binding site on GluN2 subunit. (B) NMDAR antagonists
interacting with glycine binding site on the GluN1 subunit.
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Chapter 2 Evaluation of GluN2D as a potential target for treating
schizophrenia

This chapter includes the following published manuscript (Sapkota, Mao et al. 2016):
Sapkota, K; Mao, Z; Synowicki, P; Lieber, D; Liu, M; Ikezu, T; Gautam, V; Monaghan, D.
GluN2D N-methyl-D-aspartate subunit contribution to the stimulation of brain activity and
gamma oscillations by ketamine: implications for schizophrenia. Journal of Pharmacology and
Experimental Therapeutics.2016; 356:702-712.
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2.1

Abstract

The dissociative anesthetic ketamine elicits symptoms of schizophrenia at subanesthetic doses by
blocking N-methyl-D-aspartate receptors (NMDARs). This property led to a variety of studies
resulting in the now well-supported theory that hypofunction of NMDARs is responsible for
many of the symptoms of schizophrenia. However, the roles played by specific NMDAR subunits
in different symptom components are unknown. To evaluate the potential contribution of
GluN2D NMDAR subunits to antagonist-induced cortical activation and schizophrenia
symptoms, we determined the ability of ketamine to alter regional brain activity and gamma
frequency band neuronal oscillations in wildtype (WT) and GluN2D-knockout (GluN2D-KO)
mice. In WT mice, ketamine (30 mg/kg, i.p.) significantly increased [14C]-2-deoxy-glucose
([14C]-2DG) uptake in the medial prefrontal cortex (mPFC), entorhinal cortex (ERC) and other
brain regions, and decreased activity in somatosensory cortex (SSC) and inferior colliculus (IC).
In GluN2D-KO mice, however, ketamine did not significantly increase [14C]-2DG uptake in any
brain region examined, yet still decreased [14C]-2DG uptake in SSC and IC. Ketamine also
increased locomotor activity in WT mice but not in GluN2D-KO mice. In electrocorticographic
analysis, ketamine induced a 111 ± 16 % increase in cortical gamma-band oscillatory power in
WT mice, but only a 15 ± 12 % increase in GluN2D-KO mice. Consistent with GluN2D
involvement in schizophrenia-related neurological changes, GluN2D-KO mice displayed
impaired spatial memory acquisition and reduced parvalbumin (PV)-immunopositive staining
compared to control mice. These results suggest a critical role of GluN2D-containing NMDARs
in neuronal oscillations and ketamine's psychotomimetic, dissociative effects and hence suggests
a critical role for GluN2D subunits in cognition and perception.
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2.2

Introduction

The discovery that the N-methyl-D-aspartate receptor (NMDAR) antagonists ketamine and
phencyclidine (Anis, Berry et al. 1983) can mimic the symptoms of schizophrenia prompted
genetic, biochemical and pharmacological studies resulting in the NMDAR-hypofunction theory
of schizophrenia (Coyle, Tsai et al. 2003, Lisman, Coyle et al. 2008, Kantrowitz, Javitt 2010).
Pharmacological blockade of NMDAR in healthy humans elicits a spectrum of schizophrenia
symptoms and NMDAR blockade in laboratory animals and provides a model for schizophrenia
(Kantrowitz, Javitt 2010). Further support for the NMDAR hypofunction hypothesis comes from
the identification of many schizophrenia candidate genes that impair NMDAR function (Sun, Jia
et al. 2010, Balu, Coyle 2011, Greenwood, Light et al. 2012) and observations that decreasing
NMDAR levels in mice through genetic manipulations leads to schizophrenia-associated
symptoms (hyperlocomotor activity, impaired learning, reduced social interactions, and altered
neuronal oscillations) (Mohn, Gainetdinov et al. 1999, Halene, Ehrlichman et al. 2009).
Precisely how NMDAR blockade induces schizophrenia symptoms is unclear, but many
studies support the proposal that blockade of NMDARs in GABAergic interneurons containing
parvalbumin (PV) is responsible for the psychotomimetic actions of NMDAR antagonists
(Gonzalez-Burgos, Lewis 2008, Lisman, Coyle et al. 2008, Kantrowitz, Javitt 2010). Since PVinterneurons provide negative feedback to pyramidal neurons, inhibition of NMDAR in PV-cells
causes an excitation of pyramidal neurons by disinhibition and thus alters the
excitatory/inhibitory balance in cortical circuits (Li, Clark et al. 2002, Homayoun, Moghaddam
2007, Nakazawa, Zsiros et al. 2012). PV cell modulation also generates the gamma frequency
band neuronal network oscillations that are important for cortical processing, working memory
and perceptual integration (Sohal, Zhang et al. 2009, Yizhar, Fenno et al. 2011, Korotkova, Fuchs
et al. 2010). Thus, acute administration of ketamine or PCP enhances excitatory activity in
cortico-limbic structures and increases basal levels of gamma oscillations (Duncan, Miyamoto et
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al. 2000, Duncan, Miyamoto et al. 1999, Homayoun, Moghaddam 2007, Nakazawa, Zsiros et al.
2012, Hunt, Kasicki 2013, Kocsis, Brown et al. 2013). Accordingly, selective reduction of the
common GluN1 NMDAR subunit in PV-cells, increases basal gamma oscillations, decreases
NMDAR antagonist-induced gamma oscillations, and promotes schizophrenia-associated
behavioral symptoms (Belforte, Zsiros et al. 2009, Korotkova, Fuchs et al. 2010, Billingslea,
Tatard-Leitman et al. 2014, Carlen, Meletis et al. 2011). These effects could also be mediated by
PV-containing interneurons in the thalamic reticular nucleus (Frassoni, Bentivoglio et al. 1991,
Llinás, Urbano et al. 2005). In schizophrenia, NMDAR-hypofunction may thus disturb
excitatory/inhibitory balance thereby altering neuronal oscillations and disrupting cognitive
function (Lisman, Coyle et al. 2008, Kantrowitz, Javitt 2010, Uhlhaas, Singer 2013).
The roles played by NMDARs with different subunit combinations in cortical processing
and schizophrenia-related symptoms are unknown. Such information is necessary for resolving
individual pathophysiological components of schizophrenia and for defining appropriate
therapeutics. NMDARs are tetrameric complexes composed of two GluN1 subunits and two
subunits from among the GluN2A-D and GluN3A-B subunits (Ikeda, Nagasawa et al. 1992, Ishii,
Moriyoshi et al. 1993, Mishina, Mori et al. 1993, Monyer, Burnashev et al. 1994, Traynelis,
Wollmuth et al. 2010). Pharmacological studies in vivo have indicated a predominant role for
GluN2A subunits in NMDAR antagonist-induced neuronal oscillations (Kocsis 2012). However,
in vitro experiments suggest a greater role for GluN2B subunits (McNally, McCarley et al. 2011)
and the role of GluN2C and GluN2D subunits is unclear. We hypothesized that GluN2Dcontaining NMDARs may contribute to ketamine-induced schizophrenia symptoms since
GluN2D NMDAR subunits are localized in PV-containing GABAergic interneurons in cortex,
reticular nucleus of thalamus, and hippocampus (Monyer, Burnashev et al. 1994, Standaert,
Bernhard Landwehrmeyer et al. 1996, Yamasaki, Okada et al. 2014, Engelhardt, Bocklisch et al.
2015) and because ketamine has higher affinity for GluN2D-containing NMDARs than for
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NMDARs containing the more widely-expressed GluN2A and GluN2B subunits (Watanabe,
Inoue et al. 1992, Watanabe, Inoue et al. 1993b, Dravid, Erreger et al. 2007, Kotermanski,
Johnson 2009). GluN2D involvement in schizophrenia could potentially also be mediated by
altering neuronal-oligodendrocyte signaling (Fields 2008, Micu, Plemel et al. 2016). Thus, in the
present study, we sought to determine if ketamine-induced cortical activation and gamma
oscillations are reduced in GluN2D-KO mice.
The ketamine-induced increase in neuronal activity and gamma oscillations was
determined by [14C]-2DG uptake (reflecting neuronal activation) and by electrocorticography
(ECoG) in WT and GluN2D-KO mice. In addition, if GluN2D subunits do contribute to
schizophrenia symptoms, then drug-free GluN2D-KO mice may have behavioral defects and
reduced PV expression as seen in schizophrenia patients (Lisman, Coyle et al. 2008) and in
rodents after chronic NMDAR blockade (Abekawa, Ito et al. 2007, Behrens, Ali et al. 2007,
Benneyworth, Roseman et al. 2011). Consequently, we also evaluated spatial learning and PV
expression levels in untreated WT and GluN2D-KO mice. These findings demonstrate that
GluN2D-containing NMDARs are necessary for full neuronal activation induced by ketamine and
that GluN2D-hypofunction potentially contributes to schizophrenia symptoms.
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2.3
2.3.1

Materials and methods
Drugs

All chemicals were purchased from Sigma Aldrich Co. USA, unless otherwise specified.
Ketamine was purchased from Hospira, Inc., Lake Forest, IL and [14C]-2-deoxy glucose ([14C]2DG) was purchased from PerkinElmer, Boston, MA, USA.

2.3.2

Animals

GluN2D-KO mice (Ikeda, Araki et al. 1995) that had been backcrossed onto a C57BL/6
background to 99.9 % homogeneity (Hizue, Pang et al. 2005) were used for these studies. The
background strain was confirmed to be congenic with C57BL/6 (Charles River Laboratories
genetic testing service). Mouse genotype was confirmed by PCR followed by sequencing of the
reaction product and by Western blotting. Male C57BL/6 WT and GluN2D-KO mice 10-12
weeks of age were used for behavioral and 2-DG uptake studies; 10-15 week-old male mice were
used for ECoG studies. Mice were handled in accordance with University of Nebraska Medical
Center's Institutional Animal Care and Use Committee (IACUC) guidelines. In accordance with
these guidelines, efforts were made to minimize animal suffering and the number of animals used.

2.3.3

qRT-PCR for mRNA quantification

WT and GluN2D-KO mice were sacrificed after 2 h of treatment with 30 mg/kg of ketamine or
saline. Brains were isolated and 3 regions (two hemispheres, midbrain and cerebellum) were
separated and stored at - 80 oC. Total RNA was isolated using Trizol reagent using the standard
RNA isolation procedure and samples (1 µg/ml) were stored at -80 oC. Reverse transcription was
carried out for 1 µg of RNA with reagents from applied bio-system. Reverse transcription
reaction was carried out for cDNA preparation by running thermal cycler for 10 min at 25 oC, 40
min at 48 oC, 5 min at 95 oC followed by cooling at 4 oC. qPCR quantification of the cDNA
carried out by using Taqman reagents and the reaction was carried out in StepOnePlusTM RealTime PCR system (ThermoFisher scientific, USA). Relative gene expression was calculated by
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LIVAK method [fold change = 2 (-ΔΔCT)] (Livak, Schmittgen 2001) and data are expressed as fold
change compared to WT control.

2.3.4

2-Deoxy glucose uptake assay

Regional brain activity was determined by measuring [14C]-2DG uptake (Kennedy, Des Rosiers et
al. 1975) (Kennedy et al., 1975); as previously described (Kennedy, Des Rosiers et al. 1975,
Duncan, Miyamoto et al. 1999) with minimal modifications. Animals were injected with
ketamine (30 mg/kg, i.p.) or saline and then injected after 2 minutes with [14C]-2DG (0.16 µCi/g).
After another 15 minutes (i.e. 17 minutes after ketamine/saline injection), the mice were
decapitated under isofluorane anesthesthesia. Brains were isolated, rapidly frozen, and stored at 80 oC. Horizontal brain sections (20 µm) were thaw-mounted onto glass slides, and processed for
autoradiography along with 14C-standards (ARC146, American Radiolabelled Chemicals) using
KODAK BioMax MR film (Carestream Health Inc., New York, USA). Films were developed
after 1-2 weeks of exposure and analyzed by quantitative image analysis (MCIDTM system, St.
Catharines, Canada). Six to 8 brain sections were used for determining density for each brain
region studied in each brain. Brain region absolute values were normalized by average
radioactivity concentration of the whole corresponding section (Duncan, Miyamoto et al. 1999).

2.3.5

Electrocorticography (ECoG)

Wildtype and GluN2D-KO mice were surgically-implanted with tripolar electrodes (MS333/2,
Plastics One, Roanoke, VA, USA) under xylazine/ketamine/acepromazine anesthesia as required
by IACUC regulations. Two holes were made in the skull 3 mm posterior to bregma at 1 mm and
2.5 mm lateral. Two electrodes were placed in the medial hole onto the dura surface near the
retrosplenial cortex and the third electrode was placed in the lateral hole for ground. The
electrodes were secured to the skull as described elsewhere (Jeffrey, Lang et al. 2013). After 7
days of recovery, ECoG recordings were made with a DP-311 differential amplifier (Warner
Instruments) with high pass/low pass filters set at 0.1 and 300 Hz and digitized/recorded
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(Digidata 1400, pClamp 10, Molecular Devices). Following 30 minutes of baseline recordings,
animals were injected i.p. with ketamine or saline and recorded for the period between 5 and 30
minutes post-injection. Ketamine administration (i.p.) in mice has an approximately 5 minute lag
time and a peak ketamine response up to 30-45 minutes post-injection (Phillips, Cotel et al.
2012). In our initial studies, we found the peak response to be maintained through 20 minutes
with a minor decrement by 30 minutes, so care was taken to match the recording periods between
WT and GluN2D-KO mice. Power spectrum analysis was performed with Clampfit (Molecular
Devices) using a Hamming window with 50 % overlap. In preliminary experiments, we found
that the subanesthetic dose of 30 mg/kg i.p. gave a more robust augmentation of neuronal
oscillations than 5 mg/kg. Ketamine is typically used in the 5 - 50 mg/kg range in
electroencephalography experiments (Hunt, Kasicki 2013).

2.3.6

Open field test (OFT)

The floor of a plexiglass rectangular arena (40 x 30 cm) with 40 cm high walls was divided into
twelve squares using black tape. Animals were treated with ketamine (30 mg/kg; i. p.) or saline
and their behavior was video recorded for 15 minutes. The arena was cleaned and rinsed with 70
% ethanol between each animal. Video files were coded for blinded analysis of open-field line
crosses (defined as both rear paws crossing over a line marked on the floor) and the number of
entries into the 2 central squares. The number of rearings and wall-climbing attempts were also
counted.

2.3.7

Parvalbumin immunohistochemistry

Anesthetized mice were transcardially-perfused with phosphate buffer saline (PBS, pH 7.4)
followed by 4 % paraformaldehyde (PFA)/PBS. Brains were removed and post-fixed in 4 % PFA
for 24 hours at 4 oC and then cryoprotected with 30 % sucrose for another 24 hours. Brains were
snap frozen and kept at -80 oC until sectioned. Immunohistochemistry was carried out in every 5th
coronal cryostat sections (40 µm) using the free-floating method. Sections were treated with 4 %
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PFA for 15 minutes, rinsed (PBS) and treated with 3 % H2O2 for 30 minutes. After blocking with
10 % bovine serum (BS) with 0.3 % triton X-100, sections were incubated with primary antibody
(rabbit anti-PV, 1:10,000, Swant, Switzerland) for 48 hours at 4 oC. Sections were washed and
incubated with biotinylated secondary antibody (Goat anti-rabbit, 1:200, Vectors Lab,
Burlingame, CA, USA). After washing, sections were treated with ABC solution (Vectors Lab),
developed with 3,3'-diaminobenzidine, and coverslipped. Images were obtained by laser-scanning
microscopy and PV-positive cells were counted using NIH ImageJ software.

2.3.8

Spatial memory in the Morris water maze

Mice were given a 2-minute free swim test the day before the start of training. Then for 3
sequential days, mice were given 4 trials separated by 15 minutes on each day with a submerged
platform located in the same position for all trials. In the training trials, mice were allowed up to 1
minute to find the platform and guided to the platform if they had not already found the platform.
Mice then were allowed to stay on the platform for 15 seconds. Mice were placed in a different
start location at the beginning of each trial with visual cues on the walls of the testing chamber.
On day 4, the mice were tested with the platform removed (probe test). For each trial, we
determined the time required to reach the platform. For each probe test, the percent time spent in
the correct quadrant outside of the starting quadrant and the number of platform-site crossovers
were determined.

2.3.9

Statistical analysis

Prism 6 (GraphPad Software Inc., San Diego, CA, USA) was used for statistical analysis. For
most experiments, data were analyzed by two-way analysis of variance (ANOVA) with Sidak's
multiple comparison test to determine the difference among groups or student t-test as described
elsewhere. Difference was considered to be significant if p < 0.05.
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2.4
2.4.1

Results
Effect of ketamine on c-fos gene expression

C-fos is an early expressed gene and is regarded as a marker of neuronal activity. In order to see
the effect of ketamine on neuronal activity in different anatomical regions, we measured c-fos
mRNA by RT-qPCR. The mRNA expression was measured in 3 different areas of the brain (i)
two cerebral hemispheres and hippocampi (ii) thalamus, hypothalamus and brain stem and (iii)
cerebellum. In WT mouse, ketamine treatment significantly enhanced (p = 0.04, two-way
ANOVA) the c-fos mRNA expression in cortex/hippocampus (1.96 ± 0.5; n = 6) as compared to
saline treated control mice (1.13 ± 0.3; n = 5) (Figure 2.1). We did not observe any effect of
ketamine treatment on c-fos expression in cortex/hippocampus of GluN2D-KO mice (1.39 ± 0.1;
n = 4 for saline treated mice and 1.44 ± 0.3; n = 5 for ketamine treated mice). Similarly, there was
no significant change in c-fos mRNA expression in midbrain and cerebellum also. However,
although not significant, there was a reduced level of c-fos in cerebellum of GluN2D KO mice
and ketamine did not alter its level. Using this method, it is difficult to see the subtle change in cfos expression in a particular region of the brain since multiple brain regions were combined
together. Hence, in order to visualize the anatomical change in the specific brain region after
ketamine administration, we performed an autoradiographic 14C-2-deoxy glucose assay.
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Figure 2.1 Effect of ketamine on c-fos expression in different brain regions of WT and
GluN2D-KO mice
The alteration in c-fos gene expression by ketamine after 2 h was measured by RT-qPCR in the following brain regions
(A) cortex/hippocampus, (B) thalamus/hypothalamus (c) cerebellum. Tissue from four groups of mice [WT/saline (n =
5), WT/ketamine (n = 6), GluN2D-KO/saline (n = 4) and GluN2D-KO/ketamine (n = 5)] were analysed for mRNA
expression. The change in mRNA level is expressed as fold change compared to WT/saline group as a control (mean ±
S.E.M). *p ˂ 0.05

2.4.2

Effect of ketamine on regional brain activity as demonstrated by 2-DG uptake

Ketamine-induced regional changes in neuronal activation were measured by [14C]-2-DG uptake
quantitative autoradiography. Consistent with previous reports (Duncan, Miyamoto et al. 1999,
Miyamoto, Leipzig et al. 2000), ketamine (30 mg/kg) increased relative [14C]-2-DG uptake
(Figure 2.2) in several brain regions and reduced uptake in others. [14C]-2-DG uptake was
quantified in 11 brain regions and density differences were evaluated for statistical significance
(Figure 2.3). Two-way ANOVA between regions and animal groups indicated an interaction
effect [F (30, 314) = 6.00, p < 0.0001], a region effect [F (10, 314) = 33.6, p < 0.0001] and an
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animal group effect [F (3, 314) = 13.9, p < 0.0001]. In WT mice, ketamine increased relative
[14C]-2-DG uptake in medial prefrontal cortex (mPFC, 37 %, p < 0.0001), entorhinal cortex (34
%, p = 0.0006), presubiculum (39 %, p < 0.0001, and caudate putamen (21 %, p = 0.018), and
decreased relative uptake in inferior colliculus (26 %, p < 0.0001) and somatosensory cortex (23
%, p = 0.0008) (Figure 2.3). Also, as others have reported (Duncan et al., 1999), the whole
section, absolute levels of [14C]-2-DG uptake did not significantly change with ketamine
(WT/saline: 0.57 ± 0.06 nCi/mg tissue, n = 8, WT/ketamine: 0.52 ± 0.09, n = 9, p = 0.74;
KO/saline: 0.40 ± 0.04 nCi/mg, n = 7; KO/ketamine 0.33 ± 0.04, n = 9, p = 0.74). The
distribution of [14C]-2-DG uptake in GluN2D-KO mice following saline injection was similar to
that seen in saline-treated WT mice (Figure 2.2) and was not statistically different between
genotypes in any brain region (Figure 2.3). In contrast to WT mice, administration of ketamine
did not cause a relative increase in [14C]-2-DG uptake in any of the regions examined. Ketamine,
however, decreased [14C]-2-DG uptake in somatosensory cortex (15 %, p = 0.0005), inferior
colliculus (21 %, p < 0.0001), and thalamus (13 %, p = 0.0043).
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Figure 2.2 The effect of ketamine on [14C]-2-DG uptake in WT mice and GluN2D-KO mice
Representative autoradiographic images showing the effect of administering saline (left panels) and ketamine (right
panels; 30 mg/kg, i.p.) on [14C]-2-DG uptake in horizontal sections of WT (top panels) and GluN2D-KO (bottom panels)
mice. Red to blue color spectrum indicates high to low activity, respectively, as shown in the calibration bars.
Abbreviations: CP/CPu, caudate putamen; EC/Ent Ctx, entorhinal cortex; H/HC, hippocampus; P/Presub, presubiculum;
PFC medial prefrontal cortex; Rspl Ctx, retrosplenial cortex; SSC/Sens. Ctx., somatosensory cortex; and Th, thalamus.
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Figure 2.3 The effect of ketamine on [14C]-2-DG uptake in WT mice and GluN2D-KO mice
[14C]-2-DG uptake expressed as mean relative radioactivity concentration ± S.E.M, in WT and GluN2D-KO mice after
saline (Sal.) or ketamine (Ket) injections, n = 7 - 9 per group. Statistical significance is indicated by * (p < 0.05), ** (p <
0.01), *** (p < 0.001), and **** (p < 0.0001). Abbreviations: CP/CPu, caudate putamen; EC/Ent Ctx, entorhinal cortex;
H/HC, hippocampus; P/Presub, presubiculum; PFC medial prefrontal cortex; Rspl Ctx, retrosplenial cortex; SSC/Sens.
Ctx., somatosensory cortex; and Th, thalamus.
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2.4.3

Ketamine modulation of neuronal oscillations

ECoG recordings of awake, stationary WT mice (n = 8) displayed a typical awake ECoG trace
(Figure 2.4A). Power spectrum analysis revealed that ketamine administration increased gamma
frequency power (30 - 140 Hz) (Figure 2.4B,D) over baseline while ketamine in GluN2D-KO
mice (n = 9), elicited a relatively small increase in power in the gamma range (and increased
power between 140-170 Hz). As shown in Figure 2.4D, the two genotypes appeared different
between 60 Hz and 140 Hz, largely corresponding to high-frequency gamma oscillations as
defined by Colgin and colleagues (65-140 Hz) (Colgin, Denninger et al. 2009). Ketamine
increased high-gamma power more in WT mice (110.7 ± 16.4 %, Figure 2E) than in GluN2D-KO
mice (15.0 ± 11.6 %, p = 0.0002, two-tailed t-test). In GluN2D-KO mice, ketamine treatment was
associated with a peak of variable magnitude near 155 Hz while in ketamine-treated WT mice
there was a peak near 135 Hz (Figure 2.4D), also of variable magnitude but of consistent peak
frequency.
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Figure 2.4 The effect of ketamine on neuronal oscillations
(A) Electrocorticographic recordings in WT and GluN2D-KO mice before and after administration of ketamine.
Representative power spectrum analysis of WT (B) and GluN2D-KO mice (C) ECoG responses over 2 to 200 Hz before
(baseline) or after ketamine injection. (D) The average percent power increase induced by ketamine-injection as a
function of frequency in WT (blue line) and GluN2D-KO mice (red line), S.E.M is shown by light blue/red shading. The
dotted line represents 0 % increase, no drug-induced change in power. Results shown represent the mean value ± SEM
of WT and GluN2D-KO animals (n = 8 and 9, respectively). (E) Average ketamine-induced power increases in the upper
gamma frequency band for WT and GluN2D-KO mice. *** (p = 0.0002).
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2.4.4

Ketamine-induced motor activity

As measured in the open field test (OFT), ketamine (30 mg/kg, i.p.) increased locomotor activity
in WT mice during the 15 minutes following injection (Figure 2.5A,B). In the WT mice, the
average number of squares crossed after ketamine treatment was significantly greater (528.0 ±
62.3, n = 8) than after saline treatment (264.0 ± 43.4, n = 7, p = 0.0005). Ketamine did not
significantly induce hyper-locomotion in GluN2D-KO mice (squares crossed in the saline
condition: 171.4 ± 20.0, n = 7; ketamine: 222.7 ± 31.6, n = 10, p = 0.64). The two genotypes were
different in the ketamine condition (p < 0.0001) but not in the saline condition (p = 0.31). In the
open field test, avoidance of the central, open space can reflect anxiety levels in mice. The
number of times that WT mice entered the central squares was nearly doubled in ketamine-treated
mice than in the saline treated group (Figure 2.5C). Two-way ANOVA indicated significant
effects of genotype (p < 0.0001) and treatment (p = 0.0005) and multiple comparisons testing
(Sidak's) indicated a difference between saline and ketamine in the WT (p = 0.0006) but not in
the GluN2D-KO mice (p = 0.35). Thus, ketamine failed to significantly increase entries into the
central squares by GluN2D-KO mice in parallel with effects on locomotor activity. In contrast to
the blunting effect that eliminating GluN2D had on ketamine-induced hyper-locomotion,
ketamine fully reduced rearings and climbing attempts in both WT and GluN2D-KO mice (Figure
2.5).However, in the saline controls, GluN2D-KO mice had a significantly lower level of rearings
and climbing attempts than WT mice (p < 0.0001, p = 0.019, respectively, Sidak's
multicomparison test). The stereotypical behavior of walking in circles (rotations) was induced by
ketamine administration in both genotypes (Figure 2.5F), but was significantly greater (p =
0.0008, Sidak's multicomparison test) in WT (56.4 ± 12.8, n = 9) than in GluN2D-KO mice (14.4
± 3.0, n = 10).
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Figure 2.5 Reduced ketamine-induced locomotor behavior in the GluN2D-KO mouse
WT and GluN2D-KO mice (n = 7-10 per group) were treated with saline or ketamine and their motor behavior was
monitored for 15 minutes by the open-field test. Locomotor behavior was measured by the average number of grid lines
crossed in each of the 5-minute periods (A) or for the total period (B). Also measured were the number of entries into the
open, central squares of the arena (C), rearings (D), wall-climbing attempts (E) and walking in circles, rotations (F).
Results are represented as mean number ± S.E.M * p < 0.05; *** p < 0.001.
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2.4.5

Parvalbumin immunohistochemistry

The inability of the psychotomimetic agent ketamine to increase activation of the prefrontal
cortex and increase basal gamma oscillations in GluN2D-KO mice suggests that GluN2Dcontaining NMDARs contribute to psychotomimetic activity. If GluN2D subunit activity
contributes to the defects seen with NMDAR hypofunction, which is associated with a decreased
expression of parvalbumin (PV) in schizophrenia brain and in animal models following chronic
NMDAR blockade (Abekawa, Ito et al. 2007), then the expression of PV may be reduced in the
GluN2D-KO mouse. Two-way ANOVA of PV cell staining indicated an interaction effect
[F(5,36) = 2.865, p = 0.028], a genotype effect [F(1,36) = 19.5, p < 0.0001], and a region effect
[F(5,36) = 124.1, p < 0.0001] with multi-comparison testing indicating a significantly lower
density of PV-positive cells in the GluN2D-KO substantia nigra (p = 0.0038) and in the
basolateral/lateral amygdala (p = 0.0051) compared to WT mice (Figure 2.6). PV expression
levels were also lower in mPFC and hippocampus in the GluN2D-KO, but these decreases were
not statistically significant.
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Figure 2.6 Parvalbumin immunoreactivity in different brain regions of WT and GluN2DKO mice
(A) Photomicrographs are from representative coronal sections from WT (1st and 2nd columns) and GluN2D-KO mice
(3rd and 4th column) stained by PV-immunohistochemistry at low magnification (1st and 3rd columns). Images from the
boxes in the low-magnification photographs are shown at higher magnification in the adjacent column (2 nd and 4th
columns). Each row represents the brain region indicated on the left. Scale bars = 500 µm (1st photo) or 50 µm (2nd
photo) as indicated, arrows in 2nd photograph indicate representative PV-positive cells. (B) Histograms show the mean
density of PV-positive cells for each region ± S.E.M, ** p < 0.01, adjusted for multiple comparisons, n = 4 per group.
Abbreviations: BLA, basolateral/lateral amygdala; CPu, caudate putamen; dHC, dorsal hippocampus; PFC, medial
prefrontal cortex; SNR, substantia nigra reticulata; and vHC, ventral hippocampus.

54

2.4.6

Evaluation of disruption in spatial memory and sensory-motor gating

If elimination of GluN2D subunits reproduces some aspects of schizophrenia-related NMDAR
hypofunction, then GluN2D-KO mice may have defects in spatial memory acquisition, a function
disturbed in schizophrenia and related to cortical neuronal oscillations. During spatial learning
task acquisition, WT mice appeared to show greater improvement from trial to trial than did
GluN2D-KO mice (Figure 2.7A). Two-way ANOVA analysis indicated a significant effect of
trial [F(11,216) = 6.85, p < 0.0001] and genotype [F(11,216) = 7.95, p = 0.0053] on the observed
variation, with no significant interaction [F(11,216) = 0.68, p = 0.76] and no significant
difference for any of the 12 individual training trials. However, following the 12th training trial,
removal of the platform and measurement of the percent time spent in the correct quadrant of the
time spent outside of the starting quadrant, revealed significantly better performance (more time
in the correct quadrant) by the WT mice than the GluN2D-KO mice (Figure 2.7B, WT: 56.0 ± 6.0
%, n = 10, KO: 34.6 ± 3.5 %, n = 10, p = 0.0063, two-tailed t test). Similarly, WT mice crossed
the former position of the removed platform a greater number of times than did the KO mice
(Figure 2.7C, WT: 4.1 ± 0.7, n = 10, KO: 1.5 ± 0.5, n = 10, p = 0.010, two-tailed t test). Average
swimming speed was not different between WT and KO mice. Thus, GluN2D-KO mice have
impaired learning of the spatial memory task compared to WT mice.
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Figure 2.7 Spatial memory acquisition and prepulse inhibition in WT and GluN2D-KO mice
Spatial memory was tested in the Morris Water Maze with the time necessary to first reach the submerged platform
(Latency) measured for each successive trial (4 per day, 3 successive days) shown in (A). On the fourth day, the
submerged platform was removed and in the subsequent test trial, the % time spent in the correct quadrant outside of the
starting quadrant was measured (B) as was the number of times the mouse passed over the prior location of the removed
platform (C). Both test measures of task acquisition were statistically significant between WT and GluN2D-KO (n = 10
for each group, * p < 0.05; two-tailed t-test).
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2.5

Discussion

Evidence from a variety of genetic, biochemical, and pharmacological studies support the concept
that NMDAR hypofunction contributes to many of the diverse symptoms of schizophrenia (Coyle
2006, Lisman, Coyle et al. 2008, Kantrowitz, Javitt 2010). However, the relationships between
specific NMDAR subtypes and schizophrenia symptom components are not well understood.
Psychotomimetic agents, such as ketamine and PCP, produce many of the symptoms of
schizophrenia by modulating the neuronal systems known to underlie schizophrenia, for reviews
see (Lahti, Koffel et al. 1995, Javitt 2007, Lodge, Mercier 2015). Hence, resolving how these
agents act on specific NMDAR subtypes to produce psychotomimetic symptoms should help
define mechanisms of drug action as well as neurobiological mechanisms underlying
schizophrenia.
In this study, we found that GluN2D-KO mice had a greatly reduced activation of brain
activity in response to ketamine. Using [14C]-2-DG uptake to reflect regional brain metabolic
activity and the excitatory/inhibitory balance, we found that the characteristic increase in corticolimbic activation seen in rodents (Duncan, Miyamoto et al. 1999) and humans (Vollenweider,
Leenders et al. 1997) following ketamine administration, was not seen in GluN2D-KO mice. This
finding is consistent with the very recent report that ketamine-induced nitric oxide synthase
activation is dependent upon GluN2D subunits (Yamamoto, Nakayama et al. 2016). Since
GluN2D subunits are found in PV-containing GABAergic interneurons of cortex, hippocampus,
and thalamus (Standaert, Bernhard Landwehrmeyer et al. 1996, Yamasaki, Okada et al. 2014,
Engelhardt, Bocklisch et al. 2015), these results support the hypothesis that ketamine causes
cortico-limbic activation by disinhibiting PV interneurons. Interestingly, ketamine was still able
to decrease 2-DG uptake in somatosensory cortex and inferior colliculus in GluN2D-KO mice as
it does in WT mice (Figure 2.2, Figure 2.3). In contrast to these effects of GluN2D deletion, a
global reduction in GluN1 subunits blunts both the NMDAR antagonist-induced increase in 2-DG
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uptake in cortico-limbic regions as well as the antagonist-induced decrease in other brain regions
(Duncan, Miyamoto et al. 2002). Thus, GluN2D subunits contribute to an important subset of
ketamine's actions, excitatory disinhibition, but not to other effects of ketamine. The ketamineinduced reduction in 2-DG uptake in somatosensory cortex that persists in the GluN2D-KO
potentially reflects ketamine blockade of GluN2C-containing receptors in thalamic reticular
nucleus interneurons which would promote delta/theta oscillations and reduced activity in
somatosensory cortex via the specific thalamo-cortical projections (Llinás, Urbano et al. 2005,
Zhang, Llinas et al. 2009).
Our finding that GluN2D deletion reduces ketamine-induced gamma oscillations (Figure
2.4) suggests that GluN2D-containing NMDARs have an important role in modulating neuronal
network oscillations. This has significant implications for schizophrenia. Neuronal oscillations in
the gamma frequency band are thought to be integral to cognition and perception, and their
impairment has been proposed to underlie the symptoms of schizophrenia (Gonzalez-Burgos,
Lewis 2008, Uhlhaas, Singer 2013, Gonzalez-Burgos, Hashimoto et al. 2010). Since NMDARs in
PV-cells are important for the modulation of gamma oscillations (Carlen, Meletis et al. 2011,
Uhlhaas, Singer 2013), these results are also consistent with a key role of GluN2D subunits in
cortical PV cell function. In addition, GluN2D subunits in the thalamus are likely to contribute to
ketamine-induced dysrhythmias. Nucleus reuniens participates in circuits involved in
schizophrenia-related symptoms (prefrontal cortex, hippocampus, and ventral tegmentum)
(Lisman, Pi et al. 2010, Duan, Varela et al. 2015, Griffin 2015, Ito, Zhang et al. 2015) and is
enriched in GluN2D subunits (Watanabe, Inoue et al. 1993a, Buller, Larson et al. 1994).
Additionally, inhibition of NMDAR in the reticular nucleus, which contains GluN2D and
GluN2C subunits (Watanabe, Inoue et al. 1993a, Yamasaki, Okada et al. 2014), generates
telencephalic delta oscillations and potentially schizoprhenia-related symptoms (Zhang, Llinas et
al. 2009). Thus, GluN2D subunit-containing NMDARs may have an essential role in the
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pathophysiological expression of NMDAR hypofunction that underlies schizophrenia's cognitive
symptoms. This suggestion is consistent with studies associating genetic variants of GluN2D
subunits with schizophrenia risk (Makino, Shibata et al. 2005) and with reduced GluN2D
expression in schizophrenia (Sodhi, Simmons et al. 2011) and in an animal model of
schizophrenia (Bullock, Bolognani et al. 2009).
Ketamine also produced an increase in oscillations at frequencies corresponding to high
frequency oscillations (HFO) as previously reported (Hunt, Kasicki 2013). In GluN2D mice, the
ketamine-induced peak appeared at a higher frequency (~155 Hz) than in WT mice (~135 Hz).
Interestingly, other groups have reported a similar finding in the methylazoxymethanol acetate
neurodevelopmental model of schizophrenia. In both the nucleus accumbens (Goda, Olszewski et
al. 2015) and motor cortex (Phillips, Cotel et al. 2012), ketamine elicited HFO with a higher peak
frequency in the methylazoxymethanol-treated animals. The significance of this shift in peak
frequency is unclear, but it may be noteworthy that the atypical antipsychotics (Olszewski,
Piasecka et al. 2013) and glycine (Hunt, Olszewski et al. 2015) were found to reduce the peak
frequency of NMDAR antagonist-induced HFOs.GluN2D subunits may also have key roles in
other components of schizophrenia. Ikeda and colleagues (Hagino, Kasai et al. 2010) have shown
that the enhanced release of dopamine and hyperlocomotor activity occurring after PCP
administration is absent in GluN2D mice and thus GluN2D may be contributing to the positive
symptoms of schizophrenia (Hagino, Kasai et al. 2010). These findings are supported by the
reduction in ketamine-induced hyperlocomotor and rotation activity in GluN2D-KO mice (Figure
2.5) (Yamamoto, Nakayama et al. 2016). This action of PCP/ketamine may possibly be due to the
presence of GluN2D subunits in the ventral tegmental area/substantia nigra, basal ganglia, and/or
in the midline thalamic nuclei (Beaton, Stemsrud et al. 1992, Watanabe, Inoue et al. 1992, Buller,
Larson et al. 1994, Monyer, Burnashev et al. 1994).
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Other GluN2 NMDAR subunits also are likely to be involved in schizophrenia
pathophysiology. Genetic studies show a strong association of schizophrenia with both GluN2A
and GluN2B subunit genes (Allen, Bagade et al. 2008, Greenwood, Light et al. 2012). GluN2A
subunits have also been implicated by pharmacological studies of gamma oscillation modulation
in vivo (McNally, McCarley et al. 2011, Kocsis 2012) and PV-down-regulation (Kinney, Davis et
al. 2006). However, GluN2B-selective antagonists were found to better augment kainate-induced
gamma oscillations than a GluN2A-preferring antagonist (McNally, McCarley et al. 2011).
GluN2C involvement in schizophrenia is suggested by the finding that GluN2C transcript levels
are significantly reduced in schizophrenia patients (Weickert, Fung et al. 2013) and the presence
of working memory and fear acquisition defects in GluN2C-KO mice (Hillman, Gupta et al.
2011). A potential role of GluN2C subunits in schizophrenia is also suggested by GluN2C
expression in the reticular nucleus of the thalamus which modulates hippocampal delta
oscillations and thus may explain delta oscillatory changes seen in schizophrenia patients (Zhang,
Buonanno et al. 2012).
Schizophrenia and chronic blockade of NMDARs during development (Wang, McInnis
et al. 2001) are associated with an altered excitatory/inhibitory balance, reduced PV expression
and disturbed gamma oscillation modulation (Lisman, Coyle et al. 2008, Kantrowitz, Javitt 2010,
Uhlhaas, Singer 2013). If GluN2D-containing NMDARs contribute to the excitatory/inhibitory
balance during development then one might expect similar defects in the adult GluN2D-KO
mouse as seen in schizophrenia or following chronic NMDAR blockade. Consistent with this
possibility, untreated GluN2D-KO mice are associated with a reduced expression of PV in the
substantia nigra reticulata and amygdala (Figure 2.6) and a reduced performance in a spatial
memory task (Figure 2.7). The impact of PV levels in interneurons of the basolateral amygdala
and substantia nigra on oscillations is not yet known. However, if the trend in reduced PV
expression in other brain regions (Figure 4) is meaningful, these changes could potentially
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contribute to facilitated gamma oscillations and behavioral deficits (Vreugdenhil, Jefferys et al.
2003, Wöhr, Orduz et al. 2015).
GluN2D-KO mice may thus model some, but not all components of schizophrenia.
Reduction in prepulse-inhibition (PPI) is thought to be a sensitive measure in schizophrenia.
However, GluN2D-KO mice, have a robust PPI response (Takeuchi, Kiyama et al. 2001), a result
confirmed in our laboratory. Elimination of the PPI response appears to require actions at
multiple NMDARs. Knocking-out or knocking-down individual GluN2 subunits does not reduce
PPI (Takeuchi, Kiyama et al. 2001, Spooren, Mombereau et al. 2004), but combining
pharmacological inhibition of GluN2B-containing receptors in the GluN2A KO mouse (Spooren,
Mombereau et al. 2004), or knocking-down GluN1 subunits globally (Fradley, O’Meara et al.
2005), does reduce PPI. Reduction in PPI was also not seen following GluN1 ablation from PVcells (Korotkova, Fuchs et al. 2010), thus the NMDAR-associated neural substrate for impaired
PPI function appears distinct from the system modulating gamma oscillations through NMDARs
on PV-cells. Our results are thus consistent with the report that low doses of ketamine increases,
rather than decreases, PPI in humans (Abel, Allin et al. 2003).
In summary, the inability of the psychotomimetic agent ketamine to 1) increase metabolic
activation in cortico-limbic regions, 2) increase basal gamma oscillations, 3) increase locomotor
activity, and 4) increase stereotypical rotations in GluN2D-KO mice suggests that GluN2Dcontaining NMDARs contribute to the psychotomimetic activity of ketamine. We also find that
GluN2D elimination through development results in a partial down-regulation of PV similar to
that seen in schizophrenia and following chronic NMDAR blockade. Together, these results
suggest that GluN2D subunits might contribute significantly to the neuronal networks thought to
be pivotal in cognitive processing which are disrupted in schizophrenia. These findings suggest
that pharmacological augmentation of signaling mediated by GluN2D-containing NMDARs may
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be of therapeutic benefit in schizophrenia - a finding consistent with recent animal studies
(Suryavanshi, Ugale et al. 2014).
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Chapter 3 Structure activity relationship of NMDAR modulators
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3

Identification and structure activity relationships (SAR) of novel
NMDAR: 1) positive allosteric modulators (PAMs) 2) negative
allosteric modulators (NAMs) 3) competitive antagonists

3.1

Abstract

N-methyl-D aspartate receptors are ligand-gated ion channels which play important roles in
learning and memory. Excessive activity of NMDARs is thought to be involved in neuronal loss
in stroke and neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease
whereas hypoactivity of NMDARs contributes to schizophrenia. With the goal of developing new
NMDAR-related therapeutic agents, we measured the effect of novel test compounds on agonistinduced NMDAR responses. We identified efficacious NMDAR positive allosteric modulators
(PAMs), such as UBP684 and UBP753, which activated all NMDAR subtypes with similar
affinity. We also identified NMDAR negative allosteric modulators (NAMs), such as UBP792,
which inhibit GluN2D and GluN2C more than GluN2B and GluN2A receptors. Although the
PAMs were still not very potent, NAMs such as UBP792, UBP783 and UBP789 displayed an
IC50 in the range of 2-3 µM at GluN2D-containing receptors. We also characterized new PPDA
and UBP141 derivatives as competitive antagonists of NMDARs. The most subtype-selective
compound from the series was UBP791, which had a Ki value of 0.14 µM for GluN2D receptors
which was >100 fold lower than for GluN2A and 19-fold lower than for GluN2B receptors. This
now represents the most selective GluN2C/GluN2D competitive antagonist available.
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3.2

Introduction

Glutamate receptors mediate the majority of excitatory neurotransmission in the central nervous
system. NMDARs are a subtype of ionotropic glutamate receptors whose altered function appears
to contribute to various neurological disorders. Hyperactivity of NMDAR may lead to disorders
such as epilepsy and cell death in stroke and neurodegenerative disease. Their hypofunction may
lead to neuropsychiatric disorders such as schizophrenia. Since NMDAR function is very
important for normal functioning of the CNS, modulating their activity allosterically may be
therapeutically useful. Since, allosteric drugs bind to different sites other than the orthosteric sites
where transmitters bind, PAMs do not activate inactive NMDARs. They modulate the activity of
only activated NMDARs. Hence, such compounds as PAMs do not activate all NMDARs in the
brain and affect only the activity of activated receptors.
Our laboratory, in collaboration with Dr. David Jane’s laboratory at the University of
Bristol, is developing allosteric modulators for NMDARs. Some compounds decrease NMDAR
activity and they are called negative allosteric modulators (NAMs) of NMDARs. Other
compounds have the property to increase NMDAR activity and such compounds are called
positive allosteric modulators (PAMs) of NMDARs. Since, different NMDAR subunits have
differential contributions to different diseases, it may be beneficial to modulate the activity of
specific NMDAR subtypes.
Previously, our laboratory has reported coumarin, phenanthrene, and naphthalene based
compounds (Costa, Irvine et al. 2010, Irvine, Fang et al. 2015, Irvine, Costa et al. 2012, Costa,
Irvine et al. 2012) with both PAM and NAM activity. For example, UBP512, was a GluN2Aselective phenanthrene derivative PAM. UBP512 weakly potentiates GluN2A-, moderately
inhibits GluN2C- and GluN2D- and has no effect on GluN2B-containing NMDARs (Costa,
Irvine et al. 2010). Replacement of the iodine in UBP512 with a cyclopropyl group gives the
compound UBP710 with potentiating activity at GluN2A- and GluN2B-containing NMDARs and
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inhibitory activity at GluN2C- and GluN2D- containing NMDARs. UBP646 is another
phenanthrene derivative that potentiates all subtypes of NMDAR with slightly more preference
for GluN2D-containing receptors. UBP551 is a naphthalene derivative that selectively potentiates
GluN2D-containig NMDARs and inhibits the other three subtypes of NMDARs (Costa, Irvine et
al. 2010). UBP552 is another naphthalene derivative that non-specifically inhibits all NMDAR
subunits with IC50 of 3-7 µM at GluN2A-D-containing NMDARs. Replacement of the bromo
group of UBP552 with a phenyl ring yields even more potent NAM UBP618 with IC50 values
ranging from 1.8 to 2.4 µM at GluN2A-D receptors (Irvine, Costa et al. 2012). A structurallyrelated coumarin derivative, UBP608, also has NAM activity with relatively higher potency at
GluN2A subunit-containing receptors and least potency at GluN2D-containing NMDARs (Irvine,
Costa et al. 2012). A common structural feature of all these compounds is the position of the
carboxylate group. These compounds displayed higher activity when the carboxylate group was
at the 2-position on the naphthalene ring or the 3-position of the phenanthrene ring.
In our attempt to identify additional subunit-selective and potent compounds with PAM
or NAM activity, as well as competitive antagonists, we have designed analogues of previously
characterized naphthalene and phenanthrene derivatives. The main goals of this chapter are (i) to
identify compounds with better subunit selectivity, (ii) to find compounds with greater potency
and/or efficiency, (iii) to determine the structural requirements for subunit-selective PAM or
NAM activity, (v) to determine the structural requirements for improved subunit selectivity of
competitive antagonists. These goals are achieved by testing the effect of these compounds on
agonist-evoked NMDAR-mediated current using the two-electrode voltage clamp (TEVC)
electrophysiological assay on rat recombinant GluN1-1a/GluN2A-D subtypes of NMDARs
individually expressed on Xenopus laevis oocytes.
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3.3

Materials and methods

Frogs were handled in accordance with University of Nebraska Medical Center's Institutional
Animal Care and Use Committee (IACUC) guidelines. In accordance with these guidelines,
efforts were made to minimize animal suffering and the number of frogs used.

3.3.1

Compounds

All chemical compounds were synthesized at the University of Bristol and structures were
confirmed by 1H- and 13C-nuclear magnetic resonance (NMR) as well as mass spectroscopy
(Burnell, Fang, Irvine, Jane, unpublished data). All compounds had elemental analyses where the
determined percentage of C, H and N were less than 0.4 % different from theoretical values.
Details of synthesis will be provided elsewhere. All stock solutions were prepared in DMSO,
unless otherwise indicated, to a stock concentration of 50, 25, or 10 mM. For some compounds
such as UBP684, stock solution was prepared with 1 molar equivalent of NaOH. The working
solution was prepared in recording buffer just before the experiment. Other chemicals were
obtained from Sigma unless stated otherwise. Ketamine was purchased from Hospira, Inc., Lake
Forest, IL.

3.3.2

cDNA preparation

cDNA constructs encoding the rat NMDAR subunits was generously provided by Dr. Shigetada
Nakanishi, Kyoto, Japan (GluN1-1a), Dr. Peter Seeburg, Heidelburg, Germany (GluN2A,
GluN2C, and GluN2D) and Drs. Dolan Pritchett and David Lynch, Philadelphia, USA (GluN2B).
GluN1 and GluN2A constructs with two cysteines introduced at N499C and Q686C at GluN1
LBD (hereafter GluN1c) and at K487C and N687C in GluN2A LBD (hereafter GluN2Ac) were
kindly provided by Dr. Gabriela Popescu, University of Buffalo) (Kussius, Popescu 2010).
Plasmids containing NMDAR cDNA were extracted with the Qiagen plasmid mini kit
following manufacturer's procedure. Concentration and purity of cDNA was determined by a
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NanoDrop analyzer. cDNA was confirmed by restriction digestion and further purified by
sequencing by the UNMC DNA sequencing core facility.
200 µL of bacterial stock was again grown in 200 mL of LB broth medium for
propagation of cDNA. Bacteria were incubated in LB medium supplemented with 50 mg/mL
ampicillin at 37 oC for overnight under shaking condition (300 rpm/min). cDNA was extracted
using a Qiagen plasmid maxi kit following the manufacturer's instructions. Some of the bacterial
culture was cryopreserved at -80 oC in 25 % glycerol in LB medium for future use.

3.3.3

cRNA synthesis

Linearization: Plasmid DNA was first linearized with a restriction enzyme that cuts at a single
site at the 3’ end of the cDNA insert right after the stop codon. 100 µL digest reaction was carried
out at 37 oC for 2-4 h until the digestion was complete which was monitored by gel
electrophoresis. Gel electrophoresis was carried out by running 1 µL of DNA on 1 % agarose gel
at 80 V for 45 min – 1 h and DNA bands were visualized by UV transillumination of ethidium
bromide stained gel. For 10 µg of cDNA digestion, 3-5 µL of restriction enzyme, 10 µL of
NEBbuffer specific to the restriction enzyme, 1 µL of 100X BSA if not supplemented in the
buffer, and nuclease free water to bring the final volume to 100 µL was used.
Purification of linearized cDNA: After the completion of restriction digestion, 100 µL of nuclease
free water was added and mixed with 200 µL of chloroform:phenol:isoamylalcohol (25:24:1) and
centrifuged to separate the top aqueous layer. The aqueous layer was further extracted with an
equal volume of chloroform and 1/10 volume of 3 M sodium acetate and 2.2 volume of 100 %
ethanol were added. After chilling the aqueous layer at -20 oC for more than 30 minutes, it was
centrifuged in TOMY MTX-150 centrifuge at 15,000 rpm at 4 oC for 15 minute. The pellet was
washed with 75 % ethanol and air-dried. The pellet was then re-suspended in nuclease free water
by gentle pipetting and the concentration was determined with the NanoDrop analyzer.
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cRNA synthesis: cRNA was synthesized in vitro using mMESSAGE mMACHINE ultra kit
(Ambion, Austin, TX, USA) according to the manufacturer’s manual. Reagents were thawed,
vortexed, centrifuged and placed in ice before use. The reaction was run with 1 µg of linear
cDNA and other reagents provided in the kit in total volume of 20 µL. After incubating the
reaction mixture for 2 h at 37 oC, 1 µL of TURBO DNase was added and incubated for additional
15 minutes at 37 oC. The polyA tailing reaction was also carried out with the reagents provided in
the same kit to increase the stability of cRNA. Using the LiCl precipitation solution, the reaction
mixture was chilled at -20 oC for more than 1 h and centrifuged at 15000 rpm at 4 oC for 15
minutes. The resulting RNA pellet was washed with chilled 70 % ethanol to remove the
unincorporated nucleotides. For RNA verification, gel electrophoresis was carried out in 1 %
agarose with 1 % bleach (Aranda, LaJoie et al. 2012). Restriction enzymes used for linearization
of the DNA and promoters used for the RNA synthesis of each of the subunits are given in Table
3.1.

Table 3.1 Restriction enzymes used for cDNA linearization and RNA promoters used for in
vitro synthesis of cRNA
NMDAR Subunit
GluN1-1a
GluN2A
GluN2B
GluN2C
GluN2D
GluN1c
GluN2Ac

3.3.4

Plasmid
pBS
pCDM8
pRK5
pCDM8
pCDM8
pCDNA3
pCDNA3

Restriction enzyme
Not I
ECOR I
Sal I
Not I
Not I
Not I
Not I

RNA Promoter
T7
T7
SP6
T7
T7
T7
T7

Two-electrode voltage clamp (TEVC) assay

Two-electrode voltage clamp (TEVC) electrophysiology was performed as described previously
(Costa, Irvine et al. 2010). Oocytes (stage V – VI) from mature female Xenopus laevis (Xenopus
One, Ann Arbor, MI, USA) were removed and incubated overnight with 0.25 mg/mL of
collagenase (type I, Sigma, USA) at 17 OC. Oocytes were washed first with the Ca2+ free OR-2
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buffer [OR-2 (mM): NaCl (82.5), KCl (2.5), MgCl2 (1.0), HEPES (5.0), pH:7.6)] and then with
the ND-96 medium [ND-96 (mM): NaCl (96.0), KCl (2.0), CaCl2 (1.8), MgCl2 (1.0), HEPES
(5.0); pH 7.6; supplemented with sodium pyruvate (2.5 mM) and gentamycin (50 µg/mL)].
GluN1-1a and GluN2 cRNAs were mixed in a molar ratio of 1:1-3 and microinjected (50 nl, 1530 ng total) into the cytoplasm (vegetal pole) of healthy appearing oocytes (no pigmentation on
vegetal pole, uniform color of the animal pole, no clear demarcation between animal and vegetal
pole) to obtain the currents of about 100-500 nA. If currents were high, cDNAs were diluted with
nuclease free water. Oocytes were incubated in ND-96 solution at 17 °C prior to
electrophysiological assay (1-7 days).
Electrophysiological responses were measured using the TEVC assay using a Warner
Instruments (Hamden, CT, U.S.A.) model OC-725B Oocyte Clamp amplifier and a Digidata 1440
data acquisition system with pClamp 10 software (Molecular Devices, Sunnyvale, CA, USA).
The recording buffer contained (mM): NaCl (116), KCl (2), BaCl2 (0.3) and HEPES (5), EDTA
(0.005) or DTPA (0.01) with the pH was adjusted to 7.4. NMDAR-mediated current was recorded
by holding the membrane potential constant at – 60 mV. Steady-state NMDAR responses were
determined by bath application of 10 M L-glutamate plus 10 M glycine. Then the effects of
test compounds were determined by application of compounds in presence of agonists. In initial
screening studies, compounds were dissolved in recording buffer to a final concentration of 100
µM and applied by bath perfusion. Percent of potentiation or inhibition by the test compounds
was calculated for each oocyte by comparision to currents evoked by agonist alone. The activity
is presented as % potentiation (Y-axis value above zero) or % inhibition (Y-axis value below
zero) of agonist-evoked response. Concentration-response results were fit using GraphPad Prism
(ISI Software, San Diego, CA, U.S.A.).
Concentration-response curves were fit to a single site with variable slope and using nonlinear regression, EC50 value for PAM or IC50 value for NAM activity were calculated with Prism

70

(Prism 6, GraphPad Software Inc., San Diego, CA). Apparent Ki values of competitive
antagonists were calculated by the equation Ki= IC50/(1+([agonist]/EC50) (Yung-Chi, Prusoff
1973) which corrects for agonist affinity. For agonist affinities, we averaged values from the
literature (Costa, Feng et al. 2009). The L-glutamate Kd we used for the calulation of Ki were 2.92
µM for GluN2A, 1.93 µM for GluN2B, 1.11 µM for GluN2C, and 0.44 µM for GluN2D (Costa,
Feng et al. 2009).

3.3.5

Schild analysis

UBP791 inhibition was evaluated by Schild plot (Arunlakshana, Schild 1959). Concentrationresponse curves for glutamate in absence and presence of increasing concentrations of UBP791
were obtained. The EC50 value of the agonist was determined from the glutamate concentrationresponse curve in the absence of UBP791. Also, the EC50 was determined from concentrationresponse curves in the presence of increasing concentrations of UBP71. The dose ratio (DR) for
each concentration of UBP791was calculated by dividing the corresponding EC50’ by the agonistalone EC50. Then log (DR – 1) was plotted against the log [UBP791] and fitted by linear
regression analysis, to obtain slope and pA2 value (X-intercept). The slope is expected to = 1 for a
competitive antagonist at equilibrium. Schild’s equation is given by: log (DR – 1) = pA2 + log
[B], where DR is dose ratio, pA2 is a negative log of antagonist (UBP791) concentration that
produces a two-fold shift of the agonist EC50 and [B] is the concentration of antagonist.

3.3.6

Statistical analysis

Prism 6 (GraphPad Software Inc., San Diego, CA, USA) was used for statistical analysis. All
values are expressed as mean ± S.E.M. Concentration-response relationships were fit to a single
site with variable slope. EC50, IC50, percent of maximal efficacy (% EMax) and percent of maximal
inhibition (% IMax) values were calculated using a nonlinear regression analysis using prism.
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3.4
3.4.1

Results
Effect of alkyl side-chain length at the 6-position of 2-naphthoic acid on
NMDAR activity

Various analogues of 2-naphthoic acid with varying length of alkyl chain at the C-6 position of
the 2-naphthoic acid were characterized Figure 3.1. As the length of the side-chain increased,
compound activity switched from NAM to PAM. Compounds with a shorter alkyl side-chain
UBP762 and UBP763 were inhibitors. UBP762 with a 2-carbon side-chain inhibited the GluN2B
receptor the most (51.0 ± 12.0 %, n = 3). It also inhibited the response at GluN2A (28.2 ± 4.0 %,
n = 4), GluN2C (28.9 ± 17.8 %, n = 4), and GluN2D receptors (16.9 ± 8.1 %, n = 3). UBP765
which had 4-carbon alkyl chain showed potentiating activity at GluN2A receptors (26.7 ± 9.7 %,
n = 10) and had almost no effects at the other subtypes: weak potentiation at GluN2B (6.3 ± 7.4
%, n = 11), inhibition at GluN2C (8.0 ± 4.4 %, n = 7), and GluN2D receptors (4.8 ± 2.5 %, n =
8)). When an isohexyl group was substituted at the 6-position ring, it yielded a pan-PAM
compound, UBP684, which displayed a potentiating activity at each of the four NMDAR
subtypes. UBP684 is an analogue of the previously characterized potentiator, UBP646, in which
the unsubstituted ring C of the phenanthrene is removed. UBP684 potentiated GluN2A receptors
by 71.0 ± 5.6 % (n = 17), GluN2B receptors by 71.0 ± 9.4 % (n = 11), GluN2C receptors by 92.0
± 6.2 % (n = 22), and GluN2D receptors by 107 ± 15.6 % (n = 9) (Figure 3.1). UBP684
potentiated GluN2C- and GluN2D-containing receptors more than GluN2A- and GluN2Bcontaining receptors. Removal of the ring C from the phenanthrene nucleus of UBP647 (a
previously characterized PAM) led to the 2-naphthoic acid analogue UBP676 which also
potentiated GluN2A- and GluN2C-containing receptors to similar efficacy as the parent
compound UBP647. However, UBP676 displayed lower efficacy at GluN2D-containing receptors
and no activity at GluN2B-containing NMDARs (Figure 3.2). UBP692, which was obtained by
replacing the isohexyl sidechain of UBP684 with n-butylcyclopentane, displayed reduced
potentiating activity. However, it still showed a general PAM activity. UBP692 potentiated
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agonist-induced response at GluN2A receptors by 42.0 ± 6 % (n = 4), GluN2B receptors by 47.0
± 9.0 % (n = 4), GluN2C receptors by 71.0 ± 16.0 % (n = 4), and GluN2D receptors by 47.0 ±
16.0 % (n = 4) (Figure 3.4).
Although the maximal potentiation by UBP684 was higher, it was, 3-6-fold less potent
than the 9-n-pentyl phenanthrene derivative UBP647 at GluN2A-D receptors with an EC50 of
28.0-37.2 µM (Table 3.2, Figure 3.2B). However, UBP684 had similar potency to that of
UBP676 at GluN2A-containing receptors (Table 3.2, Figure 3.2).
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Figure 3.1 SAR studies to determine the effect of length of the alkyl side-chain at the 6position of naphthalene ring on NMDAR activity
(A) Structures of tested UBP compounds with different length of alkyl side-chains. (B) NMDAR activity of UBP
compounds (100 µM) was measured by TEVC assay at rat recombinant NMDARs (GluN1-1a/GluN2A-D) expressed in
Xenopus laevis oocytes. The effect of compound on agonist (L-glutamate and glycine, 10 µM each)-induced NMDAR
current was measured and expressed as % potentiation (mean ± S.E.M.) of agonist-induced response (positive value is %
potentiation and negative is % inhibition; n˃4).
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Figure 3.2 Concentration-response study of the potentiation of NMDAR responses by (A)
UBP676 and (B) UBP684
Select PAMs were tested for activity at increasing concentrations to determine their affinity and maximal efficacy at
different NMDAR subunits. Using the TEVC assay, the current produced by co-application of different concentrations
of the compounds and the agonists (10 µM of L-glutamate and 10 µM of glycine) at rat recombinant NMDARs (GluN11a/GluN2A-D) expressed in Xenopus laevis oocytes was measured and expressed as % potentiation (mean ± S.E.M)
above agonist-alone induced response (n ˃ 4).
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3.4.2

Effect of heteroatoms or methylene substitution of alkyl side-chain at 6position of 2-naphthoic acid on NMDAR activity

Another series of compounds were developed by incorporation of different heteroatoms like
nitrogen or oxygen or a methylene group into the isohexyl side-chain of UBP684. Replacing the
second CH2 group in the isohexyl sidechain of UBP684 with an oxygen (UBP742) or sulfur
(UBP741), making an ether or thioether, eliminated the potentiating activity of UBP684.
Incorporating the amide (UBP740), or ester (UBP748) in the isohexyl side-chain of UBP684
made them moderate inhibitors. Although inserting an ether group (UBP742) or a ketone group
(UBP751) eliminated the potentiating activity, incorporating an ester group into the isohexyl
chain close to the naphthalene ring (UBP744) resulted in a pan-potentiator with activity similar to
UBP684 at each of the NMDAR subtypes (Figure 3.3). Incorporation of a double bond into the
isohexyl chain of UBP684 led to compound UBP752, which showed more potent activity than its
parent compound UBP684. It potentiated all subtypes with more preference for GluN2B, GluN2C
and GluN2D receptors (EC50 values ranged from 26 to 161 µM, Table 3.2,). UBP752 potentiation
at GluN2A, GluN2B, GluN2C and GluN2D receptors was 63.0 ± 12.0 % (n = 16), 165.0 ± 29.0
% (n = 18), 249.0 ± 45.0 % (n = 19), 210.0 ± 49.0 % (n = 18) respectively (Figure 3.4B). From
this study, it appears that polar substitution on the alkyl side-chain are tolerated as in UBP744,
which could be beneficial in enhancing the hydrophilicity of these compounds. However, polar
group substitution on the alkyl chain reduced the potentiating activity by most of the tested
compounds. Methylene group addition at the 1-position of the alkyl chain reduced the affinity on
GluN2A and GluN2B but increased the efficacy (UBP752).
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Figure 3.3 SAR studies to determine the effect of heteroatom or methylene substitution to
the alkyl side-chain at 6-position of naphthalene ring on NMDAR activity
(A) Structures of UBP compounds with different heteroatom or methylene substitutions to the alkyl side-chain of
UBP684. (B) NMDAR activity of UBP compounds (100 µM) was measured by TEVC assay at rat recombinant
NMDARs (GluN1-1a/GluN2A-D) expressed in Xenopus laevis oocytes. The effect of compound on agonist-induced (Lglutamate and glycine, 10 µM each) NMDAR current was measured and expressed as % potentiation (mean ± S.E.M.)
of agonist-induced response (positive value is % potentiation and negative value is % inhibition; n ˃ 4).
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Figure 3.4 Concentration-response study on potentiation of NMDAR responses by (A)
UBP692 and (B) UBP752
Select PAMs were tested for activity at increasing concentrations to determine their affinity and maximal efficacy at
different NMDAR subunits. Using TEVC assay, the current produced by co-application of different concentrations of
test compound and agonists (10 µM of L-glutamate and 10 µM of glycine) at rat recombinant NMDARs (GluN11a/GluN2A-D) expressed in Xenopus laevis oocytes was measured and expressed as % potentiation (mean ± S.E.M)
above agonist-alone induced response (n ˃ 4).
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3.4.3

Effect of changing the position of carboxyl or hydroxyl groups on the
naphthalene ring of UBP684 on NMDAR activity

Adding a hydroxyl group to the 3-position of the naphthalene ring of UBP684 yielded the
compound UBP743 that displayed a general PAM activity increasing the response at each of the
NMDAR subtypes. This compound showed greater activity at GluN2B-D receptors compared to
that of UBP684. It potentiated GluN2A by 78.0 ± 30 % (n = 17), GluN2B by 208.7 ± 107.0 % (n
= 15), GluN2C by 257.0 ± 92.0 % (n = 17), and GluN2D by 201.0 ± 112.6 % (n = 16) (Figure
3.5). When the position of carboxyl and hydroxyl group of UBP743 were swapped, it yielded
compound UBP738 which displayed reduced potentiating activity at GluN2B, GluN2C and
GluN2D subtypes compared to UBP684 and showed weak inhibitory activity on GluN2A
receptors. Moving the carboxyl group from the 2-position to the 3-position of the naphthalene
ring of UBP684 yielded the compound UBP749 which showed dramatically reduced potentiating
activity at GluN2A, GluN2B and GluN2C receptors compared to UBP684 and weak inhibitory
activity at the GluN2D receptor. These results show that carboxyl group at 2-position of
naphthalene ring is very important for the potentiating activity of UBP684 analogues.
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Figure 3.5 SAR studies to determine the effect of changing the position of carboxyl and
hydroxyl group substitution at naphthalene ring on NMDAR activity
(A) Structures of tested UBP compounds with carboxylic and hydroxyl group substitution at the 2- and 3-positions on
the naphthalene ring of UBP684. (B) NMDAR activity of UBP compounds (100 µM) was measured by TEVC assay at
rat recombinant NMDARs (GluN1-1a/GluN2A-D) expressed in Xenopus laevis oocytes. The effect of compounds on
agonist-induced (L-glutamate and glycine, 10 µM each) NMDAR current was measured and expressed as % potentiation
(mean ± S.E.M.) of agonist-induced response (positive value is % potentiation and negative value is % inhibition; n˃4).

80

3.4.4

Effect of nitro, amino and halogen substitution at the 1- and 7-position of the
naphthalene ring of UBP684 on NMDAR activity

Another series of UBP684 analogues were synthesized by substitution at the 1- and 7-positions of
the naphthalene ring of UBP684 with nitro, amino, hydroxyl group or halogen atoms (Figure 3.6).
The compound retained potentiating activity when a hydroxyl group was substituted at the 1position (UBP767). UBP767 had similar activity on GluN2B and GluN2C as that of UBP684.
However, it exhibited reduced potentiating activity at GluN2A (9.7 ± 13.7 %, n = 3) and GluN2D
(20.0 ± 26.7 %, n = 3) receptors. Substitution at the 7-position of the naphthalene ring with a
halogen atom reduced or eliminated the potentiating activity of parent compound UBP684. Iodine
substitution at 7-position of the naphthalene ring (UBP770) was toleratede but the potentiation
was reduced. Substitution with bromine (UBP771) or chlorine (UBP772) at the 7-position of the
naphthalene ring completely eliminated the potentiating activity of the parent compound
UBP684. They exhibited a weak inhibitory activity at NMDARs. Substitution at the 1-position of
the naphthalene ring of UBP684 with a nitro group yielded UBP759, which displayed a strong
inhibitory effect on NMDAR activity instead of exhibiting the potentiating effect of its parent
compound (Figure 3.6). At 100 µM, UBP759 inhibited GluN2A receptors by 27.3 ± 10.3 % (n =
11), GluN2B receptors by 74.3 ± 5.2 %, (n = 9), GluN2C receptors by 86.0 ± 2.6 %, (n = 10) and
GluN2D receptors by 85.4 ± 2.6 % (n = 10). Substitution at the 7-position of the naphthalene ring
of UBP684 with an amino group yielded UBP768, which also converted the potentiator parent
compound into an inhibitor. UBP768 at 100 µM inhibited GluN2A receptors by 29.4 ± 4.0 % (n =
8), GluN2B receptors by 53.4 ± 3.7 %, (n = 9), GluN2C receptors by 76.5 ± 2.3 %, (n = 9) and
GluN2D receptors by 90.7 ± 2.0 % (n = 8). UBP774 was designed by combining the structural
features thought to be important for potentiating activity by compounds UBP684 and GNE
compounds. However, this hybrid compound did not display any potentiation at any of the
subunits of NMDARs at tested concentration.

81

Concentration-response studies were also performed to investigate the subunit selectivity,
affinity and maximal efficacy at each of the NMDAR subtypes. UBP759 and UBP768 showed
more inhibitory preference for GluN2D- and least preference for GluN2A-containing NMDARs
(Figure 3.7). Neither of the NAMs showed complete inhibition of the NMDAR responses at the
maximum tested concentration. However, UBP768 was 8-fold more potent at inhibiting the
GluN2D- than GluN2A-containing receptors. The IC50 for inhibition of NMDAR responses by
UBP768 was 66 µM at GluN2A- and 8 µM at GluN2D-containing receptors (Table 3.4). The IC50
for inhibition by UBP759 at GluN2A-, GluN2B-, GluN2C-, and GluN2D-containing receptors
was ˃ 100, 30.9 ± 5.3, 19.9 ± 2.7 and 17.4 ± 2.7 µM respectively. This tells us that substitution at
the 3- and 7-position of the naphthalene ring of UBP684 with an electronegative group is not
tolerated for potentiating activity. However, this information might be helpful in designing the
GluN2D-selective NAMs.
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Figure 3.6 SAR studies to determine the effect of nitro, amino and halogen substitution at
the 1- and 7-position of the naphthalene ring on NMDAR activity
(A) Structures of tested UBP compounds with nitro, amino and halogen substitution on the naphthalene ring of UBP684.
(B) NMDAR activity of UBP compounds (100 µM) was measured by TEVC assay at rat recombinant NMDARs (GluN11a/GluN2A-D) expressed in Xenopus laevis oocytes. The effect of compound on agonist-induced (L-glutamate and
glycine,10 µM each) NMDAR current was measured and expressed as % potentiation (mean ± S.E.M.) of agonistinduced response (positive value is % potentiation and negative value is % inhibition; n˃4).
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Figure 3.7 Concentration-response study on inhibition of NMDAR current by (A) UBP759
and (B) UBP768
Select NAMs were tested for activity at increasing concentrations to determine their affinity and maximal inhibition at
NMDARs (GluN1-1a/GluN2A-D) expressed in Xenopus laevis oocytes. Using TEVC assay, the inhibition of agonistevoked (10 µM of L-glutamate and 10 µM of glycine) current by co-application of different concentrations of compounds
and agonist was measured and expressed as % NMDAR response (mean ± S.E.M) considering agonist-alone induced
response as 100 % (n ˃ 4).
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3.4.5

Effect of substitution at the 6-position on the alkyl/alkene side-chain of 2naphthoic acid of UBP684

Addition of a double bond to the 1-position of the isohexyl side-chain of UBP684 gave the
compound UBP727 which displayed comparable activity to that of parent compound and
UBP744, which had an ester group close to the naphthalene ring. UBP727, at 100 µM,
potentiated GluN2A receptors by 35.0 ± 11.3 % (n = 4), GluN2B receptors by 52.0 ± 9.3 %, (n =
5), GluN2C receptors by164.2 ± 41.3 %, (n = 5), and GluN2D receptors by 120.0 ± 39.2 % (n =
5) (Figure 3.8). When the end methyl group of the isohexyl chain of UBP727 was replaced with
carboxyl group, it yielded compound UBP729 that led to elimination of the potentiating activity.
When a CH2COOH group replaced the methyl group at the R1 position of side-chain of UBP727
to yield UBP756, it also eliminated the potentiating activity. UBP756 showed moderate inhibitory
activity on GluN2A-, GluN2B- and GluN2D-containing NMDARs and no activity on GluN2C
receptors. Substitution at R1position (Figure 3.8, Formula B) of the isohexyl side-chain of
UBP684 with a methyl group gave UBP753 which potentiated all GluN2 subtypes with a similar
potency (EC50 values ranged from 25.0 to 39.4 µM across all NMDAR subtypes (Table 3.2) to
that of UBP684 and showed even higher maximal potentiation compared to UBP684 (Figure 3.8).
UBP753 at 100 µM potentiated GluN2A receptors by 181.0 ± 41.9 % (n = 17), GluN2B receptors
by 124.7 ± 25.3 %, (n = 20), GluN2C receptors by 237.1 ± 54.8 %, (n = 21) and GluN2D
receptors by 217.5 ± 36.8 % (n = 19) (Figure 3.8). Adding a carboxylic acid at the R2 position of
the isohexyl side-chain of UBP684 (Figure 3.8, Formula B) gave UBP757 which showed a weak
potentiating activity at GluN2C-, no activity at GluN2A- and weak inhibitory activity at GluN2Band GluN2D-containing NMDARs. However, the substitution with a CH2SH group at the R3
position of n-pentyl side-chain of structure B (UBP766, Figure 3.8) was tolerated for potentiating
activity. UBP766 exhibited comparable potentiating activity as that of UBP684 as shown in
Figure 3.8. UBP766, at 100 µM, potentiated GluN2A receptors by 81.5 ± 15.1 % (n = 5),
GluN2B receptors by 73.4 ± 10.3 %, (n = 4), GluN2C receptors by 42.0 ± 2.8 %, (n = 3) and
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GluN2D receptors by 43.1 ± 9.5 % (n = 4). When ring A of the UBP684 naphthalene ring was
replaced with cyclohexane, it gave compound UBP764 which at 100 µM showed a moderate
potentiating activity at GluN2A (60.6 ± 8.8 %, n = 4) and a weak potentiating activity at GluN2B
(5.2 ± 7.3 %, n = 4), GluN2C (12.0 ± 2.8 %, n = 4) and GluN2D-contining receptors (16.4 ± 6.1
%, n = 4) (Figure 3.8).
Concentration-response studies were performed for UBP753 and UBP764 (Figure 3.9).
UBP753 potentiated all subtypes with almost equal affinity (EC50 values was ranged from ~ 3040 µM across all subtypes, Figure 3.9, Table 3.2). Although UBP764 was not efficacious,
concentration-response study shows that it potentiates GluN2A receptors more than GluN2B
receptors and does not potentiate GluN2C- and GluN2D-containing receptors. (Figure 3.9).
The results from this series of compounds shows that the addition of a double bond or
substitution with a methyl group at 1-position of isohexyl side-chain is tolerated for potentiating
activity. However, substitution with a carboxyl group in the isohexyl side-chain of UBP684 is not
tolerated for potentiating activity. Substitution with a carboxyl group on the isohexyl chain either
eliminates the potentiating activity or converts the compound from a potentiator to an inhibitor.
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Figure 3.8 SAR studies to determine the effect of substitution of the alkyl and alkene sidechain at the 6-position of the naphthalene ring on NMDAR activity
(A) Structures of test UBP compounds with different substitutions on the alkyl and alkene side-chain at C-6 position of
the naphthalene ring. (B) NMDAR activity of UBP compounds (100 µM) was measured by TEVC assay at rat
recombinant NMDARs (GluN1-1a/GluN2A-D) expressed in Xenopus laevis oocytes. The effect of compound on agonistinduced (L-glutamate and glycine, 10 µM each) NMDAR current was measured and expressed as % potentiation (mean
± S.E.M.) of agonist-induced response (positive value is % potentiation and negative value is % inhibition; n ˃ 4).
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Figure 3.9 Concentration-response study of the potentiation of NMDAR responses by (A)
UBP753 and (B) UBP764
Select PAMs were tested for activity at increasing concentrations to determine their affinity and maximal efficacy at
different NMDAR subunits. Using TEVC assay, the current produced by co-application of different concentrations of
the compound and the agonists (10 µM of L-glutamate and 10 µM of glycine) at rat recombinant NMDARs (GluN11a/GluN2A-D) expressed in Xenopus laevis oocytes was measured and expressed as % potentiation (mean ± S.E.M)
above agonist-alone induced response (n ˃ 4).

88

3.4.6

Effect of replacement of naphthalene ring of UBP684 with heterocyclic ring
on modulation of NMDAR activity

Derivatives of UBP684 with different heterocyclic structures were also tested for their NMDAR
activity (Figure 3.10). When ring A of UBP684 was replaced with pyridine, it gave compound
UBP750 which at 100 µM exhibited a moderate inhibitory activity at GluN2B- (20.3 ± 12.3 %, n
= 8), GluN2C (40.0 ± 10.1 %, n = 11), and GluN2D-containing receptors (46.4 ± 8.8 %, n = 9),
and displayed no activity at GluN2A receptors (1.0 ± 8.0 %, n = 8). When naphthalene ring B of
UBP684 was replaced with imidazole, oxazole or thiazole, it yielded compounds UBP734,
UBP754 and UBP755 respectively. Although UBP734 retained weak potentiating activity,
compounds UBP754 and UBP755 were inhibitors with moderate activity (Figure 3.10). When
naphthalene ring A was replaced with pyridine-2-one, it gave UBP747 which moderately
inhibited GluN2B, GluN2C and GluN2D receptors and did not have any activity at GluN2Acontaining NMDARs. Similarly, when ring B of naphthalene of UBP684 was replaced with
pyrrole-2,5-dione, it gave compound UBP745. UBP745 displayed no NMDAR modulatory
activity at GluN2A receptors (2.8 ± 9.2 %, n = 9), weak inhibitory activity at GluN2C (18.3 ± 5.2
%, n = 8) and GluN2D receptors (10.3 ± 7.7 %, n = 5), and moderate inhibitory activity at
GluN2B receptors (48.8 ± 8.8 %, n = 11). Hence, insertion of electronegative heteroatoms in the
naphthalene ring, or replacement with different heterocyclic ring, was not tolerated for the
potentiating activity.
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Figure 3.10 Heterocyclic analogues of UBP684
(A) Structures of test compounds with different modifications at ring A and ring B of the naphthalene ring of UBP684.
(B) NMDAR activity of UBP compounds (100 µM) was measured by TEVC assay at rat recombinant NMDARs (GluN11a/GluN2A-D) expressed in Xenopus laevis oocytes. The effect of the compounds on agonist-induced (L-glutamate and
glycine, 10 µM each) NMDAR current was measured and expressed as % potentiation (mean ± S.E.M.) of agonistinduced response (positive value is % potentiation and negative value is % inhibition; n ˃ 4). (Note: UBP734 was
screened by Georgia Culley, Ph.D.).
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3.4.7

Phenanthrene analogues of UBP684
Different analogues of UBP684 were also synthesized by adding a ring C to the

naphthalene ring. When an aromatic ring was added to the naphthalene ring of UBP684, it
yielded UBP646 which potentiated all four subtypes of NMDARs as parent compound UBP684.
Other 9-substituted 3-carboxyphenanthrenes were also characterized. UBP646 at 100 µM
potentiated GluN2A, GluN2B, GluN2C and GluN2D receptors by 131 ±10 %, 134 ± 8 %, 122 ±
8 %, and 124 ± 4 % respectively. When the isohexyl side-chain at 9-position of UBP646 was
replaced with n-butyl, n-pentyl, it gave UBP709 and UBP647 (Figure 3.11). Both of these
compounds showed potentiating activity at each of the four NMDAR subtypes. However,
potentiation by UBP709 at GluN2A and GluN2B was higher than that at GluN2C and GluN2D
receptors. UBP709 at 100 µM potentiated GluN2A, GluN2B, GluN2C and GluN2D receptors by
58.3 ± 8.3 % (n = 6), 47.9 ± 11.0 % (n = 5), 8.3 ± 1.8 % (n = 4), and 12.3 ± 1.7 % (n = 4)
respectively. Potentiation by UBP647 was 25.1 ± 5.7 % (n = 4), 34.8 ± 4.1 % (n = 3), 35.0 ± 7.6
% (n = 4), and 42.8 ± 10.3 % (n = 4) at GluN2A, GluN2B, GluN2C and GluN2D receptors
respectively. Interestingly, UBP798, which was obtained by 9-substitution with
difluorocyclopropyl group, displayed PAM activity at GluN2A- and GluN2B receptors whereas a
NAM activity at GluN2C- and GluN2D-containing NMDARs (Figure 3.11). Substitution at the 7position of the 3-phenanthroic acid led to a reduction in PAM activity as shown by UBP785.
Concentration-response study of UBP709 showed that it potentiates the 10 µM agonistinduced NMDAR response at GluN2A and GluN2B receptors more than at GluN2C- and
GluN2D-containing receptors (Figure 3.12). Although not highly potent, the selectivity of
UBP709 was better than UBP647 (Table 3.2). Unlike UBP709, UBP647 potentiated GluN2B-D
subunits with almost equal selectivity and potentiated GluN2A receptors with least preference
(Figure 3.12). It is important for the drug to be active at high agonist concentration because there
is a release of high concentrations of L-glutamate during neurotransmission. When we performed
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the concentration-response study of UBP709 in high agonist concentration, the potentiating
activity at GluN2A receptors was not affected but it was reduced at GluN2B-containing receptors.
The potentiation at GluN2D-containing receptors was increased at higher agonist concentration
compared to the potentiation obtained at lower agonist concentration (Figure 3.13). When we
studied UBP709 concentration-response with different concentrations of both of the agonists at
GluN2B-containing NMDARs, we found that the potentiation was especially reduced when we
used a higher concentration of L-glutamate (Figure 3.13).
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Figure 3.11 SAR studies of phenanthrene 3-carboxylic acid analogues with position-9
substitution on the phenanthrene ring on NMDAR activity
(A) Structural analogues of phenanthrene 3-carboxylic acid with position-9 substitution on the phenanthrene ring. (B)
NMDAR activity of UBP compounds (100 µM) was measured by TEVC assay at rat recombinant NMDARs (GluN11a/GluN2A-D) expressed in Xenopus laevis oocytes. The effect of compound on agonist-induced (L-glutamate and
glycine, 10 µM each) NMDAR current was measured and expressed as % potentiation (mean ± S.E.M.) of agonistinduced response (positive value is % potentiation and negative value is % inhibition; n˃4). (Note: UBP646 was screened
by Blaise Costa, Ph.D.).
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Figure 3.12 Concentration-response study of the potentiation of NMDAR responses by (A)
UBP647 and (B) UBP709
Select PAMs were tested for activity at increasing concentrations to determine their affinity and maximal efficacy at
different NMDAR subtypes. Using the TEVC assay, the current produced by co-application of increasing concentrations
of test compounds and agonists (10 µM L-glutamate and 10 µM glycine) at rat recombinant NMDARs (GluN11a/GluN2A-D) expressed in Xenopus laevis oocytes was measured and expressed as % potentiation above responses
induced by agonist-alone (mean ± S.E.M; n ˃ 4).
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Figure 3.13 UBP709 potentiation of NMDAR currents evoked by different concentrations of
agonists
(A) UBP709 was tested for activity at increasing concentrations to determine its affinity and maximal efficacy at rat
recombinant NMDARs (GluN1-1a/GluN2A-D) expressed in Xenopus laevis. Using the TEVC assay, the current induced
by co-application of different concentrations of the compound and the agonists (300 µM L-glutamate and 300 µM
glycine) was measured and expressed as % potentiation (mean ± S.E.M) above agonist-alone induced response (n ˃ 4).
(B) Effect of increasing concentrations of UBP709 at GluN1-1a/GluN2B-containing NMDARs on agonist-induced (10
µM L-glutamate and 10 µM glycine) current was also measured (n ˃ 4).
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Table 3.2 EC50 (µM, n ≥ 4) values for potentiation of GluN1/GluN2 NMDAR subtypesa
Compounds
UBP647
UBP676
UBP684
UBP684b
UBP692
UBP752
UBP753
UBP709
UBP709b
aEC
50

GluN2A
8.2 ± 4.3
(34.5 ± 10.7)
26.7 ± 5.6
(39.0 ± 5.9)
28.0 ± 4.6
(68.6 ± 16.2)
10.3 ± 4.8
(50.3 ± 14.1)
7.5 ± 2.8
(38.4 ± 4.7)
114.4 ± 7.2
(230.4 ± 84.6)
39.4 ± 27.5
(277.2 ± 36.8)
34.9 ± 5.2
(73.9 ± 26.7)
45.5 ± 29.1
(65.1 ± 28.0)

GluN2B
9.4 ± 0.1
(34.6 ± 3.9)
ND
34.6 ± 3
(102.0 ± 17.8)
24.8 ± 2.8
(61.5 ± 4.2)
27.0 ± 6.3
(61.9 ± 10.9)
116.4 ± 19.8
(416.6 ± 70.9)
25.0 ± 11.6
(192.3 ± 46.6)
29.5 ± 3.5
(50.4 ± 14.6)
32.6 ± 1.8
(32.4 ± 36.3)

GluN2C
5.8 ± 5.1
(35.0 ± 5.6)
113 ± 66
(42.7 ± 16.1)
37.2 ± 2.8
(117.2 ± 22.3)
33.8 ± 9.7
(108.2 ± 37.9)
22.4 ± 3.6
(105.3 ± 26.1)
26.1 ± 4.5
(136.6 ± 11.6)
36.2 ± 5.7
(262.6 ± 33.9)
30.2 ± 3.4
(1.0 ± 2.2)
ND

GluN2D
11.8 ± 5.9
(44.9 ± 10.0)
61 ± 33
(17.3 ± 16.2)
28.9 ± 4.1
(88.4 ± 9.6)
55.8 ± 4.1
(119.3 ± 37.9)
34.7 ± 10.3
(65.6 ± 18.4)
72.3 ± 15.5
(277.2 ± 36.8)
30.6 ± 7.5
(240.3 ± 63.6)
24.3 ± 1.9
(13.1 ± 1.5)
41.6 ± 21.2
(43.5 ± 10.2)

values (mean ± S.E.M.) for the potentiation of GluN1/GluN2 NMDAR responses. Values in parentheses are the

maximal potentiation values expressed as a percentage (± S.E.M.) above the agonist-alone response (L-glutamate, 10 µM
and glycine, 10 µM). ND = not determined
bHigher

concentration of agonists was used (L-glutamate, 300 µM and glycine, 300 µM).
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3.4.8

Effect of styryl group substitution at the 7-position of 2-naphthoic acid on
NMDAR activity

Substitution at 7-position of 2-naphthoic acid with a styryl group led to compounds such as
UBP718 (Figure 3.14), which displayed strong inhibitory activity at each of the four NMDAR
subtypes. UBP718 (100 µM) inhibited GluN2A, GluN2B, GluN2C and GluN2D receptors by
67.3 ± 3.8 % (n = 6), 92.7 ± 1.6 % (n = 5), 78.3 ± 0.7 % (n = 4) and 89.0 ± 3.3 % (n = 6)
respectively. When the 3-position hydroxyl group of UBP718 was replaced with a carboxyl
group, it gave UBP758, which displayed a moderate inhibitory activity at each of the NMDAR
subtypes and the NAM activity was highly reduced especially at GluN2B-containing NMDARs.
When a carboxyl group was substituted at the ortho-, meta- and para-positions of the styryl ring,
it led to compounds UBP793, UBP794 and UBP723 all of which exhibited weak inhibitory
activities at all GluN2 subtypes of NMDAR compared to its parent compound UBP718 (Figure
3.14). Replacement of naphthalene ring A of UBP718 with pyran-2-one led to UBP788, which
showed a weak potentiating activity on GluN2C and GluN2D receptors and almost no effect on
GluN2A- and GluN2B-containing receptors. This shows that naphthalene ring is critical for
inhibitory activity of styryl analogues.
We also performed a concentration-response study for UBP718 which inhibited GluN2B
and GluN2D receptors with higher potency than GluN2A and GluN2C receptors (Figure 3.15). Its
IC50 for inhibition was 18 µM for GluN2A, 8 µM for GluN2B and GluN2D and 14 µM for
GluN2C and maximal inhibition was > 83 % at each of the four NMDAR subtypes (Table 3.3).
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Figure 3.14 SAR studies to determine the effect of styryl group substitution at the 7-position
of 2-naphthoic acid on NMDAR activity
(A) Structures of test UBP compounds with styryl group substitution at C-7 of 2-naphthoic acid. (B) NMDAR activity
of UBP compounds (100 µM) was measured by TEVC at rat recombinant NMDARs (GluN1-1a/GluN2A-D) expressed
in Xenopus laevis oocytes. The effect of compound on agonist-induced (L-glutamate and glycine,10 µM each) NMDAR
current was measured and expressed as % potentiation (mean ± S.E.M.) of agonist-induced response (positive value is %
potentiation and negative value is % inhibition; n ˃ 4). (Note: UBP723 was screened by Georgia Culley, Ph.D.)
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Figure 3.15 Concentration-response for inhibition of NMDAR responses by UBP718
UBP718 was tested for activity at increasing concentrations to determine its affinity and maximal inhibition at NMDARs
(GluN1-1a/GluN2A-D) expressed in Xenopus laevis oocytes. Using the TEVC assay, the inhibition of agonist-evoked
(10 µM of L-glutamate and 10 µM of glycine) current by co-application of increasing concentrations of test compound
and the 10 µM agonists was measured. Data are expressed as % of control NMDAR response (mean ± S.E.M; n ˃ 4).
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3.4.9

Effect of nitro and methoxy group substitution on the aromatic ring of the 7position styryl group of 3-hydroxy 2-naphthoic acid on NMDAR activity

Since, the compounds with 7-styryl substitution exhibited strong NMDAR inhibitory activity,
other analogues were developed by nitro and methoxy group substitution at ortho-, para- and
meta-position of the styryl aromatic ring in UBP718 (Figure 3.16). Nitro group substitution at the
ortho-position of the styryl ring of UBP718 led to compound UBP792 which, at 100 µM, strongly
inhibited GluN2C (65.0 ± 3.2 %, n = 12) and GluN2D receptors (73.1 ± 3.4 %, n = 14),
moderately inhibited GluN2B receptors (43.9 ± 7.8 %, n = 11) and weakly inhibited GluN2A
receptors (19.5 ± 4.7 %, n = 25) (Figure 3.16). Nitro group substitution at the meta- and parapositions of the styryl aromatic ring of UBP718 yielded compounds UBP783 and UBP789 which
also inhibited all NMDAR subtypes at 100 µM (Figure 3.16).
The subunit selectivity for UBP792 inhibition was in the following order: GluN2D ˃
GluN2C ˃ GluN2B ˃ GluN2A (Figure 3.17). It inhibited GluN2D- and GluN2C-containing
receptors with an IC50 value of 3 and 8 µM respectively and inhibited 80 % of the agonistinduced NMDAR current (Table 3.3). UBP783 inhibited GluN2B, GluN2C, and GluN2D with
equal efficacy (Figure 3.17). Methoxy substitution at the ortho-position of the styryl ring of
UBP718 yielded compound UBP780 which showed weak inhibitory activity. However, when the
methoxy group was substituted at the meta-position, it (UBP782) retained the inhibitory activity
of UBP718 and inhibited GluN2B-D subtypes with equal preference and GluN2A receptors with
least preference (Figure 3.18). From this series of compounds, it shows that o-nitro is important
for subunit selectivity and o-methoxy substitution reduces the inhibitory activity. All of these
derivatives showed strong inhibitory preference for GluN2D subunits compared to other subunits
of NMDARs.
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Figure 3.16 SAR studies to determine the effect of nitro and methoxy group substitution on
the aromatic ring of the 7-position styryl group of 3-hydroxy 2-naphthoic acid on NMDAR
activity
(A) Structures of test UBP compounds with ortho-, meta-, para-substitution of nitro and methoxy groups on the styryl
ring. (B) NMDAR activity of UBP compounds (100 µM) was measured by TEVC assay at rat recombinant NMDARs
(GluN1-1a/GluN2A-D) expressed in Xenopus laevis oocytes. The effect of test compounds on agonist-induced (Lglutamate and glycine, 10 µM each) NMDAR current was measured and expressed as % potentiation (mean ± S.E.M.)
above control (agonist-alone) response (positive value is % potentiation and negative value is % inhibition; n ˃ 4).
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Figure 3.17 Concentration-response study of the inhibition of NMDAR responses by (A)
UBP792 and (B) UBP783
Select NAMs were tested for their affinity and maximal inhibition at NMDARs (GluN1-1a/GluN2A-D) expressed in
Xenopus laevis oocytes. Using the TEVC assay, the inhibition of agonist-evoked (10 µM of L-glutamate and 10 µM of
glycine) current by co-application of increasing concentrations of the test compounds and the 10 µM agonists was
measured and expressed as % of control NMDAR responses (mean ± S.E.M; n ˃ 4).
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Figure 3.18 Concentration-response study of the inhibition of NMDAR responses by (A)
UBP789 and (B) UBP782
Select NAMs were tested for their affinity and maximal inhibition at NMDARs (GluN1-1a/GluN2A-D) expressed in
Xenopus laevis oocytes. Using the TEVC assay, the inhibition of agonist-evoked (10 µM of L-glutamate and 10 µM of
glycine) current by co-application of increasing concentrations of the test compounds and the 10 µM of agonists was
measured and expressed as % of control NMDAR responses (mean ± S.E.M; n ˃ 4).
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Table 3.3 IC50 (µM, n ≥ 4) values of NAMs for inhibition of GluN1/GluN2 NMDAR subtypesa
Compounds
UBP759
UBP768
UBP718
UBP782
UBP792
UBP789
UBP783
aIC
50

GluN2A
˃ 100
(38.3 ± 30.0)
65.9 ± 15.6
(43.2 ± 7.1)
17.8 ± 4.6
(83.2 ± 11.4)
ND
6.0 ± 4.1
(30.5 ± 6.3)
5.8 ± 1.1
(54.1 ± 5.5)
9.7 ± 3.8
(49.7 ± 6.8)

GluN2B
30.9 ± 5.3
(87.6 ± 8.8)
(32.7 ± 7.4)
(72.4 ± 9.8)
7.5 ± 2.0
(93.9 ± 7.3)
11.0 ± 4.2
(81.2 ± 5.7)
32.2 ± 16.0
(61.3 ± 18.1)
11.1 ± 2.9
(48.4± 6.0)
9.2 ± 5.3
(66.3 ± 5.2)

GluN2C
19.9 ± 2.7
(112.0 ± 5.5)
20.7 ± 6.2
(89.1 ± 8.0)
13.8 ± 3.3
(86.3 ± 4.7)
14.6 ± 2.2
(78.7 ± 5.8)
8.2 ± 1.2
(80.1 ± 4.1)
6.5 ± 2.8
(55.9 ± 3.9)
7.9 ± 4.2
(74.4 ± 6.9)

GluN2D
17.4 ± 2.7
(101.2 ± 4.2)
8.2 ± 1.4
(91.1 ± 7.2)
8.6 ± 1.9
(93.6 ± 4.2)
5.4 ± 2.2
(71.6 ± 4.8)
2.9 ± 0.4
(79.7 ± 2.8)
2.9 ± 0.3
72.3 ± 2.1)
1.4 ± 0.4
(70.0 ± 4.6)

values (mean ± S.E.M.) for the inhibition of GluN1/GluN2 NMDAR responses. Values in parentheses are the

maximal percentage inhibition values (± S.E.M.) of agonist-induced response (L-glutamate, 10 µM and glycine, 10 µM).
ND = not determined.
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3.4.10

SAR studies of PPDA and UBP141 derivatives

In an effort to develop improved subunit-selective competitive antagonists of NMDARs, a new
series of compounds were made based on previously published compounds (Morley, Tse et al.
2005, Costa, Feng et al. 2009) (2R*, 3S*)-1-(Phenanthrenyl-2-carbonyl)piperazine-2,3dicarboxylic acid (PPDA) and (2R*,3S*)-1-(Phenanthrenyl-3-carbonyl)piperazine-2,3dicarboxylic acid (UBP141) (Figure 3.19). UBP791 was a structural analogue of PPDA in which
propionic acid was substituted at the 7-position of the phenanthrene moiety. Both of these
compounds were more selective at GluN2C- and GluN2D- than at GluN2A- and GluN2Bcontaining NMDARs than any known competitive antagonist (Figure 3.20). Inhibitory activity of
UBP791 at 100 µM was 59.1 ± 1.5 % (n = 5) at GluN2A-, 92.3 ± 1.7 % (n = 4) at GluN2B-, 99.7
± 0.1 % (n = 4) at GluN2C-, and 99.0 ± 0.8 % (n = 4) at GluN2D-containing NMDARs. Different
UBP141 analogues were also prepared by substitution of different groups at the 9-position of the
phenanthrene ring. Both ethyl (UBP784) and cyclopropyl group (UBP786) substitution led to
strong inhibition of GluN2C- and GluN2D-containing receptors while moderately inhibiting
GluN2A- and GluN2B-containing receptors (Figure 3.19). Although propionic acid substitution at
the 7-position of PPDA (UBP791) gave strong inhibition as well as GluN2C/GluN2D selectivity,
the propionic acid substitution at the 9-position of the phenanthrene ring of UBP 141, which
yielded compound UBP790, greatly reduced the inhibitory activity at each of the four NMDAR
subtypes. When the 9-position of the phenanthrene ring of UBP141 was substituted with –
SCH(CH3)2, it yielded compound UBP796 which showed moderate inhibitory activity at GluN2A
(41.0 ± 2.9 %, n = 7) and GluN2B (57.2 ± 1.7 %, n = 7) and strong inhibitory activity at GluN2C
(67.8 ± 1.5 %, n = 8) and GluN2D receptors (81.5 ± 1.8 %, n = 7) (Figure 3.19). Interestingly, the
9-position substitution with -SO2CH(CH3)2 led to compound UBP797 which displayed
significantly reduced inhibitory activity at GluN2B- (5.8 ± 7.2 %, n = 7), GluN2C- (15.2 ± 3.5 %,
n = 4) and GluN2D-containing receptors (26.9 ± 3.0 %, n = 4). However, it exhibited strong
inhibition at GluN2A receptors (75.2 ± 3.6 %, n = 9). UBP799 (9-position of UBP141 substituted
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with difluorocyclopropyl), strongly inhibited all NMDAR subtypes. UBP799 inhibited GluN2A
receptors by 84.4 ± 3.2 % (n = 4), GluN2B receptors by 64.2 ± 2.7 % (n = 4), GluN2C receptors
by 92.7 ± 0.1 % (n = 3), and GluN2D receptors by 92.2 ± 1.7 % (n = 4).
We performed a concentration-response study of UBP791 (Figure 3.20); the calculated Ki
values for inhibition at GluN2A-, GluN2B- GluN2C- and GluN2D-containing NMDARs were 19
µM, 2.7 µM, 0.1 µM, and 1.14 µM respectively (Table 3.5). UBP786, UBP799 and UBP796 also
inhibit GluN2C- and GluN2D- more than GluN2A- and GluN2B-containing receptors (Figure
3.21, Figure 3.22). Interestingly, higher concentrations of UBP797 showed strong inhibition at
GluN2A receptors while displaying a weak inhibition at other subtypes (Figure 3.22). This was
the only compound in this series displaying GluN2A subtype selectivity. Most of the other
compounds in the series exhibited GluN2C- and GluN2D-subtype selectivity.
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Figure 3.19 SAR studies of (2R*, 3S*)-1-(Phenanthrenyl-2-carbonyl)piperazine-2,3dicarboxylic acid (PPDA) and (2R*,3S*)-1-(Phenanthrenyl-3-carbonyl)piperazine-2,3dicarboxylic acid (UBP141) analogues at NMDARs
(A) Structural analogues of UBP141 and 145 synthesized by substitution with different groups at the C-9 position of the
phenanthrene ring. (B) NMDAR activity of UBP compounds (100 µM) was measured by TEVC assay at rat recombinant
NMDARs (GluN1-1a/GluN2A-D) expressed in Xenopus laevis oocytes. The effect of compound on agonist (L-glutamate
and glycine, 10 µM each)-induced NMDAR current was measured and expressed as % potentiation (mean ± S.E.M.) of
agonist-induced response (positive value is % potentiation and negative value is % inhibition; n˃4).

107

A.

140
G lu N 2 A

G lu N 2 B

G lu N 2 C

G lu N 2 D

R e s p o n s e (% c o n tr o l)

120

100

80

60

40

20

0
- 7 .0

- 6 .5

- 6 .0

- 5 .5

- 5 .0

- 4 .5

- 4 .0

- 3 .5

- 3 .0

lo g [U B P 7 8 4 ] M

B.

120

G lu N 2 A

G lu N 2 B

G lu N 2 C

G lu N 2 D

R e s p o n s e (% c o n tr o l)

100

80

60

40

20

0
- 7 .5 - 7 .0 - 6 .5 - 6 .0 - 5 .5 - 5 .0 - 4 .5 - 4 .0 - 3 .5 - 3 .0 - 2 .5
lo g [U B P 7 9 1 ] M

Figure 3.20 Concentration-response study of the inhibition of NMDAR responses by (A)
UBP784 and (B) UBP791
Select NMDAR antagonists were tested for their affinity and maximal inhibition at NMDARs (GluN1-1a/GluN2A-D)
expressed in Xenopus laevis oocytes. Using the TEVC assay, the inhibition of agonist-evoked (10 µM of L-glutamate
and 10 µM of glycine) current by co-application of increasing concentrations of the test compounds and the 10 µM of
agonists was measured and expressed as % of control NMDAR responses (mean ± S.E.M; n ˃ 4).
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Figure 3.21 Concentration-response study of the inhibition of NMDAR responses by (A)
UBP786 and (B) UBP799
Select NMDAR antagonists were tested for their affinity and maximal inhibition at NMDARs (GluN1-1a/GluN2A-D)
expressed in Xenopus laevis oocytes. Using the TEVC assay, the inhibition of agonist-evoked (10 µM of L-glutamate
and 10 µM of glycine) current by co-application of increasing concentrations of the test compounds and the 10 µM of
agonists was measured and expressed as % of control NMDAR responses (mean ± S.E.M; n ˃ 4).
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Figure 3.22 Concentration-response study of the inhibition of NMDAR responses by (A)
UBP796 and (B) UBP797
Select NMDAR antagonists were tested for their affinity and maximal inhibition at NMDARs (GluN1-1a/GluN2A-D)
expressed in Xenopus laevis oocytes. Using the TEVC assay, the inhibition of agonist-evoked (10 µM of L-glutamate
and 10 µM of glycine) current by co-application of increasing concentrations of the test compounds and the 10 µM of
agonists was measured and expressed as % of control NMDAR responses (mean ± S.E.M; n ˃ 4).
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3.4.11

Effect of substitution at the 6-position of the naphthalene ring of 1-(2naphthoyl) piperazine-2,3-dicarboxylic acid on NMDAR activity

A series of UBP141 analogues with the unsubstituted aromatic ring of phenanthrene (ring C)
removed, were also characterized (Figure 3.23). Different acid or ester groups were substituted at
the 6-position of the naphthalene ring. Ethyl acrylate substitution gave compound UBP633 which
inhibited all NMDARs with similar efficacy. UBP633 at 100 µM inhibited GluN2A receptors by
88.4 ± 0.5 % (n = 4), GluN2B receptors by 97.1 ± 0.6 % (n = 4), GluN2C receptors by 80.4 ± 2.9
% (n = 4), and GluN2D receptors by 96.9 ± 0.8 % (n = 5) (Figure 3.23). However, the acrylic
acid substitution led to UBP634 which inhibited GluN2A (83.4 ± 5.5 %, n = 4), GluN2C (91.0 ±
2.8 %, n = 4) and GluN2D (83.1 ± 3.5 %, n = 4) with equal efficacy whereas it showed reduced
inhibition at GluN2B-containing NMDARs (32.8 ± 9.3 %, n = 4). Propionic acid substitution
gave UBP635 which displayed reduction in inhibition at GluN2B (34.7 ± 2.6 %, n = 5) and
GluN2D (51.4 ± 6.6 %, n = 5) receptors and enhanced inhibition at GluN2A (80.0 ± 0.6 %, n = 5)
and GluN2C receptors (76.7 ± 3.3 %, n = 5). When substitution was made at the 6-position of
naphthalene ring with pentanoic acid (UBP639), it inhibited all NMDARs with slightly more
activity at GluN2C and GluN2D receptors compared to GluN2A- and GluN2B-containing
receptors. Methyl pent-4-enoate (ester) substitution or pent-4-enoic acid (acid) at 6-position of the
naphthalene ring gave compounds UBP637 and UBP638 respectively. Both UBP637 and
UBP638 showed strong inhibitory activity at each subtypes of NMDARs (Figure 3.23)
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Figure 3.23 Effect of substitution at the 6-position of the naphthalene ring of 1-(2-naphthoyl)
piperazine-2,3-dicarboxylic acid on NMDAR activity
(A) Structural analogues of 1-(2-naphthoyl) piperazine-2,3-dicarboxylic acid with 6-position substitution on the
naphthalene ring. (B) NMDAR activity of UBP compounds (100 µM) was measured by TEVC assay at rat recombinant
NMDARs (GluN1-1a/GluN2A-D) expressed in Xenopus laevis oocytes. The effect of compound on agonist-induced (Lglutamate and glycine, 10 µM each) NMDAR current was measured and expressed as % potentiation (mean ± S.E.M.)
of agonist-induced response (positive value is % potentiation and negative value is % inhibition; n˃4).
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We further studied the concentration-response for the inhibition by these compounds at
GluN2A-D receptors. UBP633 had ethyl acrylate (ester substitution) at the 6-position of the
naphthalene ring and it showed greatest potency for inhibition at GluN2B-containing receptors
and least inhibition at GluN2C-containing receptors (Figure 3.24). The Ki value for inhibition at
GluN2A, GluN2B, GluN2C and GluN2D receptors were 3.7, 0.8, 3.5, and 0.6 µM respectively
(Table 3.5). The hydrolysis of the ester group of UBP633 gave compound UBP634, which
displayed the selectivity in opposite order than that of UBP633. UBP634 displayed more
inhibitory activity at GluN2A-, GluN2C-, GluN2D- and least at GluN2B-containing receptors
(Figure 3.24). We found a similar pattern of inhibitory activity with UBP635 which had propionic
acid substitution at the 6-position of naphthalene. It inhibited GluN2A and GluN2C receptors
more than GluN2B receptors (Figure 3.25). Compound (UBP639) with pentanoic acid
substitution also showed least inhibition at GluN2A- and GluN2B- and more inhibition at
GluN2C-containing receptors (Figure 3.25). The methyl pent-4-enoate (ester) substituted
analogue UBP637 exhibited more inhibitory activity at GluN2B receptors and least inhibitory
activity at GluN2A-containing receptors. Whereas when the ester group of UBP737 was
hydrolyzed to pent-4-enoic acid analogues (UBP638), it led to a reduction in inhibitory activity at
GluN2B receptors similar to the activity we observed with other carboxylic acid-substituted
analogues (Figure 3.26). The Ki value for inhibition by UBP634 at GluN2D receptors was 16
fold-lower than that for inhibition at GluN2B receptors. Similarly, the Ki value for inhibition by
UBP637 at GluN2D was 14-fold lower than that for inhibition at GluN2A.
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Figure 3.24 Concentration-response study of the inhibition of NMDAR responses by (A)
UBP633 and (B) UBP634
Select NMDAR antagonists were tested for activity at various concentrations to determine the potency and efficacy at
different NMDAR subtypes. NMDAR activity was measured by TEVC at recombinant NMDARs (GluN1a/GluN2A-D)
expressed in Xenopus laevis oocytes. NMDAR-mediated current induced by increasing concentration of the test
compounds co-applied with L-glutamate and glycine (10 µM each) was measured and expressed as % of control (agonist
alone) NMDAR response (mean ± S.E.M; n ˃ 4).
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Figure 3.25 Concentration-response study of the inhibition of NMDAR responses by (A)
UBP635 and (B) UBP639
Select NMDAR antagonists were tested for activity at various concentrations to determine the potency and efficacy at
different NMDAR subtypes. NMDAR activity was measured by TEVC at recombinant NMDARs (GluN1a/GluN2A-D)
expressed in Xenopus laevis oocytes. NMDAR-mediated current induced by increasing concentration of the test
compounds co-applied with L-glutamate and glycine (10 µM each) was measured and expressed as % of control (agonist
alone) NMDAR response (mean ± S.E.M; n ˃ 4).
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Figure 3.26 Concentration-response study of the inhibition of NMDAR responses by (A)
UBP637 and (B) UBP638
Select NMDAR antagonists were tested for activity at various concentrations to determine the potency and efficacy at
different NMDAR subtypes. NMDAR activity was measured by TEVC at recombinant NMDARs (GluN1a/GluN2A-D)
expressed in Xenopus laevis oocytes. NMDAR-mediated current induced by increasing concentration of the test
compounds co-applied with L-glutamate and glycine (10 µM each) was measured and expressed as % of control (agonist
alone) NMDAR response (mean ± S.E.M; n ˃ 4).

116

Table 3.4 Antagonist IC50 (µM, n ≥ 4) values for inhibition of GluN1/GluN2 NMDAR
subtypesa
Compounds
UBP633
UBP634
UBP635
UBP637
UBP638
UBP639
UBP784
UBP786
UBP791
UBP796
UBP797
UBP799
aIC
50

GluN2A
16.3 ± 1.5
23.6 ± 5.3
33.4 ± 2.4
42.8 ± 9.1
25.9 ± 3.5
63.9 ± 10.2
49.3 ± 8.0
188.0 ± 39.4
85.4 ± 8.2
106.6± 5.8
48.9 ± 7.7
28.7± 5.0

GluN2B
4.8 ± 0.8
137.3 ± 43.5
188.3 ± 25.1
7.9 ± 0.8
31.3 ± 4.3
61.3 ± 7.7
35.6 ± 3.2
68.0 ± 12.1
16.8 ± 1.2
75.3 ± 4.2
507.7 ± 300.4
59.7 ± 3.8

GluN2C
35.6 ± 5.3
26.9 ± 7.2
42.7 ± 2.9
20.3 ± 1.9
15.3 ± 2.9
16.2 ± 1.6
8.7 ± 2.1
12.0 ± 2.8
1.0 ± 0.4
50.7 ± 1.7
376.6 ± 170.3
12.0 ± 1.0

GluN2D
15.8 ± 2.2
39.7 ± 4.4
121.7 ± 17.4
15.6 ± 1.5
17.8 ± 1.9
29.5 ± 1.9
8.1 ± 2.2
24.1 ± 6.3
3.3 ± 0.3
35.3 ± 3.1
167.8 ± 27.7
6.8 ± 0.8

values (mean ± S.E.M.) for the inhibition of GluN1/GluN2 NMDAR responses evoked by agonist (L-glutamate, 10

µM and glycine, 10 µM).

Table 3.5 Antagonist Ki (µM, n ≥ 4) values of for inhibition of GluN1/GluN2 NMDAR
subtypesa
Compounds
(R)-AP5
(R)-CPP
PPDA
UBP141
UBP145
UBP633
UBP634
UBP635
UBP637
UBP638
UBP639
UBP784
UBP786
UBP791
UBP796
UBP797
UBP799
aK

i

GluN2A
0.28 ± 0.02
0.041 ± 0.003
0.55 ± 0.15
14.2 ± 1.1
11.5 ± 0.8
3.7 ± 0.3
5.3 ± 1.2
7.5 ± 0.5
9.7 ± 2.1
5.8 ± 0.8
14.4 ± 2.3
11.1 ± 1.8
42.4 ± 8.9
19.3 ± 1.9
24.1 ± 1.3
11.0 ± 1.7
6.5 ± 1.1

GluN2B
0.46 ± 0.14
0.27 ± 0.02
0.31 ± 0.02
19.3 ± 1.4
8.0 ± 0.35
0.8 ± 0.1
22.2 ± 7.0
30.5 ± 4.0
1.3 ± 0.1
5.1 ± 0.7
9.9 ± 1.2
5.8 ± 0.5
11.0 ± 2.0
2.7 ± 0.2
12.2 ± 0.7
82.1 ± 48.5
9.7 ± 0.6

GluN2C
1.64 ± 0.14
0.63 ± 0.05
0.096 ± 0.006
4.22 ± 0.52
2.8 ± 0.07
3.5 ± 0.5
2.7 ± 0.7
4.3 ± 0.3
2.0 ± 0.2
1.5 ± 0.3
1.6 ± 0.2
0.87 ± 0.2
1.2 ± 0.3
0.1 ± 0.04
5.1 ± 0.2
37.6 ± 17
1.3 ± 0.1

GluN2D
3.71 ± 0.67
1.99 ± 0.2
0.125 ± 0.035
2.78 ± 0.16
1.2 ± 0.06
0.6 ± 0.1
1.7 ± 0.2
5.1 ± 0.7
0.7 ± 0.1
0.7 ± 0.1
1.2 ± 0.1
0.34 ± 0.1
1.0 ± 0.3
0.14 ± 0.01
1.5 ± 0.1
7.1 ± 1.16
0.3 ± 0.03

values (mean ± S.E.M.) for the inhibition of GluN1/GluN2 NMDAR responses evoked by agonist (L-glutamate, 10

µM and glycine, 10 µM). Values for (R)-AP5, (R)-CPP, PPDA, UBP141 and UBP145 are previously reported (Morley,
Tse et al. 2005, Costa, Feng et al. 2009) and are shown here for comparison.
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Table 3.6. Potency relative to activity on GluN1/GluN2D (Ki GluN2/Ki GluN2D)
Compounds
(R)-AP5
(R)-CPP
PPDA
UBP141
UBP145
UBP633
UBP634
UBP635
UBP637
UBP638
UBP639
UBP784
UBP786
UBP791
UBP796
UBP797
UBP799

GluN2A
0.075
0.02
4.40
5.1
9.6
6.2
3.1
1.5
13.9
8.3
12
32.6
42.4
137.9
16.1
1.5
21.7

GluN2B
0.123
0.14
2.48
6.9
6.67
1.3
13.0
6.0
1.9
7.3
8.3
17.1
11.0
19.3
8.1
11.6
32.3

GluN2C
0.44
0.32
0.77
1.5
2.33
5.8
1.6
0.8
2.9
2.1
1.3
2.6
1.2
0.7
3.4
5.3
4.3

118

3.4.12

Mechanism of competitive inhibition of NMDARs by UBP791

To determine the mechanism of inhibition by UBP791, we performed L-glutamate and glycine
concentration-response analysis at GluN2D-containing receptors in different concentrations of the
antagonist UBP791. With increasing concentrations of UBP791, the glycine EMax (maximal
response or efficacy) was changed but there was no significant change in the glycine EC50.
However, with the increasing concentrations of UBP791, the EMax response for L-glutamate was
similar but there was a reduction in L-glutamate EC50 values in the presence of higher
concentrations of the antagonist UBP791 (Figure 3.27, Table 3.7). These results are consistent
with UBP791 being a competitive glutamate antagonist. Schild plot analysis by linear fit of log
(Dose ratio - 1) versus log concentration of UBP791 gave a slope of 0.86 and pA2 of -7.1 (Figure
3.28) which corresponds to an affinity of 80 nM concentration. Which is close to the Ki value we
obtained from the dose- response study of UBP791 inhibition at GluN2D receptor.

Table 3.7 EC50 values of glutamate and glycine with/without different concentrations of
UBP791a
Glutamate
Without UBP791 (EC50)
With UBP791 (1 µM; EC50’)
With UBP791 (3 µM; EC50’)
With UBP791 (10 µM EC50’)
aData

are presented as mean ± S.E.M.

µM
0.73 ± 0.04
6.6 ± 0.4
15.6 ± 0.8
36.9 ± 3.6

Glycine
N
5
5
6
6

µM
0.31 ± 0.02
0.68 ± 0.1
0.8 ± 0.07
0.56 ± 0.06

N
6
6
5
5
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Figure 3.27 Effect of different concentrations of the antagonist UBP791 on L-glutamate and
glycine potency at GluN2D-containing NMDARs
(A) Glutamate concentration-response curve at GluN1-1a/GluN2D receptors co-activated by glycine (10 µM) in absence
or presence of different concentrations of UBP791. Data represent mean ± S.E.M from 5 – 6 oocytes. (B) Glycine
concentration-response curve at GluN1-1a/GluN2D receptors co-activated by L-glutamate (10 µM) in absence or
presence of different concentrations of UBP791. Data represent mean ± S.E.M from 5 – 6 oocytes.
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Figure 3.28 Schild plot analysis of UBP791 inhibition of glutamate response at GluN2D
subtypes of NMDAR
The EC50 value of the agonist was determined from the glutamate concentration-response curve in the absence of and in
the presence of increasing concentrations of UBP71. The dose ratio (DR) for each concentration of UBP791was
calculated by dividing the corresponding EC50’ by the EC50 in the absence of UBP791. Then log [DR – 1] was plotted
against the log [UBP791] M and fitted by linear regression, to obtain the slope and pA2 value (X- intercept).

These results show that UBP791 competes with L-glutamate for binding and thus is
likely to be binding at the L-glutamate binding site. However, since the slope of the Schild plot
was not equal to one, it may be that the assumptions for ideal Schild analysis (Colquhoun 2007)
are not valid for NMDARs. It is possible that the binding of antagonist to one glutamate binding
site may alter the conformation of another glutamate binding site since the NMDAR has two
glutamate binding sites. It is also possible that this compound can bind to an allosteric site as well
as to the orthosteric glutamate binding site.
We also measured UBP791 inhibitory activity at GluN1 and GluN2A-containing
NMDARs with a closed LBD cleft conformation using mutants with disulfide cross-linked LBD.
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By co-expression of disulfide crosslinked GluN1c (N499C and Q686C) with wildtype GluN2A or
of wildtype GluN1 with crosslinked GluN2Ac (K487C and N687C) in Xenopus laevis oocytes,
we evaluated the effect of constrained LBDs on the inhibitory activity of UBP791. The inhibition
by UBP791 (30 µM) at GluN1c containing GluN2A receptors was similar to that of wild type
GluN2A receptors. As expected, UBP791 did not inhibit the NMDAR response at GluN2Ac
containing receptors and the response was significantly reduced (****p˂0.0001, one-way
ANOVA followed by Tukey’s multiple comparison test) compared to WT GluN2A receptors and
GluN1c containing GluN2A receptors as shown in (Figure 3.29). The inhibition by UBP791 at
WT GluN2A, GluN1c containing receptor and GluN2Ac containing receptor was 79.3 ± 11.2 % (n
= 13 oocytes), 76.5 ± 11.4 % (n = 14 oocytes), 11.1 ± 12.2 % (n = 18 oocytes) respectively. These
results suggest that the inhibition by UBP791 may require the opening of the GluN2 LBD. As we
know from the previous glutamate competition experiment, UBP791 likely binds at the Lglutamate binding site and since LBD is locked in GluN2Ac containing NMDARs, it does not
allow the binding of UBP791 and hence is not able to cause any inhibition of the receptor’s
response.
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Figure 3.29 Effect of LBD cleft conformation on inhibitory activity of UBP791
Cross-linking the cleft of GluN1 LBD by introducing two cysteine point mutations (N499C and Q686C) mimics the
glycine-bound conformation and cross-linking the cleft of GluN2A LBD by introducing two cysteine point mutations
(K487C and N687C) leads to the L-glutamate-bound conformation. Both of these constructs were separately expressed
with complimentary WT subunit in Xenopus laevis oocytes and the inhibitory activity of UBP791 (30 µM) was measured.
A bar graph showing UBP791-mediated inhibition of agonists (10 µM L-glutamate and 10 µM glycine) evoked response
from oocytes expressing WT (GluN1/GluN2A, n = 13 oocytes), GluN1 LBD-locked (GluN1c/GluN2A, n = 14 oocytes)
and GluN2A LBD-locked (GluN1/GluN2Ac, n = 18 oocytes) receptors. Data represent mean ± S.E.M. **p˂0.01 (oneway ANOVA followed by Tukey’s multiple comparison test).
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3.5

Discussion

In this chapter, we screened multiple series of compounds, which displayed three types of activity
at NMDARs. Some compounds exhibited PAM activity, some exhibited NAM and the others
exhibited competitive antagonistic activity, which was confirmed by Schild plot analysis of Lglutamate concentration-response results.
To study the structure activity relationship (SAR) of 2-naphthoic acid derivatives for
displaying PAM or NAM activity, various structural modifications were made and their activity
was measured at GluN2A-D-containing NMDARs.
The SAR studies of the compounds displaying PAM activity revealed the following
information: (i) a carboxylic group at the 2-position of the naphthalene ring is essential, (ii) a long
alkyl chain at the 6-position of the naphthalene ring can be accommodated, (iii) a methyl
substituent at the 1-position of the alkyl chain attached to the naphthalene ring can be
accommodated, as can a phenyl or cyclopentyl group at the end of the chain, (iv) a hydroxyl
group at the 3-position of the naphthalene ring can also be tolerated, and (v) a hydroxyl group at
the 2-position of the naphthalene ring or ester group on the isohexyl chain is also tolerated which
will help to reduce hydrophobicity of these PAMs and still retain the activity.
The SAR studies of the compounds displaying NAM activity revealed the following
information: (i) addition of styryl group substituent to naphthalene ring at the 7-position increases
activity, (ii) substitution with a hydroxyl group at the 3-position of the naphthalene ring in a
styryl group-containing compounds enhances the activity while carboxylic group substitution
reduces it, (iii) styryl group substitution at naphthalene ring is preferable but styryl group
substitution on a coumarin ring is detrimental for NAM activity, (iv) nitro- and methoxysubstitution at the 7-position on the styryl ring is tolerated and nitro substitution at styryl aromatic
ring makes them more GluN2D-selective.
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The SAR studies of competitive antagonist derivatives revealed that the 9-position of the
phenanthrene ring of UBP141 can accommodate different kinds of substituents and most of them
display inhibitory preference for GluN2C- and GluN2D- over GluN2A- and GluN2B-containing
NMDARs. Addition of piperazine-2,3-dicarboxylic acid (which mimics aspartate) was necessary
in order to observe the competitive antagonism by phenanthrenyl-2-carbonyl compounds. Ring C
from the phenanthrene ring of these phenanthrenyl-2-carbonyl analogues could be removed
without a loss of NMDAR antagonism. Carboxylic acid substitution at position 6 of the
naphthalene-2-carbonyl analogues yields compounds with the least inhibitory preference for
GluN2B subunit whereas ester group substitution at the 6-position of naphthalene yields
compounds with the highest preference for GluN2B receptors.
Competitive antagonists characterized in this project show more inhibitory activity at
GluN2C- and GluN2D-containing receptors compared to GluN2A- and GluN2B-containing
receptors. UBP791, which is a PPDA analogue (Morley, Tse et al. 2005), displayed greater
selectivity toward GluN2C- and GluN2D-containing NMDARs compared to its parent
compound. Similarly, other derivatives of previously characterized UBP141also demonstrated
GluN2C/2D preference for their inhibitory activity. Removal of the unsubstituted ring C from the
phenanthrene ring did not have any effect on inhibitory activity. Compounds such as UBP784,
UBP791, UBP799, UBP633, UBP637, UBP638 showed high affinity for GluN2D receptors with
nanomolar Ki values. Previous studies by our laboratory involving molecular modeling suggested
that the phenanthrene ring of PPDA binds in the LBD cleft (S1/S2) along a groove in S2 at the
base of ‘H’ helix (Kinarsky, Feng et al. 2005). This groove in GluN2D receptors has a nonconserved arginine residue (Arg737). The selectivity for GluN2D receptors by PPDA, UBP141
and their derivatives may be due in part to hydrophobic contact of the phenanthrene ring of these
compounds with the hydrophobic side chain of Arg737.
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It has been reported that a GluN2A NAM binds to the same site as do potentiators at the
dimer interface of the LBDs of GluN1/GluN2A, with the major difference being that the
conformation of Y535 on GluN1 is different in the two sites (Hackos, Lupardus et al. 2016).
Thus, it is possible that some of the compounds in this study can bind in either of these two
binding modes and that the combined effect of these two activities is being measured. However, it
is also conceivable that the UBP-NAM and UBP-PAM sites are in different areas of the NMDAR
complex. Indeed, one family of negative allosteric modulator is thought to bind at a site at the top
of transmembrane regions 1 and 4 in a related family of ligand-gated ion channels known as
AMPA receptors (Balannik, Menniti et al. 2005, Sobolevsky, Rosconi et al. 2009) and an
equivalent binding site exists in NMDARs. Consistent with NAM and PAM binding sites that do
not physical overlap, we also found that compound UBP512 non-competitively blocked the PAM
activity of UBP684 (Chapter 4).
We also noticed that the PAMs displayed greater cell to cell variability in response
magnitude than routinely seen with NAMs or competitive antagonists. It is possible that these
PAMs are sensitive to a state-dependent variable such as that reported for neurosteroid
potentiation being influenced by receptor phosphorylation state (Petrovic, Sedlacek et al. 2009).
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Chapter 4 Functional properties and mechanisms of action of general
NMDAR PAMs
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4

Pharmacological and mechanistic characterization of NMDAR
positive allosteric modulators (PAMs)

4.1

Abstract

N-methyl-D-aspartate receptors (NMDARs) are a subtype of receptors for L-glutamate, the
primary excitatory neurotransmitter of the CNS. NMDAR activity is important for the induction
of long-term potentiation (LTP) and long-term depression (LTD), two components of synaptic
plasticity. Impairment in NMDARs function leads to various neuropathological consequences
such as schizophrenia. In this study, we report the mechanism and pharmacology of two nonselective NMDAR positive allosteric modulators (PAMs), UBP684 and UBP753. They potentiate
all subtypes of NMDARs with almost equal potency and efficacy. They enhance the efficacy of
both of the NMDAR agonists L-glutamate and glycine. Their mode of NMDARs potentiation is
independent of membrane potential. The mechanism of enhancement of the NMDAR-mediated
response by these compounds is by increasing the channel open probability (Popen) and by
prolonging the receptor deactivation time, especially slowing the deactivation time following
glutamate removal. The binding sites for these potentiators are distinct from the binding sites of a
class of structurally-related inhibitors that we have previously reported. These compounds can
bind to both the agonist-bound and agonist-unbound conformations. These compounds stabilize
the GluN2 LBD in the glutamate-bound state conformation. These compounds lose their
potentiating activity at alkaline pH and the GluN1 C-terminal is necessary for their PAM activity.
An allosteric interaction with the intracellular C-terminal is also suggested by the finding that
PAM activity is potentiated by PKC activity. These PAMs may be valuable in enhancing
NMDAR activity in schizophrenia where there is thought to be a reduction in NMDAR-mediated
neurotransmission.
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4.2

Introduction

The primary excitatory neurotransmitter in the vertebrate CNS, L-glutamate, activates three
distinct families of ligand-gated ion channel receptors that are named for agonists by which they
are selectively activated, N-methyl-D-aspartate (NMDA), AMPA (2-amino-3-hydroxy-5-methyl4-isoxazole propionic acid) and kainate (Monaghan, Bridges et al. 1989, Dingledine, Borges et al.
1999, Traynelis, Wollmuth et al. 2010). While AMPA and kainate receptors underlie fast
excitatory synaptic transmission in the CNS, NMDAR activation triggers multiple calciumdependent intracellular responses that regulate distinct forms of synaptic plasticity such as longterm potentiation (LTP), long-term depression (LTD) and experience-dependent synaptogenesis
(Collingridge, Isaac et al. 2004, Bliss, Collingridge 1993, Malenka, Bear 2004, Luscher, Malenka
2012, Matsuzaki, Honkura et al. 2004, Zhou, Homma et al. 2004). These and related NMDAR
mechanisms play key roles in learning, memory, and cognition. However, excessive NMDAR
activation is thought to be a common mechanism causing neuronal cell death in stroke, traumatic
brain injury and various neurodegenerative diseases (Rothman, Olney 1987, Simon, Swan et al.
1984, Faden, Demediuk et al. 1989). NMDAR hypofunction is also associated with CNS
dysfunction and may be responsible for the symptoms of schizophrenia (Olney, Newcomer et al.
1999, Coyle, Tsai et al. 2003, Coyle, Tsai 2004, Weickert, Fung et al. 2013). The findings
regarding glutamate-induced cell death have led to the development of a large number of
NMDAR inhibitors over the past 30 years to provide neuroprotection in stroke, seizures, and
neurodegenerative disorders. More recently, agents that augment NMDAR activity have been
identified and their potential application for treating neuropsychiatric and cognitive disorders is
now being determined (Mullasseril, Hansen et al. 2010, Hackos, Lupardus et al. 2016, Costa,
Irvine et al. 2010).
NMDAR complexes are composed of subunits from seven genes - GluN1, GluN2AGluN2D, and GluN3A-GluN3B (Ishii, Moriyoshi et al. 1993, Moriyoshi, Masu et al. 1991).
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These subunits assemble into hetero-tetrameric complexes in various combinations resulting in
functionally-distinct NMDARs. The majority of NMDARs are thought to be composed of two
GluN1 subunits and two GluN2 subunits and arranged in dimer of heterodimers (Karakas,
Furukawa 2014, Lee, Lü et al. 2014). While the various GluN1 subunits are alternatively-spliced
isoforms with largely similar pharmacological and physiological properties, the GluN2 subunits
confer distinct physiological, biochemical, and pharmacological properties to the NMDAR
complex (Monyer, Sprengel 1992, Monyer, Burnashev et al. 1994, Vicini, Wang et al. 1998,
Buller, Larson et al. 1994, Mishina, Mori et al. 1993, Nakanishi 1992). These properties
combined with the varied developmental profiles and anatomical distributions of GluN2 subunits
(Watanabe, Inoue et al. 1993b, Monaghan, Holets et al. 1983, Sucher, Akbarian et al. 1995) imply
that GluN2 subtype-selective agents should have distinct physiological and therapeutic properties.
Indeed, many studies now suggest that different subtypes of NMDARs can have distinct, and
even opposite, roles in neurobiological processes and in neurological disorders. Thus, the ability
to differentially enhance the function of specific NMDAR subtypes while not affecting, or even
inhibiting, other populations, may provide therapeutic advantages.
Neurosteroids such as PS have long been known for their NMDAR modulatory activity
(Wu, Gibbs et al. 1991, Compagnone, Mellon 2000, Irwin, Maragakis et al. 1992). They can
inhibit GABA-A, glycine, AMPA and kainate as well as GluN2C- and GluN2D-containing
receptors (Park-Chung, Malayev et al. 1999). However, the neurosteroid pregnenolone sulfate
potentiates GluN2A- and GluN2B-mediated NMDAR currents (Yaghoubi, Malayev et al. 1998,
Malayev, Gibbs et al. 2002). Besides neurosteroids, other positive allosteric modulators of
NMDARs have been recently identified (Mullasseril, Hansen et al. 2010, Hackos, Lupardus et al.
2016, Costa, Irvine et al. 2010). Their mechanism of action has been studied and their binding site
predicted. Chemical structures of some of the known and novel PAMs is shown in Figure 4.1
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In a recent study, we described a novel series of allosteric modulators that display both
inhibitory activity (negative allosteric modulator, NAM) and enhancing activity (positive
allosteric modulator, PAM) at NMDARs (Costa, Irvine et al. 2010, Costa, Irvine et al. 2012).
These compounds also displayed distinct patterns of selectivity at NMDARs containing different
GluN2 subunits. Thus, this class of agents offers the potential to develop agents with an optimal
profile of therapeutic / adverse effects. These agents do not act at either glutamate or glycine
binding sites nor at the N-terminal regulatory domain. They also do not appear to be NMDAR
channel blockers. Initial experiments indicate that these agents may be binding in the dimer
interface in a manner that may be homologous to the binding of the AMPA receptor allosteric
modulators GYKI-52466 and cyclothiazide (Sun, Olson et al. 2002, Johansen, Chaudhary et al.
1995). This group of compounds should be valuable tools for identifying the physiological roles
of distinct NMDAR subtypes and serve as lead compounds for a variety of therapeutic
applications.
The precise effect that a PAM has on synaptic and extra-synaptic NMDAR currents
depends upon various properties of the PAM's actions. The activity of NMDAR PAMs to
influence the receptor response time-course and sensitivity can vary and function of agonist
concentration. In turn, these properties can alter the synaptic NMDAR current's frequencyresponse and temporal integration properties, and also, differentially augment responses during
synaptic agonist saturation or at low, tonic agonist concentrations. Thus, these properties
influence the applicability of specific PAMs for the modulation of NMDAR activity in
neurological or neuropsychiatric conditions. Recently we have identified UBP684 and UBP753 as
non-selective, 2-naphthoic acid based NMDAR PAMs with relatively high efficacy in enhancing
NMDAR-mediated currents. In this chapter, we sought a better understanding of the mechanisms
by which UBP684 and UBP753 can enhance NMDAR currents.
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Figure 4.1 Structure of positive allosteric NMDAR modulators
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4.3
4.3.1

Materials and methods
Compounds

UBP684, UBP753 and UBP792 were synthesized in Dr. David Jane’s laboratory at University of
Bristol and verified as described previously (Chapter 3, section 3.2.1).

4.3.2

GluN subunit expression in Xenopus oocytes

cDNAs and cRNAs were prepared and expressed in Xenopus oocytes as described in the method
sections (3.2.2 and 3.2.3) of the previous Chapter 3.

4.3.3

Two-electrode voltage clamp (TEVC) assay

TEVC assays were performed as described before in Chapter 3 (section 3.2.4).
To study the effect of disulfide bond reduction on potentiation by UBP753 and UBP684,
oocytes were treated for 3 minutes with bath perfusion of 3 mM dithiothreitol (DTT) followed by
1-minute wash with recording buffer. Percent potentiation was calculated using the agonist-alone
response just before the co-application of UBP compounds and agonists.

4.3.4

Data analysis

For the calculation of association time constant (KON) of UBP753, we first calculated the
association time (τONSET) of GluN2D-mediated current response by increasing concentrations of
UBP753 with a single fit exponential which is considered as the time required for association of
drug with the receptor. Linear regression analysis of the plotting of 1/τONSET versus UBP753
concentration gave KON (slope) and Koff (y-intercept) values which were used to calculate the KD
(KD = KOFF/KON).
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4.3.5

Statistical analysis

Prism 6 (GraphPad Software Inc., San Diego, CA, USA) was used for statistical analysis. All
values are expressed as mean ± SEM. Paired and unpaired t-test and one-way ANOVA were used
to analyze the data. p ˂0.05 was considered as statistically significant.
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4.4
4.4.1

Results
UBP684 dose-response for the potentiation of GluN2A-D NMDARs

UBP684 enhanced the agonist-induced (10 µM L-glutamate and 10 µM glycine) current across
all subtypes of NMDARs (Figure 4.2). Maximal potentiation of GluN2A, GluN2B, GluN2C and
GluN2D receptors by UBP684 was 68.6 ± 16.2 %, 102.0 ± 17.85 %, 117.2 ± 22.3 5 % and 88.4 ±
9.6 % respectively. EC50 values at the four NMDAR subtypes ranged from 28 to 37.2 µM as
shown in the Table 4.1. When the concentration-response study of UBP684 was carried out using
high concentrations of agonists (300 µM of L-glutamate and 300 µM of glycine), its affinity for
GluN2A and GluN2B subtypes was slightly enhanced and the affinity for the GluN2D subtype
was slightly lowered. However, the maximal potentiation by UBP684 at GluN2B receptors was
lowered when agonists were used at 300 µM instead of at 10 µM (Table 4.1, Figure 4.2). There
was no significant change in maximal potentiation by UBP684 at GluN2A, GluN2C or GluN2D
in the high agonist concentration condition.
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Table 4.1 EC50 (µM, n ≥ 4) values for potentiation by UBP684 and UBP753 of GluN1/GluN2
NMDAR subtypesa
Compounds
UBP684

Glu/Gly.
10 µM each

UBP684

300 µM each

UBP753

10 µM each

aEC
50

GluN2A
28.0 ± 4.6
(68.6 ± 16.2)
10.3 ± 4.8*
(50.3 ± 14.1)
39.4 ± 27.5
(277.2 ± 36.8)

GluN2B
34.6 ± 3
(102.0 ± 17.8)###
24.8 ± 2.8*
(61.5 ± 4.2)
25.0 ± 11.6
(192.3 ± 46.6)

GluN2C
37.2 ± 2.8
(117.2 ± 22.3)
33.8 ± 9.7
(108.2 ± 37.9)
36.2± 5.7
(262.6 ± 33.9)

GluN2D
28.9 ± 4.1
(88.4 ± 9.6
55.8 ± 4.1**
(119.3 ± 37.9)
30.6 ± 7.5
(240.3 ± 63.6)

values (mean ± S.E.M.) for the potentiation of GluN1/GluN2 NMDAR responses. Values in parenthesis represent

the maximal potentiation (% EMax) expressed as a percentage (± S.E.M.) above the agonist-alone response (10 µM Lglutamate and 10 µM glycine).
*p

< 0.05 and

**p

< 0.01 (unpaired t-test) vs EC50 value for UBP684 potentiation at 10 µM L-glutamate and 10 µM

glycine.
###p

< 0.001 (unpaired t-test) vs % EMax value for UBP684 potentiation at 10 µM L-glutamate and 10 µM glycine.
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Figure 4.2 Concentration-response study of the potentiation of GluN2A-D NMDAR subtypes
by UBP684
(A) Representative current traces showing UBP684 enhancement of current mediated by rat recombinant
GluN1/GluN2A-D receptors expressed in Xenopus laevis oocytes as measured by TEVC. Current was first evoked by 10
µM L-glutamate and 10 µM glycine. After achieving a steady-state response, UBP684 (100 µM) was co-applied with the
agonists. Scale bars: X-axis =21 s, 13 s, 13 s, and 20 s and y-axis = 75 nA, 125 nA, 110 nA and 120 nA for GluN2A,
GluN2B, GluN2C, and GluN2D traces respectively. (B) UBP684 was tested for its activity at increasing concentrations
to determine the potency and efficacy at different NMDAR subunits. NMDAR-mediated currents induced by coapplication of different concentrations of UBP684 plus 10 µM L-glutamate and 10 µM glycine were measured and
expressed as % potentiation over the agonist-alone response (n = 5-12 oocytes per subunit) (C) Potentiation of NMDARmediated current by increasing concentrations of UBP684 in presence of high agonist concentration (300 µM L-glutamate
and 300 µM glycine) was also measured (n = 5 to 11 oocytes per subunit). Data represent mean ± S.E.M.
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4.4.2

Effect of UBP684 on affinity and efficacy of agonists at GluN2B- and
GluN2D-containing NMDARs

Agonist-response studies indicate that UBP684 enhances the response magnitude of both Lglutamate and glycine at GluN2B- and GluN2D-containing NMDARs. The reduction we
observed in the potentiation by UBP684 when high agonist was used, at GluN2B could be
because UBP684 may be potentiating, in part, by increasing the potency of the agonists at
GluN2B receptors. UBP684 significantly (p < 0.01, unpaired t-test) enhanced the affinity of
glycine (EC50 of 0.87 in absence of UBP684 vs 0.61 µM in presence of UBP684), but not of Lglutamate (EC50 of 2.01 in absence of UBP684 vs 2.08 µM in presence of UBP684) at GluN2Bcontaining NMDARs (Figure 4.3A,B; Table 4.2). UBP684 slightly decreased the affinity of Lglutamate and slightly enhanced the glycine affinity at GluN2D receptors (Figure 4.3C,D).
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Figure 4.3 Effect of UBP684 on affinity and efficacy of NMDAR agonists
A concentration-response study of L-glutamate (A; C) and glycine (B, D) on GluN2B- (A, B) and GluN2D- (C, D)
containing NMDARs was carried out by increasing the concentrations of a agonist in the absence (black) or presence
(red, GluN2B; blue, GluN2D) of 50 µM of UBP684 to study the effect of UBP684 on affinity and efficacy of the NMDAR
agonist for recombinant NMDARs expressed in Xenopus laevis oocytes. Concentration-response study of L-glutamate
was performed in the presence of 10 µM glycine and that of glycine was performed in the presence of 10 µM glutamate.
The response from each oocytes was individually normalized with the response obtained from the highest concentration
of the agonist-alone application from the same oocyte (n = 6-10 oocytes per curve). Data represent mean ± S.E.M.
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4.4.3

UBP753 concentration-response

UBP753 also exhibited a pan-PAM property with similar activity across all four subtypes of
NMDARs (Figure 4.4A). However, UBP753 showed a higher percentage of maximal potentiation
compared to UBP684. Its maximum potentiation at GluN2A, GluN2B, GluN2C and GluN2D
receptors was 277 %, 192.3 %, 262.6 % and 240.3 % respectively. But, its affinity as given by
EC50 was similar to that of UBP684 (Table 4.1). We also calculated the apparent affinity by
association and dissociation kinetic analysis (Figure 4.4). This gave the KD value of 73.3 µM,
which was little higher than the EC50 value we obtained from the concentration-response study.
We also studied if UBP753 increases the affinity or efficacy of agonists at NMDARs. UBP753,
similar to that of UBP684, enhanced the L-glutamate and glycine efficacy at GluN2D-containing
NMDARs (Figure 4.4 C, D). However, UBP753 slightly reduced the L-glutamate affinity and did
not alter the glycine affinity for GluN2D receptors.
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Table 4.2 EC50 (µM) and % EMax values of agonists in absence and presence of UBP684

GluN2B
GluN2D
GluN2D

GluN2B
GluN2D
GluN2D
**p

Without UBP684
With UBP684
Without UBP684
With UBP684
Without UBP753
With UB753

EC50 (µM)
2.01 ± 0.19
2.08 ± 0.12
0.88 ± 0.05
1.4 ± 0.1***
0.93 ± 0.06
1.3 ± 0.1**

Without UBP684
With UBP684
Without UBP684
With UBP684
Without UBP753
With UBP753

EC50 (µM)
0.87 ± 0.07
0.61 ± 0.05**
0.32 ± 0.04
0.25 ± 0.01
0.2 ± 0.04
0.22 ± 0.03

Glutamate
% EMax
104.6 ± 1.8
152.3 ± 6.3
99.6 ± 1.2
141.1 ± 5.5
100.7 ± 1.6
128.3 ± 3.8
Glycine
% EMax
101.9 ± 2.7
119.4 ± 3.0
97.0 ± 2.6
131.0 ± 2.9
96.5 ± 2.9
135.4 ± 3.8

Hill slope
1.58
1.48
1.6
1.7
1.8
1.9

N
9
7
10
7
15
6

Hill slope
1.4
1.38
1.17
1.99
1.3
0.9

N
19
19
9
6
14
7

< 0.01and ***p < 0.001 vs EC50 value for L-glutamate or glycine without UBP684 or UBP753 at the same NMDAR

subtypes
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Figure 4.4 Concentration-response study of UBP753 and its effect on agonist affinity
(A) UBP753 was tested at increasing concentrations to determine its potency and efficacy at different NMDAR subunits
expressed in Xenopus laevis oocytes. NMDAR-mediated current was induced by co-application of different
concentrations of UBP753 with 10 µM of L-glutamate and 10 µM glycine and expressed as % potentiation of agonistalone induced responses (n = 5-12 oocytes per subunit). (B) Affinity of UBP753 at GluN2D-containing NMDARs was
also determined by exponential fit of the on-rates and off-rates of different concentrations of UBP753. Using the linear
fit of 1/TauONSET and UBP753 concentration, KD was calculated. The equation for the regression line is given by y = mx
+ b where m is the slope of the line and b is the y-intercept of the line. (C) A concentration-response study of L-glutamate
in the presence of 10 µM glycine ± 30 µM UBP753 at GluN2D-containing NMDARs (n = 5-6 oocytes per curve). (D) A
concentration-response study of glycine in presence of 10 µM L-glutamate ± 30 µM UBP753 at GluN2D containing
NMDARs (n = 5-7 oocytes per curve). Data represent mean ± S.E.M.
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4.4.4

Effect of membrane potential on UBP753 potentiation

UBP753 potentiating activity was voltage independent. At 100 µM, UBP753 potentiated
GluN2C-containing NMDARs by 88.0 ± 12.9 % (n = 5 oocytes) at + 40 mV and by 93.8 ± 8.5 %
(n = 5 oocytes) at – 60 mV which were not statistically different (Figure 4.5A,B). Also, 50 µM
UBP753 did not change the reversal potential of GluN2B receptors (Figure 4.5C). This suggests
that UBP753 does not bind within the receptor’s ion channel. Additionally, UBP753 did not alter
the EC50 of ketamine channel blockade of the NMDAR response (Figure 4.5D). The IC50 value
for ketamine inhibition at GluN2C-containing receptors was 0.69 ± 0.12 µM (n = 5 oocytes) in
absence of UBP753 and was 0.73 ± 0.0.03 µM (n = 5 oocytes) in presence of 30 µM UBP753.
Hence, UBP753 and ketamine binding sites do not overlap and UBP753 does not allosterically
alter the ketamine binding site.
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Figure 4.5 Effect of change in membrane potential on the potentiation by UBP753
(A) The potentiating activity of 100 µM of UBP753 was measured at -60 mV and +40 mV on the GluN2C subtype of
NMDARs expressed in Xenopus laevis oocytes. A bar graph shows the percent potentiation of the agonist-induced (10
µM L-glutamate and 10 µM glycine) response at - 60 mV and + 40 mV (n = 5 oocytes). (B) A representative trace
showing the potentiating activity of UB753 (100 µM) at - 60 mV and + 40 mV on GluN2C subtype of NMDARs. Scale
bar: horizontal = time in sec, vertical = current in nA. (C) A current-voltage relationship curve in the absence (control)
or the presence of 50 µM of UBP753 at GluN2B-containing NMDARs (n = 6 oocytes). (D) Ketamine inhibition of
NMDAR response in the absence (n = 5 oocytes) or presence (n = 5 oocytes) of 30 µM of UBP753 at GluN2C-containing
receptors. The concentration-response curve in the presence of UBP753 was normalized to the maximal response
observed in the presence or absence of UBP753 (100 % Value). Data represent mean ± S.E.M.
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4.4.5

Effect of redox modulation and GluN1 splice variants on UBP potentiation

Reduction of cysteine residues on the NMDAR complex is known to potentiate the NMDAR
response. To determine if UBP753/UBP684 potentiation shares a common mechanism with
NMDAR redox modulation, we compared the potentiating activity of UBP753 and UBP684
before and after the treatment of GluN2A-containing NMDARs with 3 mM DTT for 3 min. DTT
treatment significantly (p = 0.01, paired t-test) lowered the potentiation by UBP753. The
potentiation by 50 µM UBP753 at GluN2A-containing receptors before the DTT pretreatment
was 82.1 ± 9.6 % (n = 8 oocytes). The potentiation by UBP753 was partially reduced to 62.8 ±
8.7 % (n = 8 oocytes) after the treatment with DTT (Figure 4.6A) and the difference was
significant. However, the DTT did not significantly alter (p = 0.3) the potentiation by 50 µM of
UBP684 (Figure 4.6B). UBP684 potentiated GluN2A receptors by 61.3 ± 7.3 % (n = 6 oocytes)
before and by 53.1 ± 6.8 % (n = 6 oocytes) after the DTT treatment. These results suggest that
changing the redox state of the receptor has a minimal effect on potentiation activity of UBP
compounds.
We then sought to determine if the mechanism of potentiation by UBP684 is by relieving
proton inhibition, this is the mechanism by which spermine by binding to the N-terminal domain
enhances NMDAR responses. We co-expressed the GluN2D subtype of NMDARs with the
GluN1 subunit with exon-5 (GluN1-1b) or without exon-5 (GluN1-1a), a N-terminal segment
with 21 amino acids, which reduces proton sensitivity. We did not observe any significant
difference in the potentiating activity (both EC50 and % EMax) of UBP684 at GluN2D-containing
receptors expressed with either of the two GluN1 splice variant forms (Figure 4.6C). This result
implies that the potentiating mechanism of UBP684 is not by changing proton sensitivity in the
manner by which spermine potentiates GluN2B-containing NMDARs.
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Figure 4.6 Effect of redox modulation and GluN1 splice variants on potentiation by UBPs
(A) UBP753 (50 µM) potentiation was measured before and after DTT (3 mM) treatment of GluN2A-containing
NMDARs for 3 min (n = 8 oocytes). Data represent mean ± S.E.M. *p˂0.05 (paired t-test). (B) A plot of UBP684 (50
µM) potentiation of GluN2A-containing NMDARs before and after the treatment with 3 mM DTT (n = 6 oocytes). (C)
UBP684 concentration-response for the potentiation of GluN2D receptors co-expressed with GluN1-1a (absence of exon5 segment; black curve) (n = 6 oocytes) or GluN1-1b (presence of exon-5 segment; green curve) subunits (n = 5 oocytes).
Data represent mean ± S.E.M.
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4.4.6

Non-competitive nature of PAM and NAM binding

We hypothesize that the negative allosteric activity of UBP-NAMs and positive allosteric activity
of UBP-PAMs comes from their binding to different sites. To determine if PAMs and NAMs
have different or overlapping binding sites, we studied their mode of interaction by performing a
concentration-response study of UBP684 at GluN2C-containing NMDARs in absence or presence
of UBP552, which is a general NMDAR NAM with an IC50 value of 5.1 µM at GluN2Ccontaining NMDARs. UBP552 did not change the EC50 of UBP684 but it changed the %
maximal potentiation by UBP684 (Figure 4.7A). Similarly, UBP 512, another NAM at GluN2Ccontaining receptors with an IC50 of 51 µM, did not change the UBP684 EC50 but it did change
the % maximal potentiation by UBP684 (Figure 4.7B). Both of these studies indicate a noncompetitive interaction between the binding of UBP-NAMs and UBP-PAMs. We also studied if
two PAMs are competing to each other for binding at the same site. Concentration-response study
of UBP684 in presence of 100 µM of UBP512, a GluN2A-selective PAM, also shows that both of
the PAMs do not compete for binding (Figure 4.7C). The result was interesting in that, the
presence of UBP512 significantly reduced the potentiating activity of UBP684 although both
have potentiating activity at GluN2A-containing NMDARs. Thus, UBP684 and UBP512 may
have distinct binding sites and the binding of UBP512 may non-competitively block UBP684’s
ability to allosterically modulate NMDAR activity.
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Figure 4.7 Allosteric potentiators do not compete for binding with allosteric inhibitors
(A) Concentration-response of UBP684 with (blue curve, n = 6 oocytes) or without (black curve, n = 7 oocytes) 5 µM
UBP552, a general negative allosteric modulator at GluN2C-containing NMDARs. UBP684 response curve in presence
of UBP552 was normalized to the UBP552-alone response. The dotted curve shows the expected shift in UBP684
concentration-response curve if the interaction between UBP684 and UBP552 was competitive. Data represent mean ±
S.E.M. (B) Concentration-response of UBP684 with (green curve, n = 4 oocytes) or without (black curve, n = 7 oocytes)
100 µM of the negative allosteric modulator UBP512 at GluN2C- containing NMDARs. UBP684 response curve in
presence of UBP512 was normalized to the UBP512-alone response. The dotted curve shows the expected shift in the
UBP684 concentration-response curve if the interaction between UBP684 and UBP512 was competitive. Data represent
mean ± S.E.M. (C) Concentration-response of UBP684 with (red curve, n = 5 oocytes) or without (black curve, n = 5
oocytes) 100 µM of the positive allosteric modulator UBP512 at GluN2A-containing NMDARs. The dotted curve shows
the expected shift in UBP684 concentration-response curve if the interaction between UBP684 and UBP512 was
competitive. Data represent mean ± S.E.M.
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4.4.7

UBPs bind to both agonist-bound and agonist-unbound conformations of
NMDARs

To evaluate receptor configurations to which the PAMs can bind, we performed different modes
of application of these compounds to NMDARs. When UBP753 and UBP684 were pre-applied
followed by agonist alone (sequential application), the response to the agonist was increased and
the activation kinetics of the receptor was faster. When UBP753 was pre-applied for 30 seconds,
it increased the NMDAR response to subsequent agonist application (Figure 4.8A). The time for
activation, as calculated by a single exponential fit, was significantly reduced, when UBP753 was
pre-applied, compared to the time for activation without pre-application (0.47 ± 0.06 s for preapplication versus 0.91 ± 0.09 s without pre-application; p = 0.03; n = 7-12 oocytes per group;
one-way ANOVA followed by Tukey’s multiple comparison test) (Figure 4.8B). However, coapplication of UBP753 with agonists (without-preapplication) did not change the activation time
of the receptor. Similarly, we pre-applied UBP684 (50 µM) for 30 seconds and measured
NMDAR activation time (Figure 4.8A, lower panel). The sequential application of UBP684 also
accelerated receptor activation kinetics (Figure 4.8C) and enhanced the amplitude of the
NMDAR-mediated response (Figure 4.8D). The receptor activation time for GluN2B was 1.08 ±
0.13 s (n = 8 oocytes) in the absence of the pre-application. The pre-application of UBP684 (50
µM) significantly (p = 0.007, paired t-test) shortened the activation time to 0.69 ± 0.12 s (n = 8
oocytes). These results show that both UBP684 and UBP753 can bind to the closed state of the
NMDAR. When UBP753 (100 µM) and the agonists were applied together, the activation time
was significantly slower compared to sequential application as shown in Figure 4.8A-C.
Importantly, activation was much faster than the rate of potentiation seen by UBP684/UBP753
when they were applied after obtaining a steady-state agonist response. Since UBP potentiation
rate is significantly slower than the agonist activation rate, if UBP684/UBP753 only bound to the
open state, then pre-and co-application and sequential application would have slower on-rate or
no potentiation, respectively, compared to agonist alone.

149

A.

B.

C.

1 .2 5

**

1 .0 0

0 .7 5

0 .5 0

***

N M D A R r e s p o n s e (% c o n tro l)

*

A c tiv a tio n tim e (  , S e c )

A c tiv a tio n tim e (  , S e c )

1 .2 5

D .1 5 0

1 .5 0

1 .5 0

1 .0 0

0 .7 5

0 .5 0

0 .2 5

0 .2 5

A g o n is t S e q u e n t ia l P r e - c o

Co-

100

75

50

25

0

0 .0 0

0 .0 0

125

A g o n is t

S e q u e n t ia l

A g o n is t S e q u e n t ia l

Figure 4.8 UBPs bind to both open and closed conformation of NMDARs
(A) Representative recordings from Xenopus laevis oocytes expressing GluN1/GluN2B NMDARs (top panel). Different
protocols for the application of UBP753 (100 µM) were performed to evaluate its binding preference to different states
of the receptors. In the sequential application, UBP753 was pre-applied for 30 sec and subsequent agonist- response (10
µM L-glutamate and 10 µM glycine) was measured. In the co-application, both of the agonists and UBP753 were applied
together at the same time. In the pre-co application, UBP753 alone was pre-applied first and then UBP753 with agonists
were co-applied. For the contemporaneous application, agonists were applied first to activate the receptor. After achieving
the steady-state response, UBP753 along with the agonists were applied followed by agonists-alone application.
Representative trace recording showing the effect of the pre-application of 50 µM of UBP684 on NMDAR activation by
agonist (10 µM L-glutamate and 10 µM glycine) (lower panel). Super-imposed trace is shown in the middle and
normalized trace with expanded time scale is shown on the right side of the lower panel. Scale bar: horizontal = time in
sec, vertical = current in nA. (B, C) Estimation of the activation time constant (τ) by a single exponential fit for different
application protocols of UBP 753 (B) and UBP684 (C). Data represent mean ± S.E.M. *p˂0.05,
ANOVA followed by Tukey’s multiple comparison

test); ***p˂0.001

**p˂0.01

(one-way

(unpaired t-test). (D) Bar graph showing an increase

in the NMDAR response after pre-application of UBP684 (50 µM) (n = 8 oocytes). Data represent mean ± S.E.M.
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4.4.8

Effect of UBP684 on NMDAR channel open probability

To determine the mechanism of potentiation by UBP684, we sought to measure the channel open
probability (Popen). A conventional way of estimation of NMDAR channel open probability is the
measurement of the rate of block by the open channel blocker MK-801. Since open channel
blockers require an open channel for their binding, the rate of open channel blocking is
proportional to the open probability of the channel. Inhibition by 1 µM MK-801 was significantly
faster in the presence of 100 µM of UBP684 compared to block in the absence of UBP684
(Figure 4.9A-D). The rate of block of GluN2C receptors by MK801 in the absence of UBP684
was 3.69 ± 0.9 s (n = 3 oocytes). When 100 µM of UBP684 was pre- and co-applied with MK801, the rate of MK-801 block was significantly faster (1.1 ± 0.15 s; p = 0.02; unpaired t-test; n =
4 oocytes). As a control experiment, we also measured the rate of inhibition by an allosteric
inhibitor UBP792. We did not observe any significant difference on inhibition by this compound
in the presence or absence of UBP684 (Figure 4.9E). These results show that one of the
mechanisms of potentiation of NMDAR by UBP684 is by increasing the Popen of NMDARs.

151

B.

A.

D.

E.8

6

5

*
R a te o f In h ib itio n (  , S e c )

R a te o f In h ib itio n (  , S e c )

C.

4

3

2

6

4

2

1

0

0
M K -8 0 1

M K -8 0 1 + U B P 6 8 4

UBP792

UBP792+UBP684

Figure 4.9 Effect of UBP684 on the channel open probability of GluN2C-containing
NMDARs
(A) A trace from a two-electrode voltage-clamp recording showing the inhibition of an agonist-evoked (10 µM Lglutamate and 10 µM glycine) response by co-application of MK-801 (1 µM) and agonists at the GluN2C subtype of
NMDARs. (B) Trace showing first the potentiation of the agonists-induced (10 µM L-glutamate and 10 µM glycine)
response by co-application of UBP684 (100 µM) at GluN2C and then inhibition by MK-801 (1 µM) in presence of the
agonists and UBP684. (C) Normalized trace showing the differential rate of MK-801 block in the absence (black) and
the presence (red) of 100 µM of UBP684. Scale bar: horizontal = time in sec, vertical = current in nA. (D). Bar graph
showing the rate of MK-801 block at GluN2C receptors by 1 µM of MK-801 in the presence (red bar; n = 4 oocytes) and
in the absence (black bar; n = 3 oocytes) of 100 µM UBP684. Rate of inhibition by MK-801 was obtained from a single
exponential function. Data represent mean ± S.E.M. *p˂0.05 (unpaired t-test). (E) Rate of inhibition by 10 µM of
UBP792, a novel NMDAR NAM, in presence (blue bar, n = 6 oocytes) or absence (black bar, n = 6 oocytes) of UBP684.
Data represent mean ± S.E.M.

152

4.4.9

UBP684 slows receptor deactivation following the removal of agonist

One possible mechanism of enhanced activity by UBP684 / UBP753 could be by prolonging the
deactivation of the receptors. We investigated the effect of UBP684 and UBP753 on deactivation
of GluN2D-containing receptors expressed in Xenopus laevis oocytes since GluN2D receptors
have a remarkably slow deactivation time. The deactivation of the receptors in the constant
presence of 50 µM of UBP684 was significantly slower as shown in Figure 4.10A. Deactivation
time was 9.6 ± 1.6 s (n = 11 oocytes) in the presence of UBP684 which was significantly slower
than the control (4.1 ± 0.6 s; n = 23 oocytes). Although there was a trend for prolonged
deactivation by UBP753, it was not significant. The reason behind prolong deactivation by
UBP684 might be due to slowing down the unbinding of one or both of the agonists from the
receptors. We then investigated the effect of UBP684 on the deactivation time of individual
agonists. We studied the dissociation/deactivation of glycine by washing out glycine in the
continued presence of the PAM and L-glutamate. We did not observe any significant effect of
either UBP684 or UBP753 on glycine dissociation/deactivation time (Figure 4.10B). However,
using the same approach, we find that UBP684 significantly slowed the dissociation/deactivation
time for L-glutamate (Figure 4.10C). Time for deactivation after L-glutamate removal from
GluN2D-containing NMDARs in absence of UBP684 was 9.6 ± 1.7 s (n = 6 oocytes) and in
presence of UBP684 was 20.2 ± 4.1 s (n = 7 oocytes) and the difference was significant (p = 0.04;
one-way ANOVA, followed by Bonferroni’s multiple comparison test). Interestingly, UBP753
did not have any significant effect on dissociation time of either agonists.

153

A.
D e a c tiv a tio n tim e (  w , S e c )

25

20

***
15

10

5

0
R e c b u ff-1

D e a c tiv a tio n tim e (  w , S e c )

B.

+753

+684

25

20

15

10

5

0
+ G lu

D e a c tiv a tio n tim e (  w , S e c )

C.

+ 7 5 3 G lu + 6 8 4 G lu

*

25

20

15

10

5

0
+ G ly

+ 7 5 3 G ly + 6 8 4 G ly

Figure 4.10 UBP684 slows the deactivation time of NMDARs
(A) Receptor deactivation time was studied by removing agonists (10 µM L-glutamate or10 µM glycine) after obtaining
GluN1-1a/GluN2D steady-state response with /without UBP753 (50 µM) or UBP684 (50 µM). The deactivation time
constant was obtained by a two-component exponential function. A representative trace of agonist dissociation in
presence of UBP684 is shown in the middle and the super-imposed, normalized trace with (red) and without (black)
UBP684 deactivation component is shown on the right (n = 7-15 oocytes per group). Data represent mean ± S.E.M.
***p˂0.001

(one-way ANOVA followed by Bonferroni’s multiple comparison test). (B) Deactivation time for glycine

removal was studied in presence of the corresponding PAM and L-glutamate. Traces in the middle show the
dissociation/deactivation kinetics of glycine and the trace on the right is the normalized trace of the dissociation
component (with UBP684, red; without UBP684, black; n = 5 oocytes per group). Data represent mean ± S.E.M. (C) The
deactivation time for L-glutamate removal in the presence of glycine and in presence/absence of UBP 684 or UBP753.
The trace in the middle shows the dissociation/deactivation kinetics following L-glutamate removal and the trace on the
right is the normalized trace of the deactivation kinetics (n = 6-7 oocytes per group). Scale bar: horizontal = time in sec,
vertical = current in nA. Data represent mean ± S.E.M. *p˂0.05 (one-way ANOVA followed by Bonferroni’s multiple
comparison test).
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4.4.10

UBP684 potentiation is affected by the conformation of ligand binding
domain of the GluN2 subunit

By introducing the two cysteine mutations in each ligand binding domain of GluN1 or GluN2A
subunits, two NMDAR constructs with disulfide bridges were created which constrain the
respective LBDs in the closed-cleft conformation and mimic the glycine-bound conformation of
the LBD of GluN1 or the L-glutamate-bound conformation of the LBD of GluN2A-containing
NMDARs. By co-expression of the disulfide crosslinked GluN1c with the wildtype GluN2A or
wildtype GluN1 with crosslinked GluN2Ac in Xenopus laevis oocytes, we evaluated the effect of
constrained LBDs on UBP753 potentiation. Similar to the finding by Kussius and Popescu
(Kussius, Popescu 2010), we confirmed that the receptors containing GluN1c, which mimic the
glycine bound conformation, were activated by L-glutamate alone and not by glycine alone. Also,
the receptors containing GluN2Ac, which mimic the L-glutamate bound conformation, were
activated by glycine and not by glutamate. Interestingly, the potentiation by UBP753 of GluN1c
containing GluN2A receptors was almost similar to that of wild type GluN2A receptors.
However, the potentiation by UBP753 at GluN2Ac containing receptor was significantly reduced
(****p˂0.0001, one-way ANOVA followed by Tukey’s multiple comparison test) compared to the
WT GluN2A receptors or GluN1c containing GluN2A receptors as shown in Figure 4.11A. The
potentiation by 100 µM of UBP753 at WT GluN2A, GluN1c containing receptor and GluN2Ac
containing was 51.3 ± 3.7 % (n = 17 oocytes), 39.4 ± 6.5 % (n = 9 oocytes), and 6.3 ± 1.4 % (n =
17 oocytes) respectively (Figure 4.11B). These results suggest that the mechanism of potentiation
by UBP753 is by stabilizing the glutamate bound confirmation of GluN2 receptors.
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Figure 4.11 Effect of the LBD cleft conformation on potentiation by UBP753
(A) Representative recordings showing the effect of UBP753 (100 µM) on wildtype (GluN1/GluN2A), GluN1 LBDlocked (GluN1c/GluN2A) and GluN2A LBD-locked (GluN1/GluN2Ac) NMDARs expressed in Xenopus laevis oocytes.
Scale bar: horizontal = time in sec, vertical = current in nA. (B) A bar graph showing UBP753 potentiation of agonistinduced (10 µM L-glutamate and 10 µM glycine) response from oocytes expressing WT (n = 17 oocytes), GluN1 LBDlocked (n = 9 oocytes) and GluN2A LBD-locked (n = 16 oocytes) receptors. (C) Schematic showing the two cysteine
point mutations in the LBD region of GluN1 (N499C and Q686C) leading to the glycine binding site-locked conformation
and in the LBD of GluN2A (K487C and N687C) leading to the L-glutamate binding site-locked conformation. Data
represent mean ± S.E.M. ****p˂0.0001 (one-way ANOVA followed by Tukey’s multiple comparison test).
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4.4.11

Effect of extracellular pH on NMDAR activity of UBP684 at GluN2A-D
subtypes of NMDARs

In pathological conditions, there is a change in extracellular pH in the brain’s extracellular space,
which can affect the function of allosteric modulators either making them more or less effective
(Mott, Doherty et al. 1998, Pahk, Williams 1997). To predict how such conditions would affect
PAM activity, we measured the effect of pH on the potentiating activity of UBP684 on GluN2A-,
GluN2B-, GluN2C-, and GluN2D-containing NMDARs. Interestingly, the potentiating activity of
UBP684 was eliminated at pH 8.4 and instead, it displayed NMDAR inhibitory activity in a
subunit-dependent manner (Figure 4.12). At pH 7.4, UBP684 (100 µM) potentiated GluN2A-,
GluN2B-, GluN2C-, and GluN2D-containing NMDARs by 64.6 ± 4.1 % (n = 16 oocytes), 83.3 ±
7.4 % (n = 14 oocytes), 96.9 ± 5.2 % (n = 23 oocytes), and 67.4 ± 6.6 % (n = 10 oocytes)
respectively. In contrast, at pH 8.4, UBP684 inhibited the GluN2A-, GluN2B-, GluN2C- and
GluN2D-containing NMDARs by 6.2 ± 1.0 % (n = 9 oocytes), 13.5± 1.8 % (n = 7 oocytes), 32.9
± 2.8 % (n = 6 oocytes), and 55.7 ± 6.5 % (n = 6 oocytes) respectively. Thus, at alkaline pH,
UBP684 becomes most inhibitory at GluN2D-containing receptors and least inhibitory at
GluN2A-containing NMDARs. This result implies that proton inhibition might be necessary for
the potentiating activity of UBP684.
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Figure 4.12 Effect of extracellular pH on NMDAR activity of UBP684 at GluN2A-D subtypes
of NMDARs expressed in Xenopus laevis oocytes
(A) Representative current traces showing the effect of extracellular pH (7.4 and 8.4) on UBP684 activity, as measured
by TEVC, at recombinant GluN1/GluN2A-D receptors expressed in Xenopus laevis oocytes. Currents were first evoked
by 10 µM L-glutamate and 10 µM glycine and after achieving a steady-state, UBP684 (100 µM) was co-applied with the
agonists. Scale bars: horizontal = time in sec and vertical = current in nA. (B, C, D, E) The NMDAR-mediated activity
modulated by UBP684 at GluN2A (B; n = ˃ 9 oocytes), GluN2B (C; n = ˃ 7 oocytes), GluN2C (D; n = ˃ 6 oocytes) and
GluN2D (E; n = ˃ 6 oocytes) was measured at extracellular pH of 7.4 and 8.4 from the same oocytes and the response
was expressed as % potentiation above the agonist-alone induced response. Bar graphs above zero represent the %
potentiation at pH 7.4 (blue bars) and below zero represent the % inhibition compared to agonist-alone when tested at
pH 7.4 (blue) or pH 8.4 (red). Data represent mean ± S.E.M.
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4.4.12

Effect of extracellular pH on NMDAR-mediated activity of UBP753 at the
GluN2C subtype of NMDARs

We also tested if pH affects the potentiating activity of UBP753. We determined the effect of
different pH conditions (acidic, physiological and alkaline) on potentiation by UBP753 (50 µM)
at GluN2C-containing receptors. UBP753 potentiated the NMDAR response at the pH of 6.4 and
7.4 (163.3 ± 10.2 %, n = 14 oocytes; pH 6.4 and 102.4 ± 6.7 %, n =15 oocytes; pH 7.4) (Figure
4.13). Like UBP684, this compound also displayed NMDAR inhibitory activity in the alkaline
pH condition (% inhibition was 30.5 ± 3.2, n = 16 oocytes; pH: 8.4). A sigmoidal fit of the data
from these three pH conditions estimates that the compound switches between potentiation and
inhibition at pH ~ 8.0 (Figure 4.13).
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Figure 4.13 Effect of extracellular pH on UBP753 activity at the GluN2C subtype of
NMDARs
UBP753 (50 µM) was tested at different pH conditions to study the effect of protons on its activity. Values above zero
are % potentiation and below zero is % inhibition of the agonist-evoked response. n = ˃ 14 oocytes; data represent mean
± S.E.M.
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4.4.13

Effect of UBP684 on the concentration-response of H+ inhibition at NMDARs

We next wanted to determine if compounds are affecting the sensitivity of the NMDARs for
proton inhibition. We performed the concentration-response study with increasing concentrations
of protons on GluN2B- and GluN2D-containing NMDARs in presence and absence of 50 µM
UBP684. We found that UBP684 reduced H+ sensitivity at both GluN2B- and GluN2Dcontaining NMDARs. There was a right shift on both of the curves in the presence of UBP684
(Figure 4.14). Proton inhibition at the GluN2D receptor was more affected than that at GluN2Bcontaining receptors in the presence of UBP684.
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Figure 4.14 Effect of UBP684 on H inhibition at GluN2B and GluN2D subtypes of NMDARs
(A, B) Effect of UBP684 (50 µM) on proton inhibition was studied on GluN2B- (A) and GluN2D- (B) containing
NMDARs. NMDAR responses were measured with increasing concentrations of protons in absence (black curve; n = 8
oocytes, GluN2B; n = 12 oocytes, GluN2D) or presence (blue curve; n = 10 oocytes for GluN2B; n = 11 oocytes for
GluN2D) of UBP684. Data from each oocyte was normalized to the NMDAR response obtained at pH 8.5 in absence of
UBP684 from same oocyte. Data are mean ± S.E.M.
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4.4.14

Effect of different GluN1 splice forms on UBP684-mediated changes in proton
sensitivity at GluN2D receptors

These findings suggest that the mechanism of potentiation by UBP684 may be due to relief of
proton inhibition. To evaluate this possibility, we compared the activity of UBP684 at GluN2D
receptors co-expressed with GluN1 having exon-5 (GluN1-1b) to the activity at GluN2D
receptors co-expressed with GluN1 lacking exon-5 (GluN1-1a). The exon-5 segment codes for an
extra 21-amino acid sequence, which reduces the proton-sensitivity to the N-terminal domain
(NTD) proton sensor site. Although, UBP684 significantly reduced proton sensitivity, we did not
observe any change in the potentiating activity of UBP684 at GluN2D receptors containing
GluN1-1a or GluN1-1b variants at all pH conditions tested (Figure 4.15 A) and UBP684
potentiated both variants with almost equal affinity and maximal effect (Figure 4.15 B). The EC50
values for UBP684 potentiation at GluN1-1a- or GluN1-1b-containing GluN2D receptors were
29.9 ± 6.5 µM (% EMax = 68.6 ± 9.2, n = 6 oocytes) and 28.3 ± 6.1 µM (% EMax = 67.8 ± 7.8, n =
5 oocytes) respectively, under physiologic pH conditions. However, in an alkaline pH condition,
UBP684 inhibited GluN2D receptors with either GluN1-1a or GluN1-1b splice forms. The
affinity for UBP684 inhibition at GluN1-1b-containing GluN2D receptors was slightly higher
than the GluN1-1a-containing GluN2D receptors as shown by slight leftward shift in the
concentration-response curve (Figure 4.15C). The IC50s of UBP684 at GluN1-1a- and GluN1-1bcontaining GluN2D receptors were 23.0 ± 3.2 µM (n = 4 oocytes, % IMax = 69.8 ± 6.4) and 17.0 ±
2.7 µM (n = 5 oocytes, % IMax = 73.8 ± 3.1) respectively, under the alkaline pH condition. These
findings show that both the affinity and the % EMax (or % IMax) were not significantly changed by
the presence of the GluN1 splice forms. Spermine is a GluN2B potentiator at physiological pH
and becomes an inhibitor at alkaline pH. However, its responses to GluN1-1a and GluN1-1b are
different. Thus, the requirement of protons for the potentiating activity of UBP684 is different
from the requirement of protons for the potentiating activity of spermine.
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Figure 4.15 Effect of GluN1 splice variants on UBP684-mediated change in proton sensitivity
at GluN2D receptors
(A) NMDAR activity was measured at GluN2D-containing receptors co-expressed with either GluN1 subunit without
exon-5 (GluN1-1a; black bar) or with exon-5 (GluN1-1b; grey bar) in Xenopus laevis oocytes. Potentiation by 50 µM
UBP684 was determined at different pH (7.4, 8.1, 8.4). Values above zero represent the % potentiation and below zero
are % inhibition, n = 5-7 oocytes. (B) At pH 7.4, the effect of increasing concentrations of UBP684 on its potentiating
activity at GluN2D- containing NMDARs co-expressed with either GluN1-1a (black; n = 6 oocytes) or with GluN1-1b
(blue; n = 5 oocytes) was studied. (C) At pH 8.4, the effect of increasing concentrations of UBP684 on inhibitory activity
at GluN2D-containing NMDARs co-expressed with either GluN1-1a (black; n = 5 oocytes) or with GluN1-1b (red; n =
5 oocytes) was measured. Data represent mean ± S.E.M.
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4.4.15

Effect of pH on potentiating activity of other known NMDAR PAMs

The effect of protons we observed on the potentiating activity of UBP684/UBP753 led us to test
for similar effects on the activity of other NMDAR PAMs. Pregnenolone sulfate (PS)-induced
potentiation at both GluN2A- and GluN2B-containing NMDARs was reduced at alkaline pH. At
a physiological pH of 7.4, PS (100 µM) potentiated GluN2A and GluN2B receptor activity by
95.6 ± 10.2 % (n = 12 oocytes) and 140.6 ± 20.0 % (n = 9 oocytes) respectively. At pH 8.4, the
potentiation was significantly reduced to 49.7 % ± 6.7 (n = 9 oocytes) at GluN2A and 81.3 ± 10.1
(n = 8 oocytes) at GluN2B-containing NMDARs (Figure 4.16A). Similarly, we measured the
activity of CIQ, a GluN2C/GluN2D-selective potentiator, at physiologic and alkaline pH. The
alkaline pH condition significantly reduced the potentiating activity by 30 µM CIQ at GluN2Ccontaining NMDARs (54.7 ± 4.8 %; n = 13 oocytes at pH 7.4 vs 20.3 ± 1.7 %; n = 11 oocytes at
pH 8.4) (Figure 4.16B). Although there was some reduction in the potentiating activity of both PS
and CIQ at NMDARs, they were able to maintain the potentiating activity in the alkaline pH
condition. However, GNE-8324, a GluN2A-specific potentiator, became an inhibitor at alkaline
pH, which was similar to the activity that we observed for UBP684 and UBP753. GNE-6834
potentiated at GluN2A-containing receptors by 32.3 ± 2.6 % (n = 17) at pH 7.4 and inhibited the
receptors by 5.6 ± 1.6 % (n = 16) at pH 8.4 (Figure 4.16 C). This finding suggests that GNE-8324
and UBP684 or UBP753 may share similar mechanisms of potentiation of NMDAR response.
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Figure 4.16 Effect of extracellular pH on the potentiating activity of other NMDAR PAMs
(A) The effect of pH on the enhancement of agonist-evoked (10 µM L-glutamate and 10 µM glycine) responses by
pregnenolone sulfate (100 µM) at GluN2A and GluN2B subtypes of NMDARs expressed in Xenopus laevis oocytes.
Pregnenolone sulfate-induced NMDAR current potentiation was studied at pH 7.4 (blue bars) and pH 8.4 (red bars) (n =
˃ 8 oocytes for each bar). Data represent mean ± S.E.M. *p<0.05, **p<0.01. (B) Effect of pH on potentiation by 30 µM
CIQ (a GluN2C/GluN2D-selective positive allosteric modulator of NMDARs) at GluN2C NMDARs (n = 11 oocytes).
Data represent mean ± S.E.M. ****p<0.0001. (C) Effect of pH on potentiation by 30 µM GNE-8324 (a GluN2A-selective
positive allosteric modulator of NMDARs) of NMDAR-mediated activity at GluN2A NMDARs. Values below zero
represent % inhibition of agonist-induced responses (n = 15 oocytes). Data represent mean ± S.E.M.
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4.4.16

Effect of GluN1 or GluN2A C-terminal truncation on the potentiating activity
of UBP684 and pregnenolone sulfate

We then sought to determine role of the C-terminal on the potentiating activity of UBP684 since
the C-terminal can control the gating of the NMDAR channel. Also, it has been reported that the
phosphorylation state of the C-terminal is necessary for PS potentiation. We measured the
potentiating activity of UBP684 (100 µM) at GluN2A-containing NMDARs with or without the
C-terminal of either GluN1 or GluN2 subunits. The C-terminal deletion was achieved by
introducing the stop codons at K838 of GluN1-1a (GluN1Δct) and K844 of GluN2A subunits
(GluN2AΔct). We observed a significant reduction (p = 0.0002, one-way ANOVA followed by
Bonferroni’s multiple comparison test) on the potentiating activity of UBP684 at GluN2A
receptors co-expressed with GluN1 having truncated C-terminal. However, there was no
significant change in the potentiating activity of UBP684 at GluN2A subunits with the C-terminal
truncation. The potentiation by UBP684 at GluN2A-WT, GluN1Δct /GluN2A, and GluN2A Δct
were 36.0 ± 4.7 % (n = 13 oocytes), 8.4 ± 2.1 % (n = 13 oocytes), and 25.2 ± 5.4 % (n = 12
oocytes) respectively (Figure 4.17A). In contrast to the activity of UBP684, the potentiating
activity of pregnenolone sulfate at these receptors was opposite. GluN1 C-terminal truncation did
not change the potentiating activity of 100 µM of PS at GluN2A-containing receptors. However,
the C-terminal truncation from GluN2A subunit eliminated the potentiating activity of PS and
converted it into an inhibitor. The potentiation by PS at WT GluN2A and GluN1Δct/GluN2A was
35.4 ± 6.8 % (n = 16 oocytes), and 32.0 ± 6.2 % (n = 14 oocytes) respectively and the difference
was not statistically significant. However, PS was an inhibitor at NMDARs containing GluN2A
Δct
,

and GluN1Δct/ GluN2A Δct subunits. PS inhibited the GluN2A Δct, and GluN1Δct/ GluN2A Δct

subunit-containing NMDARs by 45.0 ± 3.0 % (n = 11 oocytes) and 55.0 ± 2.0 % (n = 4 oocytes)
respectively (Figure 4.17 B). These results indicate that the C-terminal of GluN2A receptors is
required for the potentiating activity of PS.
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Figure 4.17 Effect of GluN1 or GluN2A C-terminal truncation on the potentiating activity
of UBP684 and pregnenolone sulfate
(A) NMDARs truncated at K838 on GluN1-1a or K844 on GluN2A were expressed in Xenopus laevis oocytes and tested
for potentiation by 100 µM UBP684 as indicated (n = 12 -13 oocytes). Data represent mean ± S.E.M. *p˂0.05, ***p˂0.001
(one-way ANOVA followed by Tukey’s multiple comparison test). (B) Effect of C-terminal deletion from GluN1-1a
and/or GluN2A was also tested for potentiating activity by 100 µM pregnenolone sulfate (n = 11-16 oocytes for WT and
single truncation, n = 4 for double truncation). Data represent mean ± S.E.M.
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4.4.17

Effect of intracellular calcium on the potentiating activity of UBP684 at
GluN2A- and GluN2B-containing NMDARs

In the previous section, we found that the intracellular portion of the C-terminal can have a
profound effect on PAM activity. Thus, intracellular factors may potentially alter PAM
sensitivity. One of the intracellular factors to control the PAM activity may be Ca2+. Intracellular
calcium plays an important role in regulating NMDAR function. Similarly, receptor
phosphorylation could also be changing PAM sensitivity as reported for PS. To study the effect of
Ca2+ on the potentiating activity of UBP684, we removed intracellular Ca2+ from oocytes
expressing GluN2A and GluN2B receptors by injecting a Ca2+ chelator (EGTA) and examined
the UBP684 activity with reduced intracellular Ca2+ levels. We used two agonist-application
paradigms: Sequential and contemporaneous. In the sequential application, UBP684 was applied
first for 30 sec and the subsequent agonist-evoked response was measured and compared to the
agonist-alone response before UBP684 application. In the contemporaneous application, we first
activated receptors with agonists and then UBP684 was co-applied with agonists and the response
obtained with co-application was compared with the agonist-alone induced response before the
co-application. The sequential application of UBP684 (50 µM) enhanced the agonist-induced
response by 15.3 ± 2.5 % (n = 9 oocytes) in water injected and by 1.7 ± 1.5 % (n = 13 oocytes) in
the EGTA injected GluN2A oocytes (Figure 4.18A). The sequential application of UBP684 (50
µM) potentiated the agonist-induced response by 40.3 ± 5.5 % (n = 8 oocytes) in water-injected
oocytes and by 30.0 ± 3.5 % (n = 10 oocytes) in the EGTA-injected GluN2B-expressing oocytes
(Figure 4.18B). Similarly, the contemporaneous application of UBP684 (50 µM) in GluN2A
receptors expressing oocytes potentiated the agonist response by 34.0 ± 13.0 % (n = 8 oocytes) in
water-injected control oocytes and by 9.2 ± 2.7 % (n = 19 oocytes) in the EGTA-injected oocytes
(Figure 4.18A). In GluN2B expressing oocytes, the contemporaneous application of UBP684 (50
µM) potentiated the agonist-induced response by 49.2 ± 7.5 % (n = 11 oocytes) in water-injected
control oocytes and by 32.1 ± 2.2 % (n = 10 oocytes) in the EGTA-injected oocytes (Figure
4.18B)
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Figure 4.18 Effect of intracellular calcium on the potentiating activity of UBP684 at GluN2Aand GluN2B-containing NMDARs
(A) Xenopus laevis oocytes expressing GluN2A NMDARs were pre-injected with 100 nL of water as a control (black
bar) or 100 nL of 5 mM of the EGTA (Ca2+ chelator; blue bar) and incubated in ND-96 for 2-3 h at 17 OC. Responses are
shown for agonist-alone (10 µM L-glutamate and 10 µM glycine; bar A), agonist response following a 30-second preapplication of 50 µM of UBP684 (bar B; sequential application) or the agonist response when co-applied with UBP684
(Bar C) after obtaining an agonist-alone steady-state response (n = 8-19 oocytes). (B) Using similar methods as that for
GluN2A, the effect of chelating intracellular Ca2+ with 5 mM of EGTA on the potentiating activity of UBP684 was
studied on GluN2B-containing receptors. n = 8-16 oocytes in each group, data represent mean ± S.E.M.
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4.4.18

Effect of PKC activation on the potentiating activity of UBP753 and PS at
GluN2B-containing NMDARs

Since the removal of intracellular calcium by injecting EGTA reduced the potentiating activity of
UBP684, we studied the effect of PKC on PAM activity of UBP753 to determine if reduced
potentiation could potentially be due to blocking PKC dependent phosphorylation. We measured
the potentiation by UBP753 (100 µM) and PS (100 µM) before and after the treatment of oocytes
with PMA (2 µM), a PKC activator, for 10 minutes. PKC treatment significantly increased the
UBP753-induced potentiation at GluN2B-containing NMDARs. UBP753 potentiated the GluN2B
receptors mediated response by 141.0 ± 15.0 % (n = 6 oocytes) before and by 234.0 ± 45.0 % (n =
6 oocytes) after the PMA treatment (Figure 4.19A). However, the PMA treatment did not cause
any change on potentiation by PS at GluN2B-containing NMDARs. The PS potentiated the
NMDAR response by 79.0 ± 7.0 % (n = 5 oocytes) before and by 75.3 ± 8.4 % (n = 5 oocytes)
after the treatment with PMA (Figure 4.19B). These results show that UBP753 activity is
enhanced by PKC phosphorylation while PS activity is not dependent on PKC phosphorylation.
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Figure 4.19 Effect of the PKC activation on the potentiating activity of UBP753 and PS at
GluN2B-containing NMDARs
(A) After obtaining a stable agonist response with 10 µM L-glutamate and 10 µM glycine at GluN1-1a/GluN2B receptors,
UBP753 (100 µM) was co-applied. Then, the same oocytes were treated with 2 µM of the PMA (PKC activator) for 10
minutes by bath perfusion and UBP753-induced potentiation was measured again. This UBP753-induced enhancement
of the responses was compared to the potentiation produced before the PMA treatment (n = 6 oocytes). Data represent
mean ± S.E.M, *p˂0.005 (paired t-test). (B) The effect of PKC activation on the activity of pregnenolone sulfate was
determined as in A by measuring agonist-induced responses before and after PMA treatment (n = 5 oocytes). Data
represent mean ± S.E.M.
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4.5

Discussion

Our laboratory previously has reported various NMDARs PAMs with different patterns of
subunit selectivity. UBP512, a phenanthrene derivative, selectively potentiated GluN2A, did not
have any effect on GluN2B, and inhibited GluN2C and GluN2D subtypes of NMDARs (Costa,
Irvine et al. 2010). UBP710 selectively potentiated GluN2A and GluN2B and UBP551 selectively
potentiated GluN2D and inhibited the other NMDAR subtypes (Costa, Irvine et al. 2010).
Although these PAMs were selective, they did not exhibit a high magnitude of potentiation and
were not highly potent. In attempt to identify general NMDAR PAMs, we recently have
identified two compounds with NMDAR PAM activity, UBP684 and UBP753, which show
greater efficacy and potency at NMDARs than our previously reported PAMs. Both of these
compounds showed potentiating activity across all subtypes of NMDARs. These are the mosteffective general NMDAR PAMs reported to date.
Since, during synaptic neurotransmission, there is a high level of glutamate release, it is
important to know if UBP684 and UBP753 retain their PAM activity in the presence of saturating
agonist concentration. We found that these compounds were able to potentiate all NMDAR
subtypes in the presence of high agonist concentration (Figure 4.2). Consistent with this finding,
these compounds increased glutamate and glycine efficacy with minimal effects on agonist
affinity. There was a small reduction in potentiation by UBP684 at GluN2A and GluN2B
receptors at high agonist concentration (Figure 4.3) which is consistent with the previous report
that potentiation by PS at GluN2B receptors is reduced in presence of 1 mM glutamate (Horak,
Vlcek et al. 2004). This might imply that UBP684 would increase agonist affinity at GluN2A or
GluN2B receptors. UBP684 increased the apparent affinity of the glycine but not of the Lglutamate at GluN2B receptors. Similarly, UBP753 enhanced the efficacy of both L-glutamate
and glycine but did not increase the apparent affinity of either of the agonists at GluN2D
receptors. These results, in part, are consistent with the effect of PS on glutamate and glycine
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efficacy and affinity where PS slightly increases agonist potency at GluN2B containing receptors
and has a reduced effect on efficacy with high agonist concentrations (Malayev, Gibbs et al.
2002).
UBP684 enhances the NMDAR current by increasing the channel open probability of the
receptor as evident by increase in rate of inhibition by an open channel blocker MK-801.
Although it increased the channel Popen, it did not change the potency of blockade by ketamine, an
open channel blocker of NMDARs. This implies that UBP684 binding does not alter the ketamine
binding site in the pore or have a binding site that partially overlaps with ketamine. Previous
studies with other PAMs like PS and SGE-201 also have shown that they do not have any effect
on the potency of channel blockers such as memantine and ketamine at GluN2A receptors
(Emnett, Eisenman et al. 2015) consistent with a binding site outside of the channel pore. These
drugs are voltage-independent and they potentiate receptor responses with almost similar efficacy
at both positive and negative membrane potentials. They also do not change the reversal potential
of the NMDAR current (Figure 4.5).
From our previous studies, it is known that the activity of this class of drugs is not
affected by deletion of the N-terminal domain of the NMDARs. Also, to determine if they bind to
the C-terminal, we injected UBP684 directly inside the oocytes and measured UBP684
potentiation by bath application. UBP684 was still able to potentiate the current to the same
magnitude (unpublished observation). This implies that UBP684 does not bind to C-terminal of
the NMDARs. These findings suggest that UBP684/UBP753 must be binding either to the LBD
domain similar to binding of recently reported GluN2A-selective potentiator GNE-6901(Hackos,
Lupardus et al. 2016) or close to the transmembrane region similar to binding of GluN2C/
GluN2D potentiator CIQ (Mullasseril, Hansen et al. 2010).
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Our study shows that these potentiators are still able to potentiate in a reducing
environment. Although there was some reduction in % potentiation by UBP753 (Figure 4.6),
absolute magnitude of potentiation could be similar because DTT treatment enhances the agonist
response (Sullivan, Traynelis et al. 1994) and the enhanced agonist response after DTT treatment
was used for the normalization of UBP753 potentiation after DTT treatment, which could have
resulted in lower % potentiation by UBP753 after DTT. We also found that UBP684 potentiation
is not reduced in the GluN1 splice form with exon-5. NMDARs with exon-5 show a reduction in
proton inhibition (Traynelis, Hartley et al. 1995) and a corresponding reduction in spermine
potentiation (which also reduces proton inhibition). Hence, the equal potentiation of NMDARs
with GluN1-1a and GluN1-1b splice variant (Figure 4.6) suggests that the potentiation by
UBP684 is not by relieving the proton inhibition of the receptors, at least not by the same
mechanism as seen by spermine (Traynelis, Hartley et al. 1995). It also implies that spermine and
UBP753 bind to different sites for their potentiating activity, which is supported by our previous
report that the N-terminal deletion does not eliminate the PAM activity (Costa, Irvine et al. 2010).
From PAM/NAM competition studies, we know that the binding site for the potentiating
and inhibiting activities of PAMs and NAMs are different. Although the NAMs and PAMs have
similar structural features, they do not compete for binding and appear to exert their effect via
different binding sites (Figure 4.7). Interestingly, the presence of one PAM (UBP512) eliminated
the potentiating activity of another PAM (UBP684). This suggests that these two PAMs may have
different binding sites. Given the multiplicity of homologous, but non-identical interfaces in a
heteromeric complex, UBP684 and UBP512 may be binding in distinct, but structurally similar,
binding sites.
Molecular docking studies of UBP684 binding shows that this compound can dock in the
LBD region of GluN1-1a/GluN2A dimer interface (Figure 4.20) . The end of the alkyl side-chain
of UBP684 terminates near the hinge region of GluN1 near Y535 residue and the carboxylic acid
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group at 2-position of naphthalene in UBP684 interacts with the positively charged amino acid
residues on the top of the LBD and near from NTD. The binding region revealed by this docking
was similar to the binding site for GluN2A-selective PAM GNE-6901 as demonstrated by its
crystal structure (Hackos, Lupardus et al. 2016).

Figure 4.20 UBP684 docking at the LBD dimer-interface
Molecular modeling of UBP684 binding to the GluN1/GluN2A receptor LBD dimer. (Top) UBP684 (space filled) is
shown docked into the GluN1/GluN2A LBD intersubunit interface. Modelling suggests that the carboxylic acid group of
UBP684 interacts with positively charged residues on the top of the LBD away from the transmembrane domains and
near the N-terminal domains. The alkyl side-chain terminates near the LBD hinge region near the GluN1 Y535 shown in
green. (Bottom) The same docking of UBP684 is shown rotated in the horizontal plane with the GluN1 LBD removed
and GluN1’s Y535 (green) shown for reference.
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Our results also indicate that these PAMs bind in both presence and absence of agonists.
Sequential application of both PAMs increased the onset time and NMDAR response of the
agonist (Figure 4.8). Also, pre- and co-application of these compounds showed a rapid onset and
sustained response. Both of these application paradigms suggest that UBP753 can bind to the
agonist-unbound confirmation. In contrast, when agonist was co-applied with UBP753, with no
prior exposure, the response displayed a slow onset rate. Contemporaneous application also
displayed a slow onset of drug potentiation. These results imply that UBP753 can also bind in the
presence of the agonists. The NMDAR response observed after pre-co-application was sustained
for UBP753, whereas pre-co-application led to reduction in response for PS (Horak, Vlcek et al.
2004). This suggests that UBP753’s affinity is not reduced by agonist as it is for PS.
Consistent with an increase in Popen, we found that UBP684 prolongs the deactivation
time for GluN2D receptors (Figure 4.10). It especially slows the dissociation of L-glutamate from
its binding site or the associated deactivation. Similar findings have been previously reported with
PS where PS prolongs the GluN2A and GluN2B receptors deactivation rate (Ceccon, Rumbaugh
et al. 2001).
The effect of UBP684 on deactivation time following L-glutamate removal (but not that
following glycine removal) and the inability of UBP753 (or UBP684, data not shown) to
potentiate GluN2A receptors with disulfide cross-linked LBD (Figure 4.11) implies that these
drugs stabilize the glutamate-bound close-cleft conformation of the GluN2 LBD. In turn, this
conformation stabilizes the open channel, thus increasing open channel probability.
Proton concentration in the tissue varies during different pathological conditions. During
ischemic conditions, acidification occurs in brain tissue (Katsura, Asplund et al. 1992,
Matsumoto, Obrenovitch et al. 1990). Hence, our aim was to determine the effect of different
proton concentrations on the activity of these PAMs. Our study shows that the extracellular
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proton concentration is crucial for the potentiating activity of these PAMs (UBP753 and
UBP684). The loss of potentiating activity of UBP684 at GluN2A, and reversal of activity from
potentiating to inhibitory at GluN2B-, GluN2C- and GluN2D-containing NMDARs when tested
at alkaline pH condition (Figure 4.12), shows that protons were important for PAM activity. This
is also supported by the enhanced UBP753 PAM activity at acidic pH (pH 6.4) (Figure 4.13).
These findings suggest that protons enhance the potentiating activity of PAMs and that reducing
the proton concentration adversely affects the PAM activity at NMDARs. Also, proton-dependent
activity of PAMs was dependent upon the type of the NMDAR subunit. These results suggest that
the PAMs cannot potentiate a highly efficacious NMDAR at alkaline pH, but if the receptor is
inhibited by protons, the PAMs can restore the channel function.
The inhibition by NAMs such as ifenprodil comes from increased apparent affinity of
protons for NMDAR inhibition (Pahk, Williams 1997, Mott, Doherty et al. 1998). Thus, it may be
possible that the potentiating activity of our PAMs was coming from a reduction in the affinity
for proton inhibition. The rightward shift in the proton concentration-response curve by the
presence of UBP684 at both GluN2B- and GluN2D-containing receptors (Figure 4.14) implies
that our PAM reduces the affinity/sensitivity of proton for NMDAR inhibition.
Since the potentiating activity of these tested PAM was highest at acidic pH, it is also
possible that UBP684 potentiating activity was coming from the relief of the proton block and it
should not have any effect at the NMDARs co-expressed with the GluN1-1b splice form which
has an extra 21 amino acid segment which is believed to block the proton sensor region.
However, similar activity observed at GluN2D with either GluN1-1a or GluN1-1b in all tested pH
conditions suggests that these drugs potentiate by different mechanisms (Figure 4.15A,B). The
slight increase in affinity for UBP684 inhibition at GluN1-1b compared to GluN1-1a containing
GluN2D receptors (Figure 4.15C) might be due to increase in the affinity of protons for NMDAR
inhibition. This finding is distinct from that found for the potentiating activity of spermine at
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GluN2B receptors. Spermine does not potentiate at alkaline pH and has the highest level of
potentiation at acidic pH, which is consistent with our finding about PAMs activity. However,
spermine does not potentiate NMDARs with the GluN1-1b splice form, which was not consistent
with the activity of our PAMs. UBP684/ UBP753 potentiate equally both the GluN1-1a and the
GluN1-1b forms containing NMDARs at both acidic and physiologic pH conditions and there
was even an enhanced inhibitory activity at GluN1-1b containing receptors in the alkaline pH
condition. Also, spermine binds to the N-terminal domain and may reduce the sensitivity of the
ATD proton sensor region by blocking the access to protons as. It is unlikely that
UBP684/UBP753 bind to the N-terminal domain because the potentiating activity of structurally
similar PAMs from our laboratory were not affected by deletion of N-terminal domain. Hence,
these results show that the potentiating mechanism of our PAMs is different from that of
spermine potentiation, but may involve other proton-sensitive regions such as the channel gating
region (Low, Lyuboslavsky et al. 2003).
Although reduced proton concentration decreased the potentiating activity of the
neurosteroid PS at GluN2A- and GluN2B- and that of CIQ at GluN2C-containing NMDARs,
these PAMs were still able to retain their potentiating activity unlike the UBP PAMs (Figure
4.16A,B) and the GluN2A-selective PAM (GNE-8324) was not able to potentiate at alkaline pH
(Figure 4.16C). Crystal structure shows that GNE-6901 binds at the heterodimer interface of the
LBD. From molecular docking studies, we find that UBP PAMs may also be binding to the same
binding site in the LBD dimer interface. It is possible that although they are not binding to the Nterminal domain close to the proton sensor region, their binding in LBD may change the
conformation of the proton sensor region in the pore region thereby altering the proton sensitivity
and NMDAR response.
During the course of study of these NMDAR modulators, we observed that there was
more variability in the response of PAMs as compared to NAMs and competitive antagonists.
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Thus, some cells displayed much greater PAM responses than other cells. This may be related to
phosphorylation state or intracellular Ca2+ levels. The activity of other PAMs such as
neurosteroids are affected by the phosphorylation state of the NMDARs. The C-terminal has
many sites for phosphorylation. S897 in GluN1 and S900 and S929 in GluN2A are
phosphorylation sites for PKA. Similarly, S890 and S897 in GluN1 and S1291, S1312 and S1416
in GluN2A are phosphorylation sites for PKC (see review by (Wang, Guo et al. 2014). Using the
C-terminal truncated GluN1 or GluN2A subunits, we were able to measure and compare the
potentiating activity of UBP PAMs and pregnenolone sulfate. There was a significant effect of
GluN1 C-terminal truncation on the potentiating activity of UBP684 and GluN2A C-terminal
truncation on the potentiating activity of pregnenolone sulfate. This finding with pregnenolone
sulfate is consistent with the previous findings that activity of pregnenolone sulfate is
phosphorylation dependent (Petrovic, Sedlacek et al. 2009). Our result, for the first time, shows
that the GluN2A but not the GluN1 C-terminal is more important for the potentiating activity of
PS (Figure 4.17B). Our results with UBP684 also implies that its potentiating activity is highly
dependent on the GluN1 C-terminal, possibly due to phosphorylation state (Figure 4.17A).
However, it is also possible that by deleting the C-terminal, it not only eliminates the
phosphorylation sites for protein kinases, but also eliminates the binding site of intracellular
anchor proteins, which may adversely affect the channel function. However, it is less likely that
the elimination of C-terminal reduces the potentiating activity by deleting the PAM binding sites
because the intracellular injection of UBP684 does not affect the potentiation by bath perfusion of
UBP684.
Calcium is an important second messenger and regulates the function of many kinases,
and thus affects phosphorylation. We observed that intracellular calcium is important for
potentiating activity especially at GluN2A receptors (Figure 4.18). UBP684 displayed
significantly-reduced potentiation in oocytes with chelated intracellular calcium. Thus, calcium is
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necessary for PAM potentiating activity at GluN2A receptors. It is possible that reduced calcium
might reduce the phosphorylation on GluN1 receptors as discussed previously which may affect
potentiation. Interestingly, there was little effect of intracellular calcium reduction on the activity
of UBP684 at GluN2B receptors.
We also found that the potentiating activity of UBP753 was enhanced by PKC activation
(Figure 4.19A). However, PKC activation did not change the activity of pregnenolone sulfate
(Figure 4.19B). Which is consistent with the previous finding that the potentiating activity of PS
is dependent on PKA but not on PKC phosphorylation (Petrovic, Sedlacek et al. 2009). It will be
interesting to test further the effect of PKC activation on the activity of UBP753 on GluN1-1b
expressing NMDARs. Because, PMA treatment increases NMDAR response by 20-fold at
NMDARs complexed with GluN1-1b splice form whereas just by 4-fold at NMDARs complexed
GluN1-1a form (Durand, Gregor et al. 1992).
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Chapter 5 Pharmacological and mechanistic characterization of novel
NMDAR NAM

181

5

Mechanism of allosteric inhibition of NMDARs by the 2-napthoic
acid derivative UBP792

5.1

Abstract
NMDARs are a subtype of ionotropic glutamate receptor that plays an important role in

learning and memory. While optimal NMDAR function is necessary for CNS function, excessive
NMDAR activity leads to neuro-pathological damage as seen in neurodegenerative diseases and
epilepsy. Thus, agents that inhibit NMDAR function have therapeutic applications. In this
chapter, we have characterized the inhibition mechanism of the prototype 2-naphthoic acid
compound, UBP792, which shows a strong inhibitory activity at GluN2D receptors and least
inhibitory activity at GluN2A-containing NMDARs. Inhibition by this compound is noncompetitive and voltage-independent. This compound inhibits NMDARs responses by reducing
the maximal efficacy and affinity of the agonists. The effect of protons on its activity was
different from the effect seen on previously reported NAMs. This compound shows greater
inhibition when the proton concentration is low and inhibition is not affected by exon-5 thus
suggesting that the N-terminal proton sensor is not involved. The binding site of this compound is
different from that of the general PAM (e.g. UBP684). Inhibition by this compound appears to
involve stabilizing the open conformation of the GluN2 ligand-binding domain (LBD). These
findings helps to define the mechanisms of allosteric inhibition of NMDARs by this compound,
which can be utilized in the development of future NMDAR modulators with greater subunit
selectivity and potency that can be used for therapeutic benefit as well as for experimental
purposes.
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5.2

Introduction
As discussed before, optimum activity of NMDARs is important for generation of LTD and

LTP which are thought to play key roles in learning, memory, and cognition [see review by
(Traynelis, Wollmuth et al. 2010)]. However, excessive NMDAR activation is believed to be the
cause of neuronal cell death in stroke, traumatic brain injury and various neurodegenerative
diseases. These findings have led to the development of a large number of NMDAR inhibitors
over the past 30 years to provide neuroprotection in stroke, seizures, and neurodegenerative
disorders. Since, maintaining normal NMDAR function is crucial, optimal inhibition of these
receptors may possibly be achieved by the use of allosteric inhibitors. Since NAMs do not bind to
the highly conserved orthosteric ligand-binding site, it provides an opportunity for subtype
selectivity by binding to more varied, non-conserved regions of the receptor.
The GluN2 subunit determines many of the biological and pharmacological properties of the
NMDARs (Vicini, Wang et al. 1998, Gielen, Retchless et al. 2009, Buller, Larson et al. 1994).
These properties, combined with the varied developmental profiles and anatomical distributions of
GluN2 subunits (Monyer, Burnashev et al. 1994, Ishii, Moriyoshi et al. 1993), imply that GluN2
subtype-selective agents would have distinct physiological and therapeutic properties. The ability
to differentially inhibit specific NMDAR subtypes by the use of negative allosteric modulators
(NAMs), while not affecting other populations, may provide therapeutic benefit.
Recently, research has focused on developing subtype-selective inhibitors to specifically
target the subtypes responsible for the disease (Figure 5.1). Our group previously has published a
series of novel NAMs such as UBP710, UBP552, UBP608 (Costa, Irvine et al. 2010, Irvine, Costa
et al. 2012) with distinct patterns of selectivity at NMDARs GluN2 subunits. These agents do not
act at the agonist binding site, the NTD or the channel pore. Hence the advantage of using these
NAMs are (i) they may offer greater receptor subtype selectivity, and hence reduce adverse effects
and (ii) they can have partial maximal inhibitory effects thus providing protection from excessive
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NMDAR blockade. The compounds TCN-201 (Edman, McKay et al. 2012) and MPX-007
(Volkmann, Fanger et al. 2016) are NAMs, which selectively inhibit only GluN2A-containing
NMDARs. Similarly, ifenprodil (Williams 1993), RO 25-6981 and 93-31(Yuan, Myers et al. 2015)
are NAMs that selectively inhibit GluN2B-containing NMDARs. UBP512 (Costa, Irvine et al.
2010), QNZ46 (Mosley, Acker et al. 2010), DQP-1105(Acker, Yuan et al. 2011) and UBP710
(Costa, Irvine et al. 2010) selectively inhibit GluN2C- and GluN2D-containing NMDARs. Other
compounds such as UBP552 and UBP618, inhibit all NMDAR subtypes with almost equal
selectivity (Costa, Irvine et al. 2012).
In this chapter, we have studied the pharmacology and the mechanism of inhibitory action of
UBP792, a prototype from this series of compounds.
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Figure 5.1 Chemical structures of known NMDAR allosteric inhibitors
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5.3
5.3.1

Materials and methods
Chemicals and compounds

See the details in Chapter 3 (section 3.3.1).

5.3.2

cDNA and cRNA preparation

See the details described in Chapter 3 (sections 3.3.2 and 3.3.3).

5.3.3

Two-electrode voltage clamp electrophysiology

See the details described previously in Chapter 3 (section 3.3.4).

5.3.4

Statistical analysis

See the details described previously in Chapter 3 (section 3.3.5).
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5.4
5.4.1

Results
Concentration-response study of UBP792 at recombinant GluN1/GluN2A-D
receptors

UBP792 inhibited all four subtypes of NMDARs. It inhibited GluN2C and GluN2D receptors the
most and GluN2A receptors the least (Figure 5.2). It showed a moderate inhibitory activity at
GluN2B subtypes of NMDARs. The maximal inhibition by UBP792 at GluN2A-, GluN2B-,
GluN2C-, and GluN2D-containing NMDARs was 30.0 ± 6.3 % (n = 12 oocytes), 61.3 ± 18.0 %
(n = 5 oocytes), 80.1 ± 4.1 % (n = 16 oocytes), and 79.2 ± 3.0 % (n = 12 oocytes) respectively.
The IC50 values for UBP792 inhibition were 30.0 ± 6.0 µM at GluN2A-, 32.0 ± 16.0 µM at
GluN2B-, 8.0 ± 1.0 µM at GluN2C-, and 3.0 ± 0.5 µM at GluN2D-containing receptors (Table
3.3). It displayed a preference for inhibition at GluN2D- and GluN2C-containing receptors
compared to GluN2B- and GluN2A-containing receptors. However, UBP792 inhibited only
partially at the tested concentration (100 µM) and we did not try higher concentration to see if it
causes full inhibition due to limited solubility.

187

U B P792
120
G lu N 2 A

G lu N 2 B

G lu N 2 C

G lu N 2 D

R e s p o n s e (% c o n tr o l)

100

80

60

40

20

0
- 6 .5

- 6 .0

- 5 .5

- 5 .0

- 4 .5

- 4 .0

- 3 .5

lo g [U B P 7 9 2 ] M

Figure 5.2 Concentration-response study of UBP792 at rat recombinant GluN1/GluN2A-D
receptors expressed in Xenopus laevis oocytes.
NMDAR-mediated current was first evoked by agonists (10 µM of L-glutamate and 10 µM glycine) and after achieving
a steady state response, UBP792 was tested for inhibitory activity at increasing concentrations to determine the potency
and efficacy at GluN2A-D subtypes of NMDAs. The NMDAR response was measured and expressed as % inhibition of
agonist-alone (control) response (n = 5-16 oocytes per subunit). Data represent mean ± S.E.M.
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5.4.2

Effect of UBP792 on affinity and efficacy of NMDR agonists at GluN2Dcontaining NMDARs.

In order to determine the mechanism of UBP792 inhibition, we wanted to know if it is competing
with agonists at the ligand binding sites. We performed a concentration-response study of Lglutamate and glycine at GluN2D-containing NMDARs in presence or absence of 5 µM of
UBP792. The compound reduced the % EMax for both L-glutamate and glycine at GluN2Dcontaining receptors. UBP792 inhibited the L-glutamate-induced NMDAR response by 40 %.
The L-glutamate-mediated maximal NMDAR response in absence of UBP792 was 99.7 ± 1.2 %
(n =10 oocytes) while it was 60.0 ± 2.5 % (n = 7 oocytes) in presence of 5 µM UBP792 (Figure
5.3). Similarly, UBP792 also inhibited the glycine-induced NMDAR response by 35 %. The
glycine-mediated maximal NMDAR response in absence of UBP792 was 101.0 ± 2.1 % (n =12
oocytes) while it was 64.3 ± 2.4 % (n = 7 oocytes) in presence of 5 µM UBP792 (Figure 5.3).
Although, UBP792 caused a slight increase in the EC50 for L-glutamate, there was a 6-fold
increase in EC50 for glycine (Table 5.1). We also evaluated the effect of high agonist
concentration on the inhibitory activity of UBP792. UBP792 (10 µM) inhibited the glycine
(mM)-mediated response with the same % of maximal inhibition (% Imax,) similar to the inhibition
of the 10 µM glycine-induced response. Hence, these results suggest that UBP792 is an allosteric
modulator, not competitive, and is binding to a different site than the ligand binding site unlike a
competitive antagonist.
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Table 5.1 EC50 (µM) and % EMax values of agonists in absence and presence of UBP792

*p

Without UBP792
With UBP792

EC50 (µM)
0.88 ± 0.05
1.61 ± 0.3*

Without UBP792
With UBP792

EC50 (µM)
0.4 ± 0.12****
2.55 ± 0.4

< 0.05 and

****

NMDAR subtypes

Glutamate
% EMax
99.7 ± 1.2
59.8 ± 2.5
Glycine
% EMax
101.0 ± 2.4
64.3 ± 1.9

Hill slope
1.6
1.2

N
10
7

Hill slope
1.3
1.55

N
12
7

p < 0.0001 (unpaired t-test) vs EC50 value for L-glutamate or glycine without UBP792 at the same
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Figure 5.3 Effect of UBP792 on affinity and efficacy of NMDAR agonists
(A) Concentration-response study of L-glutamate at GluN2D-containing NMDARs was carried out with increasing
concentrations of L-glutamate and a fixed concentration of glycine (10 µM) in the absence (black, n = 10 oocytes) and
the presence (blue curve, n = 7 oocytes) of 5 µM of UBP792 to study the effect of UBP792 on affinity and efficacy of
NMDAR agonists for recombinant NMDARs expressed in Xenopus laevis oocytes. Data from each oocyte were
normalized to the response from the highest concentration of agonist-alone. Data represent mean ± S.E.M. (B)
Concentration-response study of glycine at GluN2D-containing NMDARs was carried out with increasing concentrations
of glycine and a fixed concentration of L-glutamate (10 µM) in absence (black, n = 12) and presence (blue curve, n = 7)
of 5 µM UBP792. Data represent mean ± S.E.M. (C,D) The concentration-response curves for L-glutamate (C) or glycine
(D) in absence and presence of UBP792 were normalized to the responses of 30 µM glutamate or 30 µM glycine and
superimposed for better illustration of the shift in glutamate EC50. Data represent mean ± S.E.M.
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5.4.3

Effect of high agonist concentration on NMDAR inhibitory activity of UBP792

We also studied the effect of high agonist concentrations on the inhibitory activity of UBP792 to
mimic the synaptic environment. Interestingly, UBP792 inhibition was stronger at GluN2Ccontaining NMDARs in high agonist condition (300 µM of L-glutamate and 300 µM of glycine,
IC50 of 7.5 ± 0.9 µM, n = 5) compared to low agonist condition (10 µM of L-glutamate and 10
µM of glycine, IC50 of 10.5 ± 0.7 µM, n = 6) (Figure 5.4), and the difference in affinities was
statistically significant (p = 0.035, unpaired t-test). This is also evident by the leftward shift in the
concentration-response curves at GluN2C receptors (Figure 5.4). There was no difference in
affinity at GluN2D receptors when tested at low or high agonist concentrations. The IC50 for
UBP792 inhibition at GluN2D receptors was 3.7 ± 0.8 (n = 5) at low and 4.0 ± 0.5 µM (n = 5) at
high agonists condition. Also, the % of maximal inhibition was increased in high agonist
condition at both GluN2C- and GluN2D-containing receptors compared to the low agonist
condition. This result also demonstrates that UBP792 is not a competitive antagonist at ligand
binding site.
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Figure 5.4 Effect of high agonist concentration on NMDAR inhibitory activity of UBP792
The inhibitory activity of UBP792 in different agonist concentrations was studied at recombinant GluN2C- and GluN2Dcontaining NMDARs in the presence of 300 µM L-glutamate and 300 µM glycine (open circles or squares) or in presence
of 10 µM L-glutamate and 10 µM glycine (filled circles or squares) ( n ˃ 6 for each condition). Data are mean ± S.E.M.
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5.4.4

Effect of membrane potential on UBP792 NMDAR inhibitory activity

At 30 µM, UBP792 inhibited GluN2C-containing NMDARs by 58.0 ± 11.6 % (n = 6) at + 40 mV
and by 55.6 ± 9.3 % (n = 7) at – 60 mV; the difference was not statistically significant (Figure
5.5). Hence, UBP792 inhibition is voltage-independent.
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Figure 5.5 Effect of membrane potential on the NMDAR inhibitory activity of UBP792
(A) A trace showing the inhibitory activity of UBP792 (30 µM) was measured at - 60 mV (black) and + 40 mV (red) on
the GluN2C subtype of NMDARs expressed in Xenopus laevis oocytes. Scale bar: horizontal = time in sec, vertical =
current in nA. (B) Bar graph showing the percent inhibition of agonist-evoked (10 µM L-glutamate and 10 µM glycine)
current at -60 mV (n = 6 oocytes, black bar) and +40 mV (n = 7 oocytes, red bar). Data represent mean ± S.E.M.
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5.4.5

Effect of pH and GluN1 splice variant on the inhibitory activity of UBP792 at
GluN2D-containing NMDARs

During different pathological conditions, there is a change in the concentration of protons in the
extracellular space inside the brain. Thus, we were interested to determine if UBP792 maintains
its inhibitory activity under different pH conditions. Although the % inhibition in the acidic
condition was significantly lower compared to physiological and alkaline pH condition, UBP792
still inhibited across the pH range that we tested. UBP792 (30 µM) inhibited the GluN2Dmediated current by 45.1 ± 2.9 % (n = 11 oocytes), 76.5 ± 2.1 % (n = 8 oocytes) and 78.1 ± 2.2 (n
= 10 oocytes) at pH 6.4, 7.4 and 8.4 respectively (Figure 5.6). We also measured UBP792
inhibitory activity GluN2D-containing receptors co-expressed with different GluN1 splice
variants. GluN1 splice variants with an exon-5 segment (GluN1-1b) shows a reduction in proton
inhibition compared to the splice variant without exon-5 (GluN1-1a). To find out if the
mechanism of inhibition by UBP792 is similar to that of proton inhibition, we measured the
inhibitory activity of UBP792 at GluN1-1b/GluN2D receptors and there was no apparent change
in UBP792 inhibitory activity. We also performed a concentration-response study of UBP792 at
pH 7.4 and pH 8.4 at GluN2D receptors co-expressed either with GluN1-1a or with GluN1-1b.
The inhibitory activity of UBP792 was enhanced in the alkaline pH condition. This is similar to
our finding with the PAMs in both case there is increased inhibitory activity in the alkaline
condition. UBP792 showed similar inhibitory activity at GluN2D receptors with both of the
GluN1 splice forms under both pH conditions (Figure 5.6,Table 5.2)
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Table 5.2 IC50 (µM) and % IMax values of UBP792 at GluN2D-containing NMDARs with
different GluN1 splice variant forms at different pH conditions

***p

pH: 7.4
pH: 8.4

IC50 (µM)
4.1 ± 0.3
2.0 ± 0.08***

pH: 7.4
pH: 8.4

IC50 (µM)
4.3 ± 0.15
2.4 ± 0.1****

GluN1-1a/GluN2D
% IMax
94.9 ± 7.1
95.9 ± 2.3
GluN1-1b/GluN2D
% IMax
97.3 ± 3.3
98.0 ± 2.0

<0.001 (t-test) vs IC50 value for the same receptor at pH 7.4.

****p<

0.0001 (t-test) vs IC50 value for the same receptor at pH 7.4.

Hill slope
1.0
1.0

N
6
4

Hill slope
1.1
1.1

N
5
5
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Figure 5.6 Effect of pH and GluN1 splice variants on the inhibitory activity of UBP792 at
GluN2D-containing NMDARs
(A) The inhibition of NMDAR activity by 30 µM UBP792 was measured at GluN1-1a/GluN2D receptors under different
pH conditions. UBP792 inhibited GluN2D-mediated NMDAR current evoked by 10 µM L-glutamate and 10 µM glycine
at every pH tested (pH 6.4, n = 11 oocytes; pH 7.4, n = 8 oocytes; pH 8.4, n = 10 oocytes). Data represent mean ± S.E.M.
****p˂0.0001

(one-way ANOVA followed by Tukey’s multiple comparison test. (B) Concentration-response of UBP792

inhibition of GluN2D receptors co-expressed with GluN1-1a (absence of exon-5 segment) or GluN1-1b (presence or
exon-5 segment) splice variants at pH 7.4 (GluN1-1a, black curve, n = 6 oocytes; GluN1-1b, green curve, n = 5 oocytes)
and pH 8.4 (n = 4 oocytes at GluN1-1a, red curve and 5 oocytes at GluN1-1b containing receptors, blue curve). Data
represent mean ± SEM.
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5.4.6

Binding interactions of the NAM UBP792 and the PAM UBP684

We hypothesized that the binding site for the PAMs and NAMs are different. To determine if the
PAMs and the NAMs are interacting with each other during binding, we performed a
concentration-response study of the NAM UBP792 in the presence of 50 µM of the PAM
UBP684. The potency of UBP792 in the presence of UBP684 was enhanced (Figure 5.7). The
IC50 values for UBP792 at GluN2C receptors without UBP684 was 10.8 ± 1.8 µM and with
UBP684 it was 3.0 ± 0.4 µM and the difference was statistically significant (p = 0.007, unpaired
t-test). This shows that PAM and NAM bind to different sites. The binding interactions are noncompetitive. This is consistent with the converse experiment where a fixed concentration of a
NAM reduced the maximal response of a PAM but not its potency (Figure 4.7). The shift in
UBP684 affinity suggests that these binding sites are allosterically coupled.
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Figure 5.7 Effect of the PAM UBP684 on NMDAR response inhibition by the NAM UBP792
A concentration-response study of UBP792 with (blue curve, n = 5 oocytes) or without (black curve, n = 13 oocytes) 50
µM UB684, a positive allosteric modulator of GluN2C-containing NMDARs. The UBP792 response curve in presence
of UBP684 was normalized with the UBP684-alone response as being 100 %. The dotted curve shows the expected shift
in the UBP792 concentration-response curve if the interaction between UBP792 and UBP684 was competitive. Data
represent mean ± S.E.M.

199

5.4.7

The inhibition by UBP792 is affected by the LBD-conformation of the GluN2
subunit

By introducing two cysteine residues in each ligand binding domain of GluN1 or GluN2A
subunits, two mutant subunits are created with disulfide crosslinked LBDs which constrain the
LBDs in the closed-cleft conformation and mimic the glycine-bound conformation of the LBD of
GluN1 or the L- glutamate-bound conformation of the LBD of GluN2A receptors. By coexpression of disulfide-crosslinked GluN1c (N499C and Q686C) with wildtype GluN2A or of
wildtype GluN1 with crosslinked GluN2Ac (K487C and N687C) in Xenopus laevis oocytes, we
evaluated the effect of constrained LBDs on the inhibitory activity of UBP792. Interestingly, the
inhibition by 100 µM of UBP792 at GluN1c-containing GluN2A receptors was similar to that of
inhibition at wild type GluN2A receptors. However, UBP792 maximal inhibition at GluN2Accontaining receptor was significantly reduced (**p ˂ 0.01, one-way ANOVA followed by Tukey’s
multiple comparison test) compared to WT GluN2A receptors and GluN1c-containing GluN2A
receptors as shown in Figure 5.8. The inhibition by UBP792 at WT GluN2A, GluN1c-containing
receptors and GluN2Ac-containing receptors was 45.5 ± 8.6 % (n = 8 oocytes), 47.7 ± 5.5 % (n =
11 oocytes), and 14.7 ± 4.3 % (n = 10 oocytes) respectively. This suggests that the inhibition by
UBP792 may require the opening of the GluN2 LBD or related down-stream conformational
states. This finding also implies that UBP792 stabilizes the open conformation of the GluN2
LBD.
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Figure 5.8 Effect of LBD cleft conformation on the inhibitory activity of UBP792
Cross-linking the cleft of the GluN1 LBD by introducing two cysteine point mutations (N499C and Q686C) locks the
receptor in a conformation that mimics the glycine-bound conformation and cross-linking the cleft of the GluN2A LBD
by introducing two cysteine point mutations (K487C and N687C) mimics the L-glutamate-bound conformation. Both of
these constructs were separately expressed with complimentary WT subunit in Xenopus laevis oocytes and inhibitory
activity of UBP792 (100 µM) was measured. A bar graph showing UBP792-mediated inhibition of agonists (10 µM Lglutamate and 10 µM glycine) evoked response from oocytes expressing WT (GluN1/GluN2A, n = 8 oocytes), GluN1
LBD-locked (GluN1c/GluN2A, n = 11 oocytes) and GluN2A LBD-locked (GluN1/GluN2Ac, n = 10 oocytes) receptors.
Data represent mean ± S.E.M. **p˂0.01 (one-way ANOVA followed by Tukey’s multiple comparison test).
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5.5

Discussion
In this chapter, we studied the mechanism of the inhibitory action of UBP792, a

prototype compound from a new series of 2-naphthoic acid derivatives. UBP792 was found to be
a potent NAM which shows partial maximal inhibition at NMDARs. It is more potent and
efficacious, although partial, at GluN2D- and GluN2C- than at GluN2B-containing receptors
Figure 5.2, Table 3.3). Our findings indicate that this NAM maintains its inhibitory activity even
at high agonist concentrations, which is important because of the high concentrations of
glutamate released during synaptic neurotransmission (Figure 5.4). The non-competitive nature of
UBP792’s interaction with glutamate and glycine (Figure 5.3, Table 5.1) also implies that
UBP792 binds allosterically to a site(s) other than the agonist binding sites. UBP792 inhibition
was voltage-independent and use-independent (Figure 5.6). UBP792 can bind to the closed state
of the receptor as indicated by a reduction in agonist-induced response after pre-application of
UBP792 (unpublished observation).
In some pathological conditions, acidification occurs in the brain (Katsura, Asplund et al.
1992, Matsumoto, Obrenovitch et al. 1990). Some NAMs such as ifenprodil enhance the proton
sensitivity thereby enhancing the proton inhibitory activity (Mott, Doherty et al. 1998, Pahk,
Williams 1997). Similarly, another GluN2B NAM (93-31) also shows enhanced potency under
acidic conditions (Yuan, Myers et al. 2015). However, in contrast to the enhanced inhibitory
activity of ifenprodil and compound 93-31 at GluN2B-containing receptors at acidic pH, UBP792
displayed a reduced inhibitory activity at acidic pH and enhanced activity at alkaline pH
condition suggesting that protons adversely affect the inhibitory activity of UBP792 (Figure 5.6).
Also, there was no change in inhibitory activity of UBP792 at GluN2D receptors co-expressed
with GluN1-1a or GluN1-1b splice forms. Both of these findings indicate that the mechanism of
inhibition by UBP792 is different from the mechanism of inhibition by ifenprodil (Mott, Doherty
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et al. 1998, Pahk, Williams 1997) and other GluN2B-selective NAMs such as 93-31 (Yuan,
Myers et al. 2015).
We also found from this study that PAMs (e.g. UBP684) and NAMs have distinct
binding sites (Figure 5.7). Interestingly, the PAM UBP684 even enhances the inhibitory potency
of the NAM UBP792. It is possible that the binding of PAM may change the conformation of the
NAM binding pocket and may increase the access of NAM to its binding site, thereby enhancing
the activity.
This study also shows that UBP792 activity requires a conformational change in the
GluN2, but not in GluN1, LBD. Thus, we suggest that UBP792 stabilizes the open conformation
of the GluN2 LBD (Figure 5.8). It is possible that by stabilizing the GluN2 LBD, it may facilitate
glutamate dissociation and receptor deactivation by a mechanism similar to that by which MPX007 facilitates the glycine dissociation from GluN1 LBD causing receptor deactivation (Yi, Mou
et al. 2016).
The possible binding sites and mechanisms of action of other subtype-selective NAMs
have also been reported. QNZ46 is a quinazolin derivative with GluN2C/2D-specific NAM
activity (Mosley, Acker et al. 2010). It requires the binding of L-glutamate for activity and is
thought to bind at the LBD near the TMD (Hansen, Traynelis 2011) close to the possible binding
site of CIQ, a GluN2C-PAM. Also, DQP-1105 is another GluN2C/2D-selective NAM which is
also thought to bind, from mutagenesis study of GluN2D receptor, at the S2 domain (Acker, Yuan
et al. 2011). TCN-201 and TCN-213 are GluN2A-selective NAMs (Bettini, Sava et al. 2010) and
are thought to bind at the heterodimer interface of ligand binding domains (LBDs) of
GluN1/GluN2A receptors (Bettini, Sava et al. 2010). TCN201 acts through the glycine binding
site in a non-competitive manner (Edman, McKay et al. 2012).
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We have also identified NAMs displaying greater subunit-selectivity. Compound
UBP608, a coumarin carboxylic acid derivative, inhibits GluN2A receptors with 23-fold
selectivity compared to GluN2D-containing receptors (Costa, Irvine et al. 2010) and 4-methyl
substitution of this compound makes it a PAM from NAM (UBP 714) (Irvine, Costa et al. 2012).
Other general NAMs developed from our group are UBP618 and UBP552, naphthalene
derivatives, which are relatively potent NAMs (Costa, Irvine et al. 2012). UBP552 has an IC50 in
the range of 3-7 µM and UBP618, has an IC50 of ~ 2 µM at each of the four NMDAR subtypes
(Costa, Irvine et al. 2012). We expect that these previously described compounds share similar
binding sites and mechanism of action with those described here for UBP684, UBP753 and
UBP792. However, we found that the GluN2A PAM UBP512 could non-competitively inhibit
the PAM activity of UBP684. This may indicate that there are two distinct PAM binding sites or
that UBP512 also has NAM activity at NAM binding site that is completely inhibiting UBP684’s
PAM activity.
This study provides mechanistic insight into UBP792 inhibition at NMDARs. Although it
is not highly selective for a particular subtype of NMDARs, its limited selectivity for GluN2Cand GluN2D-containing receptors should make it useful for studying the function of these
receptors and provide opportunities for the discovery of future allosteric modulators with better
potency and selectivity.
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Chapter 6 Discussion and conclusions
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In this dissertation research, we first evaluated the role of the GluN2D subunit in an acute animal
model of schizophrenia. We studied the effect of acute administration of ketamine on different
aspects of behavior and neurological functions, which are thought to be correlated to
neuropathological changes seen in schizophrenia. We found that GluN2D plays an important role
in most, but not in all, of the behavioral and neuropathological assays we tested. Ketamineinduced hyperactivation of prefrontal cortex required GluN2D subunits. This was supported by a
c-FOS experiment as well as by the [14C]-2-DG-uptake assay. This might be due to the result of
ketamine blockade of NMDARs in inhibitory interneurons, especially PV-containing neurons in
the cortex thereby causing disinhibition of pyramidal cell firing which is reflected by an increase
in [14C]-2-DG-uptake. It is also possible that ketamine may block NMDARs in inhibitory neurons
in the thalamus which disinhibit the thalamic excitatory cells projecting to cortex. In both of these
scenarios, there is increased prefrontal cortical activity. It is well known that ketamine and other
non-competitive NMDAR blockers like MK-801 and PCP cause schizophrenia-like symptoms in
animals. However, ketamine and PCP are not able to increase the locomotory activity in GluN2DKO mice. Since, ketamine-induced locomotor activity is thought to correspond to the positive
symptoms of schizophrenia, the absence of ketamine-induced activity in the GluN2D-KO mice
suggests an important role for GluN2D subunits in the positive symptoms of schizophrenia. This
might be either due to blockade of NMDARs in substantia nigra, which leads to disinhibition of
dopaminergic cells projecting to striatum or by controlling other dopaminergic pathways.
Consistent with this possibilities, others have shown that the GluN2D-KO mouse has a reduction
in PCP-induced dopamine release (Hagino, Kasai et al. 2010).
The observation that mice lacking GluN2D subunits have defective memory retrieval
suggests their importance in cognition and memory, which is also impaired in schizophrenics.
Also, PV cells, which are found to be reduced in schizophrenics in the DLPFC and other brain
areas were also reduced in mice lacking GluN2D. However, we did not see any role of GluN2D
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in sensorimotor gating function (prepulse inhibition). Taken together, the findings in Chapter 1
imply that GluN2D subunit-containing NMDARs play an important role in regulating
neurological, behavioral as well as memory functions impaired in schizophrenia. Enhancing
NMDAR function, especially GluN2D subunit-mediated NMDAR function, by use of allosteric
modulators may thus be therapeutically beneficial. Hence, research in subsequent chapters was
focused on identifying novel NMDAR modulators with enhanced potency and selectivity.
The SAR studies (Chapter 3), revealed that the 2-position carboxyl group is critical for
PAM activity of naphthalene derivatives. A 5-6 carbon chain length of the alkyl side-chain at the
6-position of naphthoic acid is optimal for PAM activity. Heteroatoms cannot be accommodated
in the naphthalene ring and still retain PAM activity. If we substitute the naphthalene ring at 7position of a PAM compound with a styryl group, it changes the property of the compound to a
NAM. UBP684 and UBP753 were compounds with robust PAM activity and UBP792 with
subtype-selective NAM activity in this series of 2-naphthoic acid derivatives. For both PAMs and
NAMs we identified regions which tolerate substitutions. Future discoveries will target these
allowed spaces. Also, we identified improved GluN2C- and GluN2D-selective derivatives of
PPDA and UBP141 that are competitive antagonists. UBP791 is now the most GluN2C/GluN2Dselective competitive antagonist known. From this chapter, we obtained SAR properties of
compounds for NAM, PAM and competitive antagonism.
From the PAM mechanism study (Chapter 4), we found that the PAMs enhance the
NMDAR response by increasing agonist efficacy and slightly increasing the affinity of glutamate
and glycine for NMDARs in a subunit-dependent manner. The activity of these PAMs is not
affected by membrane voltage. Their binding does not change the conformation of channel pore
as revealed by the ketamine concentration-response study. PAMs are able to potentiate even when
the redox state of the receptor is changed. Thus, their mechanism of potentiation is different from
that seen by redox agents. UBP684/UBP753 enhance the NMDAR current by increasing the open
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probability of NMDARs and also by slowing down the dissociation of glutamate from its binding
site (or the subsequent conformational change). Mainly, these PAMs stabilize the GluN2
conformation of the receptors in an active conformation (LBD-closed conformation). Consistent
with this idea, molecular docking studies with UBP684 show that it can be docked in the interdimer space in the GluN1/GluN2A LBD with its alkyl chain terminating close to the hinge
region. This site is similar to the site for the GluN2A-selective potentiator (GNE-6901) as
revealed by crystallography (Hackos, Lupardus et al. 2016). This docking is consistent with our
finding of slow glutamate dissociation/deactivation in the presence of UBP684 as well as reduced
potentiation by UBP684 in GluN2Ac (LBD-locked) receptors.
The findings from this chapter also reveal that these compounds decrease the sensitivity
to proton inhibition. However, their mechanism of action is not by relieving proton inhibition in
the manner shown in spermine potentiation. We found that the extracellular proton concentration
controls PAM activity in a subunit-dependent manner. We also observed that the GluN1 but not
the GluN2A C-terminal was important for UBP684-induced PAM activity. We also observed that
intracellular calcium is necessary for the PAM activity in GluN2A but not in GluN2B receptors.
Also, the activation of PKC increases PAM activity indicating that PAM activity is at least
partially PKC phosphorylation-dependent. Taken together, these studies suggest that the
intracellular environment can alter the conformation of the transmembrane domains and in turn
alter PAM activity and/or PAM binding. This is not surprising given that PKC, PKA and Ca2+ can
alter the response of NMDARs to agonists.
From the NAM mechanism study (Chapter 5), we found that NAMs decrease the
NMDAR response by reducing the efficacy and affinity of agonists. These NAMs are more
potent at high agonist concentration and at high pH. The activity of these NAMs were adversely
affected by proton concentration. Unfortunately, this property means that these NAMs loose
inhibitory activity in acidic pathological conditions such as stroke. UBP792 may be binding near
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a cluster of pH-sensitive residues near the channel gating mechanism as proposed for
neurosteroids. Like PAMs, NAM activity was also not affected by a change in membrane
potential and they do not compete with PAMs for binding to the NMDAR complex. Indeed, in a
related family of ligand-gated ion channels known as AMPA receptors, negative allosteric
modulators are thought to bind at a site at the top of transmembrane regions 1 and 4 (Balannik,
Menniti et al. 2005, Sobolevsky, Rosconi et al. 2009) and an equivalent binding site may exist in
NMDARs. However, it is also possible that they may bind to the PAM binding site. It has been
reported that a GluN2A inhibitor binds at a similar site to potentiators at the dimer interface of the
LBDs of GluN1/GluN2A, with the major difference being that the conformation of Y535 on
GluN1 is different in the two sites (Hackos, Lupardus et al. 2016).
PAMs and NAMs discovered in this research have various potential therapeutic
applications. PAMs may be useful in enhancing NMDAR function in a disease like schizophrenia
and, perhaps, depression. Similarly, NAMs may help in protecting against neurological damage
caused by excessive activation of NMDARs such as in stroke and traumatic brain injury. Studies
have shown that GluN2D plays a role in tissue plasminogen activator (tPA)-induced stroke
damage (Jullienne, Montagne et al. 2011). Hence GluN2D-preferring NAMs such as UBP792
should be useful in protecting from such damage. These GluN2C/GluN2D NAMs should also be
useful in neuropathic pain since GluN2D receptors are also involved in pain pathways (Shiokawa,
Kaftan et al. 2010, Tong, Kaftan et al. 2008).
Since these allosteric modulators bind to sites different from the highly conserved ligand
binding sites and the receptor’s channel pore, it may be possible to develop a modulator with yet
greater subtype-selectivity. Also, different modulators offer different unique properties. For
example, some modulators show high activity at reduced agonist concentration, which would be
useful in regulating tonically-activated NMDARs only. Some modulators display high activity at
the reduced pH, such modulators would therefore be more effective in the treatment of
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pathological conditions which are associated with acidification of the brain tissue. Also, these
modulators can have different maximal effects. For example, UBP792 and other NAMs show
partial maximal inhibition of NMDAR response which therefore will help in reducing the side
effects caused by maximum blockade of NMDARs by full antagonists. Since modulators offer
better selectivity, we can control the activity of only certain subtypes and not affect the function
of others. Modulators which enhance the NMDAR activity can also be used for cognitive
enhancement as well (Collingridge, Volianskis et al. 2013). Overexpression of GluN2B receptors
in mouse forebrain causes enhancement of memory and cognition (Tang, Shimizu et al. 1999).
Another study also shows that increasing the GluN2B receptors expression in frontal lobe and
hippocampus improves the memory in aged mice (Brim, Haskell et al. 2013). Enhancing GluN2C
and GluN2D receptors function by use of a PAM improves MK-801-induced impairment in
working memory (Suryavanshi, Ugale et al. 2014). Thus, GluN2B PAMs should be beneficial for
improving memory and GluN2C/GluN2D PAMs may be beneficial for treating cognitive deficits
seen in schizophrenia.
From this study, we identified prototype PAMs (UBP684/UBP753), NAMs (UBP792)
and competitive antagonists (UBP791) and studied their mechanisms of action and different intraand extra-cellular factors affecting their activity in vitro. Future studies should be focused on
identifying the binding sites of these modulators. Although, our preliminary data indicate that
they are possibly binding at the interface of GluN1/GluN2 LBD dimers, it is still possible that
they may be binding to the regions near the membrane where CIQ (Ogden, Traynelis 2013) or
neurosteroids are also thought to be bound (Kostakis, Jang et al. 2011). By carrying out a
chimera/mutagenesis study, we should be able to find the location of the binding site and the
amino acid residues important for their activity. If the binding site of these modulators is on
GluN1 receptors, it may be difficult to develop compounds with subunit selectivity. However, if
the binding site is on the GluN2 subunit, it may be possible to develop compounds with greater
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selectivity. Our finding also suggests that there may be multiple binding sites for these
modulators and they may display both PAM and NAM activity by binding to these different sites.
Thus, the SAR information we have obtained is confounded by these factors. For example, if we
observe an enhanced PAM activity of a compound by modification of certain structural features,
it does not necessarily mean that the modification increased the PAM activity. It is possible that
the modification could have resulted in a compound with less inhibitory activity.
The existence of native NMDARs in triheteromeric arrangements makes it important to
test these modulators at triheteromeric NMDARs. The activity of these modulators at
diheteromeric NMDARs might not be the same in triheteromeric receptors. For example, the
inhibition by NAM UBP792 at GluN1/GluN2B/GluN2D containing heteromeric receptors could
be different from inhibition at GluN1/GluN2B or GluN1/GluN2D-containing receptors. In
addition, these compounds should be tested for their activity in neurons.
It will be interesting to test the PAM compounds with GluN2D receptors selectivity (e.g.
UBP551) in vivo to determine if they are able to rescue the schizophrenia-like behavioral,
cognitive and neuropathological deficits in a mouse model of schizophrenia. We anticipate from
the findings in Chapter 2 that pretreatment of mice with UBP551 would reverse the behavioral
deficits observed in mice with schizophrenia phenotype. However, it should be noted that
UBP551 not only has GluN2D-PAM activity, but also has GluN2A-C NAM activity, which may
affect the outcome of results. We are still developing other new compounds for PAM activity,
especially at GluN2D receptors, utilizing the information obtained from Chapter 3. Our ultimate
goal is to test a GluN2D specific PAM in a mouse model of schizophrenia.

This study reveals the importance of GluN2D subunit in schizophrenia-like behavior and
neuropathology. Experimental findings from the SAR studies will help in designing selective
PAMs and NAMs in future. We were able to develop efficacious general NMDAR PAMs,
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GluN2C/GluN2D-preferring NAMs and potent GluN2C/GluN2D-preferring glutamate-site acting
competitive antagonists. These agents can be used as experimental tools to further define the
function of NMDAR subtypes. Unique mechanisms of NMDARs modulation by these PAMs and
NAMs have been identified. These findings too will aid in future studies involved in drug design
and development for the treatment of neurological diseases.
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